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 Summary 
Introduction 
Urothelial carcinoma of the bladder (UCB) is a public health problem in Spain because of 
its high incidence in the male population. Its chronic nature requires continuous monitoring 
of the patient for the rest of his life. This implies deterioration in the quality of life of 
patients and a major expense for the national health system. 
The incidence of this tumor is between 3-7 times higher in men in comparison to women 
and increases with age, peaking between 50 and 70 years. In addition, the geographical 
distribution is heterogeneous, with a much higher incidence in developed countries, except 
in northeast Africa. 
About 80% of cases are diagnosed in patients with non-muscle invasive bladder cancer 
(NMIBC) and the rest suffer the invasive subtype (MIBC). However, there is a marked 
heterogeneity between superficial tumors in terms of biology, pathological features - 
Ta/G1-G2 in low-risk, TaG3 + T1/G2-G3 for high risk - and prognosis. This stratification 
is further supported by the identification of genetic alterations in FGFR3 and PI3KCA in 
low-risk NMIBC and p53 and Rb in high-risk NMIBC and invasive bladder cancer. 
Risk factors established for UCB are tobacco smoking and occupational exposures to 
aromatic amines or polycyclic aromatic hydrocarbons. Although, occasionally, it has been 
described familial aggregation for this tumor, no high penetrance gene has been identified. 
On the other hand, bladder cancer represents a paradigm regarding the participation in the 
development of low-penetrance variants: GSMT1-null and NAT2-slow, the latter in 
interaction with tobacco smoking. Massive genotyping initiatives (Genome Wide 
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Association Studies, GWAS) have recently identified 10 additional variants associated with 
the risk of developing the disease. Although some studies have suggested the role of 
genetic factors in the prognosis of bladder cancer, the results are still limited, inconclusive 
and to date there is no study at genome-wide level. 
To establish the prognosis of the NMIBC, urologists consider mainly the extent and depth 
of tumor invasion, presence of multiple tumors and the size of the major mass. The TNM 
staging system is used for the MIBC assessment. However, these prognostic factors are 
insufficient to subclassify the patients and accurately predict the evolution of UCB. 
Objectives 
The overall objective was to prove that inherited genetic variants are also involved in 
cancer progression, specifically UCB. Therefore, the specific objectives were: 1) to identify 
SNPs independently associated with UCB (NMIBC and MIBC) outcomes through a 
genome-wide tiered association study; 2) To detect pairs of interacting SNPs associated 
with UCB outcomes, also at a genome-wide scale; 3) To identify biological functions 
altered by an overrepresentation of SNPs identified in the first phase and associated with 
each UCB outcome. 
Methodology 
We studied a cohort of 1,300 patients from the Spanish Bladder Cancer SBC/EPICURO 
Study with genetic information obtained from high-throughput genotyping by Illumina 
Infinium HumanHap 1M probe Beadchip platform. This study was carried out between 
1998 and 2001 in 18 general hospitals in five Spanish regions. The SBC/EPICURO Study 
provides an invaluable source of information regarding epidemiological data, clinical 
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monitoring, molecular and genetic as well as being one of the largest studies on this topic 
worldwide. 
The initial phases of the project focused on individualized analysis of SNPs regarding the 
assessment of recurrence, progression and death due to UCB. The analysis was performed 
using uni-/multivariate Cox regressions considering the traditional prognostic factors. The 
results were combined and analyzed using a meta-analysis with an independent cohort of 
bladder cancer patients from the MD Anderson Cancer Center Hospital, Houston, USA. 
Subsequently, we validated the top results in other European and American series with 
which collaboration was established. 
The screening of all pairs of possible interactions between the genotyped SNPs was carried 
out using the algorithm BOOST. Survival analyses followed for those interactions 
described as statistically significant. Additionally, we studied the potential synergies that 
may arise between the SNPs associated with common biological functions by analyzing 
biological pathways. The algorithms called ALIGATOR, GeSBAP, i-Gsea4Gwas, GSA-
SNP and ICSNPathway were used to assess the potentially altered biological functions 
related to cancer development. 
Results 
We initially identified a total of 57 SNPs whose survival adjusted models showed to be 
independently associated with NMIBC. After being validated in five independent cohorts, 
rs754799 and rs4246835 SNPs hold their significance for recurrence and progression, 
respectively. Other 7 SNPs showed associations with disease close to the statistical 
significance level. The survival analysis of the patients who develop MIBC showed 57 
SNPs potentially associated with the outcomes. The SNPs rs16927851 and rs1015267 were 
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with the top SNPs associated with progression and cancer-related death in patients with 
MIBC. The validation of the latter findings in independent patient series will take place in 
the near future. 
We also proceeded with the pairwise survival analysis of all the non-correlated SNPs 
contained in the genotyping platform. In this way, we found pairs of SNPs whose combined 
effect was associated with UCB prognosis 
Finally, we studied whether some biological function could be altered due to an 
overrepresentation of SNPs in genes contained in particular biological pathways. After 
evaluating five different methods, specific results were obtained for non-invasive bladder 
cancer. These are associated to biological functions regarding the inflammatory system and 
the immune response. Moreover, in all the UCB outcomes we identified SNP enrichment in 
pathways in which the GTPases, the membrane transport systems, neuro/ axonogenesis and 
angiogenesis play important roles. 
Conclusions 
We identified SNPs whose main effects are associated with UCB prognosis. In addition, we 
observed synergistic actions of these markers by analyses based on both the effect of their 
interactions and their possible role in gene networks associated with biological functions. 
Therefore, it was verified that germline common variants are associated with several UCB 
clinical outcomes. The identification of these genetic variants makes possible to use them 
as prognostic markers that may allow a better classification and treatment of the patients. 
 
 
 Resumen 
Introducción 
El carcinoma urotelial de vejiga (CUV) constituye un problema de salud pública en España 
debido a su alta incidencia en la población masculina y a su naturaleza crónica que requiere 
de un seguimiento continuado del paciente durante el resto de su vida. Ello conlleva un 
deterioro en la calidad de vida de los pacientes y un gasto muy importante para el sistema 
nacional de salud. 
La incidencia de este tumor es entre 3-7 veces mayor en la población masculina y aumenta 
con la edad, con un pico entre los 50 y 70 años. Además, su distribución geográfica a escala 
mundial es heterogénea, con una incidencia muy superior en los países desarrollados, 
excepto en el noreste africano. 
Alrededor del 80% de los casos diagnosticados corresponden a pacientes con tumores de 
vejiga no-invasivos del músculo (NMIBC) y el resto al subtipo invasivo (MIBC). Además, 
en los tumores no-invasivos, la heterogeneidad es acusada en cuanto a la biología, 
características patológicas - Ta/G1-G2 en los de bajo riesgo y TaG3+T1/G2-G3 para los de 
alto riesgo - y al pronóstico. Esta clasificación está sustentada en alteraciones genéticas en 
FGFR3 y PI3KCA en los no- invasivos de músculo de bajo riesgo y en p53 y Rb en los no-
invasivos de alto riesgo e invasivos de músculo. 
Los factores de riesgo establecidos para el CUV son el tabaco y las exposiciones 
ocupacionales a aminas aromáticas o hidrocarburos aromáticos policíclicos. Aunque se ha 
descrito ocasionalmente agregación familiar para este tumor, no se ha identificado ningún 
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gen de alta penetrancia. No obstante, el CUV representa un paradigma en cuanto a la 
participación en su desarrollo de variantes de baja penetrancia: GSMT1-null y NAT2-slow; 
este último en interacción con el tabaco. Iniciativas de genotipación masiva (Genome Wide 
Association Studies, GWAS) han permitido, recientemente, identificar 10 variantes 
genéticas adicionales asociadas a este tumor. Aunque algunos estudios han sugerido el 
papel de estos factores genéticos en el pronóstico del CUV, los resultados son aún escasos, 
poco concluyentes y, hasta la fecha, no hay ninguno a nivel pan-genómico. 
Para establecer el pronóstico del cáncer de vejiga no-invasivo del músculo, los urólogos 
consideran, principalmente el grado de diferenciación y la profundidad de invasión tumoral 
de la pared vesical, la presencia de múltiples tumores y el tamaño de éstos. Por otra parte, 
se usa el sistema TNM en los subtipos invasivos de de la enfermedad. No obstante, estos 
factores pronósticos son insuficientes para subclasificar a los pacientes con precisión y 
predecir la evolución del CUV. 
Objetivos 
El objetivo principal era probar que las variantes genéticas de línea germinal están asocidas 
con la progresión del cáncer de vejiga, específicamente de CUV. Por ello, los objetivos 
específicos fueron: 1) la identificación de los SNPs independientemente asociados con los 
desenlaces del CUV (NMIBC y MIBC) mediante un estudio pan-genómico; 2) La 
detección de parejas de SNPs en interacción asociados con los desenlaces del CUV, 
también a escala pan-genómica; La identificación de las funciones biológicas alteradas por 
una sobrerrepresentación de SNPs identificados en la primera fase y asociados con cada 
uno de los desenlaces del CUV. 
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Metodología 
Se estudió la cohorte de 1.300 pacientes del estudio EPICURO, que dispone de información 
genética obtenida mediante la genotipación masiva por la plataforma Illumina Infinium 
HumanHap de 1 millón de SNPs. Este estudio se llevó a cabo entre 1998 y 2001 en 18 
hospitales generales de 5 regiones españolas. El estudio EPICURO proporciona una fuente 
de valor inestimable en cuanto a datos epidemiológicos, clínicos, de seguimiento, 
moleculares y genéticos, además de ser uno de los estudios más grandes sobre esta 
patología a escala mundial. 
Las fases iniciales del proyecto se centraron en el análisis individualizado por SNP de la 
información procedente del genotipado de los pacientes en relación a la predicción de 
recurrencia, progresión y muerte por CUV. El análisis se llevó a cabo mediante regresiones 
de Cox uni-/multivariantes considerando los factores pronósticos clásicos en el estudio 
sobre la evolución de la enfermedad. Los resultados de estos análisis se analizaron 
mediante un meta-análisis en una serie independiente de pacientes de CUV procedente del 
Hospital MD Anderson Cancer Center, Houston, USA. Posteriormente se replicaron parte 
de los resultados en otras series europeas y americanas con las que se estableció una 
colaboración. 
El cribado de todos los pares de interacciones posibles entre los SNPs genotipados se 
realizó mediante el algoritmo BOOST, seguido del análisis de supervivencia descrito para 
aquellas interacciones más significativas. Adicionalmente se estudiaron las posibles 
sinergias que puedan aparecer entre los SNPs asociados a funciones biológicas comunes 
mediante el análisis de grupos génicos. Se utilizaron los algoritmos ALIGATOR, GeSBAP, 
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i-Gsea4Gwas, GSA-SNP e ICSNPathway para evaluar el valor predictivo de las presuntas 
funciones biológicas alteradas en relación al desarrollo del cáncer. 
Resultados 
Inicialmente se identificaron un total de 57 SNPs cuyos modelos ajustados de supervivencia  
mostraban estar potencialmente asociados al cáncer de vejiga no-invasivo del músculo. 
Tras ser evaluados en cinco cohortes independientes, los SNPs rs754799 y rs4246835 se 
validaron para recurrencia y progresión, respectivamente. Otros 7 SNPs presentaron 
asociaciones con la enfermedad cercanas al nivel de significación estadística. Al analizar la 
supervivencia de los pacientes que desarrollan variantes invasivas del músculo, se 
obtuvieron 57 SNPs potencialmente asociados con los desenlaces de la enfermedad. Los 
SNPs rs16927851 y rs1015267 mostraron una potencial asociación con los eventos de 
progresión y muerte por CUV en los pacientes que presentaban neoplasias invasivas. La 
validación de estos resultados en series independientes de pacientes tendrá lugar en un 
futuro próximo. 
También se procedió al análisis de supervivencia de todas las posibles interacciones entre 
los SNPs de la plataforma de genotipación utilizada. De este modo se detectaron aquellas 
parejas de SNPs cuyo efecto combinado estaba asociado con el pronóstico del CUV. 
Finalmente, se estudió si alguna función biológica pudiera estar alterada debido a una 
sobrerrepresentación de SNPs con valor pronóstico asociados a los genes que la conforman. 
Tras evaluar cinco métodos distintos, se obtuvieron resultados específicos para el cáncer de 
vejiga no-invasivo del músculo. Éstos corresponden a funciones biológicas relativas al 
sistema inmune y a la respuesta inflamatoria. Por otra parte, se identificaron posibles 
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alteraciones en aquellas funciones biológicas en las que las GTPasas, los sistemas de 
transporte de membrana, la neuro/axonogénesis y la angiogénesis juegan un papel 
importante. 
Conclusiones 
Se identificaron SNPs cuyos efectos principales están asociados al pronóstico del CUV. 
Además, se estudiaron las acciones sinérgicas de estos marcadores mediante análisis 
basados tanto en el efecto de sus interacciones como en su posible papel desarrollado en 
redes génicas reguladoras de funciones biológicas. 
Así, se verificó que las variantes genéticas de línea germinal están asociadas con diversos 
tipos de desenlace del CUV. La identificación de estas variantes genéticas hace posible su 
uso como marcadores pronósticos que podrían posibilitar una mejor clasificación y 
tratamiento de los pacientes. 
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 Chapter 1: Introduction 
Part I: Bladder cancer 
1.1.1. An overview of bladder cancer 
Cancer is the main cause of death in the economically development countries and the 
second cause of death in developing countries (Jemal, Bray et al. 2011). The present work 
is focused on bladder cancer, which represents one of the major types of cancer. According 
to the last available information in GLOBOCAN 2008 (Ferlay, Shin et al. 2010), the 
number of bladder cancer cases and deaths reach up to 382,660 and 150,282 respectively. 
The world age-standardized incidence rate is 5.3 per 100,000 but it shows higher rates in 
economically developed countries. 
 
Figure 1. Bladder cancer world map. The age-standardized incidence rates for each country 
(GLOBOCAN 2008). 
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Bladder cancer represents the fifth most common cancer in Spain. However, the incidence 
is much higher among men (4
th
 most frequent cancer) than among women (15
th
 most 
frequent cancer). The Spanish population exhibits one of the highest incidence rates among 
men (27.7 per 100,000 person-year) and one of the lowest among women (3.2 per 100,000) 
worldwide, with a gender man:woman ratio of 7:1, in contrast with the 3:1 ratio in the other 
industrialized countries. The five-year prevalence is 3.4 times (592,663 vs. 174,815 cases) 
higher than the incidence in Westernized countries. This fact jointly with the need of 
clinical surveillance of patients with cystoscopies to avoid tumor progression results in an 
important cost for all heath care systems (Ferlay, Shin et al. 2010). 
 
 
Figure 2. Age-standardized incidence and mortality rates of bladder cancer in the top European 
countries (GLOBOCAN 2008). 
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1.1.2. UCB symptoms, diagnosis and treatment 
There are several types of bladder cancer (BC) according to the morphology/histology of 
the tumor. In the present work we focus on the of urothelial or transitional cell carcinoma 
of the bladder (UCB), which is the most common and it is diagnosed in about 90% of the 
bladder cancer patients (Silverman, Devesa et al. 2006). Patients with UCB usually present 
painless hematuria. However, the irritative symptoms (frequency, urgency or dysuria) can 
be present at early stages. There is usually a common delay in the diagnosis because of the 
similarity and the possible intermittence of these symptoms to other disorders or diseases 
(presence of renal calculi, cystitis, infection, or even prostatitis) that leads to a poorer 
prognosis. In advanced stages of the disease, metastases may be responsible of initial 
symptoms. 
An initial physical examination must be performed in patients that are suspected to suffer 
UCB. It includes a digital rectal examination in men and a bimanual examination of the 
vagina and rectum in women. Nevertheless, this examination is normally unremarkable. If 
there is not a clear source of glomerular bleeding, a full urologic evaluation of the entire 
urinary tract is indicated. It consists of cystourethroscopy and urinary cytology followed by 
an evaluation of the upper tracts. Radiographic imaging of the upper tract and urinalysis 
may be also performed. The gold standard for the initial diagnosis and management of 
UCB is cystoscopy. Visible tumors are either biopsied to determine the histology and depth 
of invasion into the bladder submucosa and muscle layers. Additionally tumors could be 
resected by transurethral resection (TUR). Low-grade, non-invasive tumors are normally 
stalked and papillary. On the other hand high-grade, invasive tumors are frequently sessile. 
The less common carcinoma in situ (Tis) is a high-grade, non-invasive tumor that appears 
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as a flat lesion. Tumoral characteristics such as the size, stalk and location may predict the 
muscle invasion. Urine cytology is commonly used in combination with cystoscopy to 
assed the presence of Tis and to evaluated for possible upper tract malignancies. However, 
urine cytology has a relatively poor sensitivity, particularly for low-grade tumors (Lotan 
and Roehrborn 2003).  
The patients with UCB are classified in two subgroups according to their prognosis and the 
tumor genetic alterations (Netto 2012): non-muscle invasive bladder cancer (NMIBC), 
representing 75-85% of UCB, and muscle invasive subtype (MIBC) (Babjuk, Oosterlinck et 
al. 2011). This classification is based on the tumor invasiveness or stage (T) and grade (G). 
Non-muscle invasive tumors are further classified based on the depth of the invasion into 
papillary carcinoma (Ta and T1, the latter invading subepithelial connectivity tissue) and 
Tis. Muscle-invasive tumors are classified as T2 when they only invade the muscle layer of 
the bladder, T3 when they invade perivesical tissue, and T4 when the tumor spreads to 
nearby organs. UCB is further subclassified according to the histological grading (G) of the 
tumors as well (G1), moderately (G2) or poorly differentiated (G3). By combining T and G, 
UCB are diagnosed as low (TaG1/G2) or high risk tumors (TaG3, T1 and Tis), a 
classification that is highly correlated with the probability to progress. The World Health 
Organization (WHO) and the International Society of Urological Pathology (ISUP) have 
proposed a new classification based on the histopathology of the tumor. It consists on a 
biopsy followed by a microscopic examination of its tissue slide, in which it could be 
observed two or three grades of cellular differentiation, ranging from poor to well 
differentiated, according to the distinct WHO/ISUP classifications: WHO1973 and 
WHO/ISUP 1999/2004 (Babjuk, Oosterlinck et al. 2011). 
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The treatment to be applied as first line therapy is determined by the kind of tumor. In 
NMIBC patients TUR is the standard treatment. Additionally in can be followed 
immunological therapy based on bacille Calmette-Guérin (BCG), chemotherapy or both. 
Tumor recurrence represents a clinical problem as far as, in 70% of the patients diagnosed 
with a NMIBC, the tumor reappears after a TUR (Kurth, Denis et al. 1992). Fortunately the 
additional BCG instillation reduces this event by 30% (Smith, Labasky et al. 1999). The 
benefits of using BCG over chemotherapy are well established for recurrence but its role in 
progression remains unclear (Gontero, Bohle et al. 2010). The treatments applied to MIBC 
patients are much aggressive compared with those mentioned before: radical cystectomy, 
multimodal therapy or cisplatin-containing chemotherapy (Stein, Lieskovsky et al. 2001). 
After treatment, the patients need to be routinely monitored by cystoscopies to control the 
reappearance of tumoral growth. There is not any established period of time to perform this 
follow-up process but the European Association of Urology (Babjuk et al., 2008, 2009) 
gives some clues. Nevertheless, a cystoscopy after three months after the treatment has 
been shown to be predictive for the relapse of the disease. After that, the schedule of 
follow-ups is suggested to be different for low-risk and high-risk patients. If the results of 
the last mentioned cystoscopy are negative, it is recommended to perform a new one after 9 
months and then annually for the next 5 years. The high-risk patients need a more 
exhaustive follow-up based on new cystoscopies every 3 months for the next 3 years, every 
4 months in the third year, every six months until the fifth year and annually thereafter 
(Babjuk, Oosterlinck et al. 2011). 
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1.1.3. Evolution and prognosis of UCB 
UCB can be classified in two groups: 75-80% of cases are NMIBC and the rest have 
muscle invasive or metastatic neoplasms. Just a few of the MIBC patients (3-15%) have a 
previous history of papillary tumors (Dinney, McConkey et al. 2004; van Rhijn, Burger et 
al. 2009). A patient with a primary non-muscle invasive tumor can be diagnosed as a new 
bladder neoplasm (called tumor relapse) during his follow-up. It may reappear in the form 
of a recurrence or a progression and lead to muscle invasive or metastatic forms of the 
disease. For primary diagnoses MIBC patients the progression is considered as the 
appearance of an advanced stage of the disease that may lead to death due to UCB or any 
other cause. 
Clinical and pathological variables for UCB 
Around 70% of NMIBC patients present as Ta stage, 20% as T1, and 10% as Tis. 
Recurrence occurs in 50–80% of the patients and is the main threat for patients with Ta 
tumors. On the other hand, progression, which appears in 10–30% of patients, is the main 
problem in T1 and Tis affected subjects (van Rhijn, Burger et al. 2009). The percentage of 
recurrence in NMIBC patients at 1 and 5 years ranges from 15–61% and 31–78%, 
respectively. The percentages for patients who suffered progression at 1 and 5 years range 
from <1–17% and 1–45%, in each case (Sylvester, van der Meijden et al. 2006). The wide 
range for recurrence and progression rates is due to the presence of tumor heterogeneity in 
these patients (Kurth, Denis et al. 1995; Allard, Bernard et al. 1998). High-risk non-muscle 
invasive tumors (TaG3 and T1G2/G3) tend to progress into muscle-invasive and metastatic 
forms of disease. Around 25% of T2 tumors, 50% of T3 tumors and 80% of T4 tumors 
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eventually evolve into metastasis. The MIBC 5-year survival is 67% for T2 tumors, 35% 
for T3 tumors and 27% for T4 tumors (Herr, Dotan et al. 2007). 
The most accepted clinical prognostic factors for tumor recurrence in NMIBC are 
multiplicity (Parmar, Freedman et al. 1989; Shinka, Hirano et al. 1990; Kiemeney, Witjes et 
al. 1994; Millan-Rodriguez, Chechile-Toniolo et al. 2000), tumor stage (Shinka, Hirano et 
al. 1990; Kiemeney, Witjes et al. 1994), tumor grade (Shinka, Hirano et al. 1990; Kurth, 
Denis et al. 1995), and tumor size (Kurth, Denis et al. 1995; Millan-Rodriguez, Chechile-
Toniolo et al. 2000). However, the result of the first cystoscopy performed after 3 months 
after TUR [9] can be considered the strongest prognostic factor (Parmar, Freedman et al. 
1989). On the other hand, the most important variables for prediction of progression in 
NMIBC are the presence of Tis, a grade 3, and a stage T1 tumor (Sylvester 2006). 
Additional variables for this outcome have been suggested: a recurrence a first cystoscopy, 
stage, grade and prior tumor (Fernandez-Gomez, Solsona et al. 2008). 
The most important predictor of MIBC outcome is radical cystectomy, followed by tumor 
stage (Stein, Lieskovsky et al. 2001). Lymph-node involvement is also one of the most 
important prognostic factors when progression and survival are evaluated (Margulis, Lotan 
et al. 2008). In addition, the presence of metastasis is a widely known prognostic factor 
incorporated in the TNM system. Resistance to neoadjuvant chemotherapy and divergent 
histology are suggested to take into account (Sternberg 2002; Jeon and Chang 2005; 
Turkolmez, Tokgoz et al. 2007; Bruins and Stein 2008). The roles of sex, MNA (mean 
nuclear area) and tumor grade remain uncertain in the prognosis of these patients (Jeon and 
Chang 2005). 
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There is a need to provide predictive tools to the physicians in order to assess the need for 
intravesical therapy and early cystectomy for NMIBC patients. On the other hand, MIBC 
patients also can take advantage of treatment assignment if the prediction of advanced 
disease response to primary treatment is available. The traditional way to estimate the risk 
of developing a particular outcome has been based in the TNM staging system. 
Somatic genetic prognostic markers for UCB 
The list of candidate biomarkers to improve the prediction of NMIBC events has been 
growing over the last decade. The earliest genetic alterations thought to have a potential 
diagnostic and prognostic value were those located in chromosome 9. After that, new 
chromosomal alterations located in 3q, 7p and 17q gains were suggested. Urine assays 
based on fluorescence in situ hybridization were shown to be useful to detect those 
alterations (Kruger, Mess et al. 2003; Kawauchi, Sakai et al. 2009). Genetic alterations on 
receptor protein kinase genes (RTK), such as FGFR3, HRAS and PIK3CA, have been 
associated to the pathogenesis of NMIBC. Mutated and/or altered expression of some of 
them (FGFR3, EGFR, ERBB2 and ERBB3) is thought to have prognostic value for both 
NMI/MIBC. Multiplex PCR assays have been developed in order to detect these alterations 
(Lopez-Knowles, Hernandez et al. 2006; Kompier, Lurkin et al. 2010). Epigenetic analyses, 
which used quantitative methylation specific PCR (MSP-PCR), were applied on bladder 
tumor specimens and associated the disease progression to promoter hypermethylation of 
RASSF1, DAPK, APC, CDH1 and EDNRB (Yates, Rehman et al. 2007). Ploidy and S phase 
kinetics have also been suggested as potential prognostic factors for recurrence and 
progression in NMIBC using automated image or flow cytometry (Loughman, Lin et al. 
2003). The most promising prognostic factors for NMIBC are tumor proliferation index 
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(calculated from either KI67 or MIB1) and a molecular grade parameter based on 
combining FGFR3 gene mutation status and MIB1 labeling index (van Rhijn, Vis et al. 
2003). 
There is also an extensive list of potential biomarkers specific for MIBC. The alteration of 
tumor suppressor genes involved in the cell cycle regulation (TP53, P16 and RB1) has been 
shown to be associated with the prognosis of MIBC (Sanchez-Carbayo, Socci et al. 2002; 
Mitra, Datar et al. 2006). The epigenetics also seems to play a significative role in the 
assessment of MIBC prognosis. The promoter hypermethylation of RASSF1, CDH1 and 
EDNRB has been suggested (Yates, Rehman et al. 2007). The overexpression of RTKs also 
seems to be associated to MIBC and the alteration of ERBB2 seems to be important in 
assessing for the death due to UCB (Bolenz, Shariat et al. 2010). One particular protein 
emerges Recent evidence suggest the importance of mTOR pathway alterations in MIBC 
and it is being used as a potentially useful biomarker in targeted therapy in phase II trials 
(Tickoo, Milowsky et al. 2011). 
There are evidences that suggest the potential prognostic value for some biomarkers in both 
NMIBC and MIBC. One of the most prominent is the angiogenesis marker overexpression 
(VEGF, HIF1A and THBS1). Protein Ras is supposed to promote survival and angiogenesis 
by upregulating the PI3K–AKT–mTOR pathway. Phase II clinical trials are being 
conducted using bevacizumab, a recombinant humanized monoclonal anti-VEGF antibody, 
in combination with gemcitabine/carboplatin chemotherapy in patients with metastatic 
UCB (Hahn, Stadler et al. 2011). Another phase II study is evaluating the same antibody 
with MVAC (methotrexate, vinblastine, adriamycin, and cisplatin) adjuvant chemotherapy 
(Elfiky and Rosenberg 2009). The loss of E-cadherin and gain of N-cadherin have been 
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studied and it was suggested that the latter is associated to UCB recurrence (Muramaki, 
Miyake et al. 2011; Muramaki, Miyake et al. 2012). On the other hand, N-cadherin-
negative in muscle-invasive tumors is associated to poor prognosis (Jager, Becker et al. 
2010). 
Nomograms and scoring systems for UCB 
The International Bladder Cancer Consortium (IBCC) developed a nomogram in which 
there were included more than 9,000 patients from 12 centers to predict the risk of tumor 
reappearance at 5 years after radical cystectomy. Its predictive accuracy was better than 
TNM staging (75% vs. 68%) (Bochner, Kattan et al. 2006). The Bladder cancer Research 
Consortium (BCRC) used a multi-center cohort of 731 patients, who went though radical 
cystectomy, in order to predict tumor reappearance and mortality (due to UCB or any other 
cause) at 2, 5 and 8 years after treatment. They obtained accuracies between 73-78% 
(Karakiewicz, Shariat et al. 2006; Shariat, Karakiewicz et al. 2006). The IBCC and BCRC 
nomograms have been validated in independent cohorts (Zaak, Burger et al. 2010). 
A scoring system and risk tables for NMIBC has been developed by the European 
Organization for Research and Treatment of Cancer (EORTC) using individual data for 
2,596 patients diagnosed with TaT1 tumors with neither a second TUR nor BCG 
maintenance therapy. This system relies on six clinical and pathological factors: T category, 
number of tumors/multiplicity, tumor grade, tumor size, presence of concomitant Tis, and 
prior recurrence rate. The scores are distributed into four categories that assess the 
probability of developing recurrence or progression at 1 and 5 years and define a 
classification system based on low-, intermediate- and high-risk groups (Sylvester, van der 
Meijden et al. 2006). Recently, the Club Urológico Español de Tratamiento Oncológico 
INTRODUCTION: Evolution and prognosis of UCB 
11 
 
(CUETO) has developed another scoring model based on BCG-treated patients. Some 
differences in the risk assessment arise when both methods are compared: The EORC 
tables offer lower risks for recurrence and progression in high-risk patients (Fernandez-
Gomez, Madero et al. 2009). To our knowledge, there is a lack of reliable prognostic 
factors to predict the evolution of Tis tumors. There are only two reports regarding the poor 
prognosis of patients with concurrent Tis and T1 tumors compared with primary/extended 
Tis and the lack of response to the BCG instillation (Chade, Shariat et al. 2010; Babjuk, 
Oosterlinck et al. 2011). The use of molecular prognostic markers is not common yet 
though new tools came up recently such as a nomogram to predict NMIBC recurrence that 
makes use of increased concentration of nuclear matrix protein 22 (NMP22) in urine 
(Lotan, Capitanio et al. 2009).  
The nomograms are believed to provide more predictive accuracy when compared to 
categorical models. Furthermore, they can be easily adapted in the clinical practice. 
Recently, a new generation of nomograms has incorporated biomarkers but we are still 
waiting for the addition of validated ones and new elements as modern imaging data. 
Nowadays, one of the weak points is the lack of standardized data collection methods that 
leads to the important heterogeneity within the variables used in this predictive tool. 
Another important limitation in the assessment of UCB prognosis is the presence of tumor 
heterogeneity that leads to inefficient classification of the patients, clearly seen in the wide 
ranges of recurrence and progression mentioned before, that makes difficult to assign the 
correct treatment to the patient. Molecular diagnosis is routinely used in the clinical 
management of some cancers such as breast, lung and colon. However, its clinical use in 
UCB has been neglected. There is lack of validated biomarkers that may help the clinicians 
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to identify correctly the patients needing and early and aggressive kind of treatment; or the 
other way around, when patients are over-treated. The most studied UCB biomarkers are 
the somatic ones but the huge heterogeneity among them makes difficult to be validated. 
An extensive list of promising biomarkers is presented below. 
 
 Part II. The role of the inherited genetics 
1.2.1. Germline genetic susceptibility markers for UCB 
The assessment of UCB risk factors reveals the predominant effect of cigarette smoking, 
which triples the risk of developing UCB and accounts for 50-75% cases in men and 14–
35% in women (Zeegers, Tan et al. 2000; Samanic, Kogevinas et al. 2006; Wu, Ros et al. 
2008). Environmental risk factors and occupational exposures to potential carcinogens 
explain 10-20% of the cases (Silverman, Hartge et al. 1992; Vineis and Pirastu 1997). 
Other proposed non-genetic exposures still need to be confirmed, among them are 
chlorinated water, halogenated hydrocarbons, low arsenic levels, HPV, pioglitazone, 
nitrates/nitrites and second hand smoke (Kiriluk, Prasad et al. 2012). Genetic susceptibility 
to UCB etiology is suspected as far as just a few of the individuals with environmental 
exposures to potential risk factors will develop the disease. 
Studies performed decades ago determined that UCB does not have a strong familial 
aggregation with no high-penetrance genetic variant being identified till present (Mueller, 
Caporaso et al. 2008). A large twin study conducted in Scandinavian population-based 
cohorts estimated that 31% of the total variance in UCB is explained by genetic factors, 
whereas non-shared environmental factors within the family would explain as much as the 
67% (Lichtenstein, Holm et al. 2000). Studies on first-degree relatives of UCB patients 
reported an almost two-fold increased risk compared with general population (Aben, Witjes 
et al. 2002; Murta-Nascimento, Silverman et al. 2007). These studies present some 
limitation, among them the case-control study design, the reliability of past history of 
cancer in relatives, and the low number of high-risk families studied. As soon as the 
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beginning of 90’s the role of GSTM1-null and NAT2 in UCB susceptibility was described 
(Butler, Lang et al. 1992; Bell, Taylor et al. 1993). However at mid-2000’s the common 
opinion was that “no major gene” model could explain the occurrence for sporadic UCB, 
even after conducting a large scale analysis of 1,193 families (Aben, Baglietto et al. 2006). 
All this background of knowledge suggested a role for common low-penetrance 
susceptibility loci. 
The research of candidate genetic markers for susceptibility has been mainly based on the 
close study of a small number of genetic variants in genes and pathways whose 
involvement in UCB was already suspected (candidate markers). A considerable number of 
studies based on a candidate-approach pattern were conducted to assess the role of low 
penetrance genes (Malats 2008; Wu, Hildebrandt et al. 2009; Netto 2012). The studies 
focused mainly on polymorphisms in carcinogen metabolizing and DNA repair genes 
taking into account the role of confounding factors such as tobacco smoking and the 
occupational exposure to potential carcinogens. An astonishing number of potential genes 
that may play a role in the development of UCB have been reported (Grotenhuis, 
Vermeulen et al. 2010). Nevertheless, the vast majority of these results suggested false-
positive findings due to underpowered studies and a worrying lack of interest or resources 
to reply them in larger and independent series (Wu, Hildebrandt et al. 2009; Grotenhuis, 
Vermeulen et al. 2010). Before GWAS (Genome-Wide Association Studies) were 
undertaken robust findings in susceptibility only existed for variants in NAT2 that result in 
a slow acetylator phenotype and homozygous deletions of GSTM1. Both are involved in 
detoxification of carcinogens, environmental toxins and products of oxidative stress. 
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Hypothesis-driven candidate variant/gene/pathway approach is limited by the current 
knowledge of the disease and the number of biomarkers that are examined. The scarce 
reliable results using this approach made UCB a suitable target to apply a hypothesis-free 
approach based GWAS. This strategy has dramatically increased the number of 
susceptibility loci whose effects have been replicated in large sets of patients. Low-
penetrance susceptibility loci have been identified in four independent studies (Kiemeney, 
Thorlacius et al. 2008; Wu, Ye et al. 2009; Rothman, Garcia-Closas et al. 2010; Garcia-
Closas, Ye et al. 2011). 
 
1.2.2. Germline genetic prognostic markers for UCB 
All the germline-based studies published until now assessed for the prognostic potential of 
genes related to candidate pathways. Some of these studies reported statistically significant 
associations with different UCB outcomes (Grotenhuis, Vermeulen et al. 2010). These are 
the most commonly studied pathways: inflammation, DNA repair, xenobiotic metabolism, 
apoptosis, cell cycle control, cell adhesion, apoptosis, angiogenesis, stem cell biology and 
growth factor. 
The inflammation pathway has been extensively studied searching for markers associated 
with recurrence in NMIBC. It was found that a variant in IL6 is associated with longer 
survival times (Ahirwar, Kesarwani et al. 2008). Another popular set of genes to be 
evaluated for recurrence was the DNA repair pathway. Variants associated with shorter 
survival times in ERCC6 (Gu, Zhao et al. 2005), XRCC1 (Mittal, Singh et al. 2008) and 
ERCC4 (Wang, Wang et al. 2010) were discovered. The cell-cycle control gene TP53 was 
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also found to be associated with recurrence as far as a variant within the gene protects from 
developing this outcome (Horikawa, Nadaoka et al. 2008). Variants in the detoxification 
genes hGPX1 (Zhao, Liang et al. 2005) and NQO1 (Sanyal, Ryk et al. 2007) have been 
proven to be also associated with UCB recurrence, being associated to longer and shorter 
survival times, respectively. Moreover, the angiogenesis pathway was evaluated in high-
grade NMIBC and two encoding variants, associated to high risk to develop recurrence 
were identified in HIF1A (Nadaoka, Horikawa et al. 2008). In addition, the role of cell 
adhesion genes in cancer was evaluated and an encoding variant with protective effect was 
discovered within CDH1 (Lin, Dinney et al. 2006). 
The variant in IL6 found to be associated with UCB recurrence (rs1800795) is also 
significantly associated to NMIBC progression in an independent study (Leibovici, 
Grossman et al. 2005). This outcome was studied in Ta/T1 patients when the cell-cycle 
control genes were considered in two independent studies. A significant risk variant in 
CDKN2A was found in the first study (Leibovici, Grossman et al. 2005). The second one 
provided two variants in CCND1 and HRAS, which were associated to shorter and longer 
progression times (Sanyal, Ryk et al. 2007). A haplotype-based study was conducted for 
the G-protein signaling pathway in NMIBC patients that develop progression and a risk 
haplotype was discovered in the first intron of GNB4 (Riemann, Struwe et al. 2008). 
The studies trying to discover genetic variants associated to UCB mortality have evaluated 
essentially the same pathway candidates mentioned before. The evaluation of the 
inflammation pathway offered two variants in IL6 and TNFA associated to longer and sorter 
survival times, respectively (Leibovici, Grossman et al. 2005). Interestingly, the SNP 
mapping IL6 (rs1800795) has a protective effect when recurrence and survival were 
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evaluated, but the opposite effect for NMIBC progression. Variants in the cell-cycle control 
pathway were also studied in MIBC patients after radical cystectomy and it was found that 
one variant in TP53 is associated to shorter survival times (Horikawa, Nadaoka et al. 2008). 
The low sample sizes and alternative tumoral classification criteria make usual to consider 
altogether the high-grade NMIBC and MIBC cases. A study of that kind looked for 
prognostic variants in the angiogenesis pathway and found two of them in HIF1A 
associated with poor prognosis (Nadaoka, Horikawa et al. 2008). The mentioned haplotype 
in GNB4 associated with progression was found to be also significantly associated with 
shorter survival times (Riemann, Struwe et al. 2008). The role of TGF-beta signaling has 
been studied in advanced stages of the disease. This is a dual-function cytokine that 
promotes tumor suppression and epithelial-mesenchymal transition that yields to cancer 
progression followed by metastasis (Wendt, Allington et al. 2009). In a population of 859 
NMIBC and 246 MIBC patients, two SNPs associated with TGFBR1 were found as 
significantly associated with disease-specific mortality when MIBC were evaluated 
(Castillejo, Rothman et al. 2009). A large-scale candidate gene study based on 400 cancer-
related genes was conducted in a smaller population of 617 patients. The study successfully 
identified a list of SNPs with prognostic value for UCB survival. Longer survival was 
clearly associated with the detoxification gene EPHX1. Variants in several genes were 
found to be associated with shorter survival times: the surface antigen gene CD80, the 
apoptotic gene BCL21, the DNA repair gene ERCC4, the transcription factor GATA3 and 
the inflammatory gene CXCR2 (Andrew, Gui et al. 2009). 
One of the most interesting gene sets to be analyzed is the inflammation pathway. The 
identification of SNPs with prognostic value in this pathway may give us some clues 
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regarding the success of BCG instillation treatments in NMIBC patients. The mentioned 
study of Leibovici et al. identified rs1800795 as a variant that increases the risk of 
recurrence and progression in patients receiving maintenance BCG (Leibovici, Grossman et 
al. 2005). However, the opposite effect is observed in other study (Ahirwar, Kesarwani et 
al. 2008). An additional assessment conducted by the same authors discovered two SNPs in 
IFNG and TNFA associated with shorter and longer times to recurrence, respectively 
(Ahirwar, Mandhani et al. 2009). The DNA repair pathway has been another popular 
approach in order to identify SNPs with prognostic value in patients with BCG instillation. 
Important risk associated with recurrence (HR between 3.07 and 6.80) was observed in 
studies discovering prognostic SNPs in XRCC1 (Mittal, Singh et al. 2008), ERCC2 
(Gangawar, Ahirwar et al. 2010), ERCC6 (Gu, Zhao et al. 2005) and XPC (Gangawar, 
Ahirwar et al. 2010). The last mentioned pathway has been extensively evaluated in MIBC 
patients that received aggressive treatments. Sakano et al. discovered two SNPs mapping 
XRCC1 and ERCC2 associated with good prognosis in T1G3 and MIBC patients that 
received chemoradiotherapy. Shinohara et al. conducted a study looking for prognostic 
variants in the cell-cycle control pathway. They found two SNPs mapping MDAM2 and 
TP53 associated with longer survival times in T1G3·and MIBC chemoradiotherapy-treated 
patients (Shinohara, Sakano et al. 2009). 
As can be observed, the number of candidate-pathways studies is large but most of the 
studies are underpowered due to low sample sizes. This situation and the lack of replication 
in independent patient series may lead to contradictory results. An exception in this 
scenario is the prognostic evaluation of the Sonic hedgehog (Shh) pathway conducted by 
Chen et al. The MD Anderson Cancer Center (MDACC) recruited 419 patients treated with 
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TUR alone and discovered two SNPs associated with recurrence that could be replicated in 
an independent cohort, which consisted of 356 patients, from the Spanish Bladder Cancer 
SBC/EPICURO Study (Chen, Hildebrandt et al. 2010). The mentioned limitations have 
been tried to be solved using hypothesis-free approaches such as the genome-wide studies 
that now are going to be presented. 
 
1.2.3. Fundamentals of genome-wide studies 
Genome-wide approaches to assess the role of genetic biomarkers in human diseases date 
back to the early 80s. The first challenge was to select an appropriate approach to construct 
a linkage map of the human genome. The biotechnological knowledge in those days 
pointed out that restriction fragment length polymorphisms (RFLPs) may be the makers of 
choice (Botstein, White et al. 1980). The study of RFLPs, followed by Southern blot 
assays, exploits the presence of variations in homologous DNA sequences due to sequence 
changes through base deletions, substitutions or insertions that alter the common pattern of 
restriction enzyme recognition sites. Despite of the tediousness of the analysis of these 
biomarkers and the limitation to a few Mendelian diseases, in 1986 the first conclusions of 
this approach came out suggesting that most of the human traits and their associated 
diseases follow complex modes of inheritance (Lander and Botstein 1986). Based on 
previous knowledge on genetic animal models, an approach based on linkage 
disequilibrium (LD) mapping was proposed. The year after, the first genetic linkage map of 
the human genome was reported (Donis-Keller, Green et al. 1987) but the LD mapping in 
general human population was considered as impracticable because of the need of high 
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marker density. Thus, this approach was relegated to the study of populations with high 
founder effect. 
The popularization and improvement of PCR (polymerase chain reaction) techniques in the 
late 80s and early 90s made possible to design PCR-based assays for microsatellite markers 
(Weber and May 1989; Weissenbach, Gyapay et al. 1992). The combination of family-
linkage designs and LD to correct the gene locations became popular in genome-wide 
studies (Kerem, Rommens et al. 1989; Houwen, Baharloo et al. 1994; Puffenberger, 
Kauffman et al. 1994). Genetic susceptibility of many common diseases were studied and 
the hypothesis that few genes could explain the susceptibility to develop the disease was 
slowly rejected due to the evidences of a higher level of complexity based on the small 
effect of many loci acting altogether. This was a dead end because of the low ability to 
detect those loci in family-linkage studies. 
In the mid-90s the efforts were focused on overcoming the mentioned limitations. A new 
approach based on association studies was suggested as a more powerful way to detect 
those common loci with small effects (Risch and Merikangas 1996). The family-linkage 
studies have a clear disadvantage when compared with the association studies because 
common alleles can be present in the family through multiple founders and show unclear 
inheritance patterns. In addition, it is much easier to recruit large numbers of unrelated 
individuals than relatives. On the other hand, the hypothesis of disease-common variant 
became the new cornerstone in genome-wide studies and the possible application of single 
nucleotide polymorphisms (SNPs) was pointed because their abundance, low mutation rate 
and ease of genotyping would made possible the construction of a dense map of 
polymorphisms for LD mapping (Lander 1996; Collins, Guyer et al. 1997). In 1999 the 
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U.K. Welcome Trust philanthropy and a group of the world's leading pharmaceutical 
companies1 founded The SNP Consortium in order to create a LD map of the human 
genome using 300,000 common SNPs (Masood 1999). Early empirical observations 
highlighted a likely variation of the LD patterns across the genome and among different 
ethnical populations all over the world. These issues made necessary the construction of LD 
maps that had variable SNP densities in different locations and take into account the genetic 
background in several representative human populations. In addition, the initial suggested 
number of SNPs proved to be insufficient and it was extended to at least one million. All 
these observations and corrections contributed to the creation of the International HapMap 
Project in 2003 and the development of affordable genotyping platforms that would lead to 
the first GWAS just a few years later (Klein, Zeiss et al. 2005). From then, the number of 
GWAS has been increased every year with a total of 1533 GWAS which have reported 
8699 significant loci have been published up March 2013 (Hindorff, Sethupathy et al. 
2009). 
 
                                                 
1 AP Biotech, AstraZeneca Group PLC, Aventis, Bayer Group AG, Bristol-Myers Squibb Co., F. Hoffmann-
La Roche, Glaxo Wellcome PLC, IBM, Motorola, Novartis AG, Pfizer Inc., Searle, and SmithKline Beecham 
PLC. 
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1.2.4. Genome-wide association studies of UCB 
Three independent UCB GWAS have been conducted at the Radboud University Nijmegen 
Medical Center (The Netherlands) in collaboration with deCODE Genetics (Iceland), the 
MD Anderson Cancer Center (Texas, USA) and the U.S. National Cancer Institute (USA) 
(Kiemeney, Thorlacius et al. 2008; Wu, Ye et al. 2009; Kiemeney, Sulem et al. 2010; 
Rothman, Garcia-Closas et al. 2010; Garcia-Closas, Ye et al. 2011). The published GWAS 
on UCB reveal twelve independent SNPs that modify the susceptibility to the disease. 
The first published GWAS on bladder cancer pointed to an increase on susceptibility due to 
rs710521, which is located in a LD-block that affects TP63. It encodes P63, which 
regulates the cell-cycle arrest and the apoptotic process regarding the progression of UCB 
to the invasive subtype of the disease (Koga, Kawakami et al. 2003). 
All UCB GWAS reported that chromosomal region 8q24 contains several loci that increase 
the cancer susceptibility. Although this region shows a scarce number of genes, several loci 
associated with breast, prostate, ovary, and colorectal cancer have been described to be 
located in this region (Ioannidis, Thomas et al. 2009). It has been hypothesized that they 
may play a role based on the regulation of MYC through epigenetic elements (Ahmadiyeh, 
Pomerantz et al. 2010). This gene encodes c-MYC, which is a nuclear phosphoprotein that 
regulates cell differentiation, apoptosis and growth regulation in regular situations. 
However, when it is deregulated it triggers malignant cell growth. The amplification of 
MYC gene has been observed in up to 30% of patients with UCB (Mahdy, Pan et al. 2001). 
In the same region a SNP (rs2294008) that alters the start codon of PSCA was located on its 
first exon. PSCA is a glycosylphosphatidylinositol-anchored cell surface protein that may 
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play a role in cell proliferation and migration. This gene is expressed at low levels in the 
transitional epithelium of normal bladder but has been shown to be overexpressed in most 
UCBs (Amara, Palapattu et al. 2001). In addition, PSCA may be a predictor for recurrence 
in NMIBC (Elsamman, Fukumori et al. 2006). 
Following up on the results obtained in a GWAS initially performed on basal cell 
carcinoma and then extended to 16 additional cancer types, Rafnar et al. discovered two 
new SNPs (rs2736098 and rs401681) at 5p15.33 that increased the susceptibility for UCB. 
They are located in an LD-block that overlaps with TERT and CLPTM1L. The former 
encodes the catalytic subunit of the telomerase ribonucleoprotein complex, which adds 
telomeric repeat sequences at the end of the chromosomes. The latter is a predicted 
transmembrane protein expressed in a wide range of tissue carcinomas (Rafnar, Sulem et al. 
2009). 
Kiemeney et al. followed their first GWAS and extended it. A new SNP (rs798766) came 
up in 4p16.3 and was validated. This SNP is located in intro 5 of TACC3, which plays a 
role in the regulation of microtubules organization. The most interesting point is its close 
location at 70 kb from FGFR3. Activating mutations in this gene are the most common 
alterations in low-grade, NMIBC. A hypothetical link between these two genes has been 
considered in which germline variation in TACC3 may lead to an overexpression of protein 
levels of FGFR3. It would make possible a higher rate of urothelial proliferation or an 
increased chance of mutation of this gene (Kiemeney, Sulem et al. 2010). 
Rothman et al. performed the next GWAS of UCB in 2010. They identified four new 
susceptibility SNPs and confirmed four loci previously described on 3q28, 4p16.3, 8q24.21 
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and 8q24.3. The strongest signal came out for rs1014971 on 22q13.1 at 25 kb from 
APOBEC3A which plays a role on immunity, by restricting transmission of foreign DNA. 
However, no relation with carcinogenesis is known. The second SNP (rs8102137) resides 
into the genomic region of CCNE1 on 19q12. Its transcript regulates the cell cycle control 
in the G1-S phase and its overexpression has been observed in many tumors, including 
UCB (Meyer 2004; Daly 2010). The third hit (rs11892031) is placed in an intronic UGT1A 
on 2q37.1 and plays a role in detoxification of endo- and xenobiotics through bile or urine 
by glucoronidation (Azzato, Pharoah et al. 2010; Sato, Yamamoto et al. 2011). Several 
gastrointestinal cancers and UCB have shown tissue-specific loss or reduced expression of 
UGTs (Huang, Heist et al. 2009; Penney, Pyne et al. 2010). This study also identified 
rs1495741 as a new locus mapping the well-known susceptibility gene NAT2. 
Two simultaneous GWAS appeared on 2011 describing rs17674580 as a new susceptibility 
locus (Garcia-Closas, Ye et al. 2011; Rafnar, Vermeulen et al. 2011). It is located within 
SLC14A1, which is a urea transporter that regulates cellular osmotic pressure in kidney 
whereas it determines the Kidd blood groups in erythrocytes. In addition, Garcia-Closas et 
al. discovered another SNP perfectly correlated with the mentioned one (rs10853535) and a 
new independent one (rs7238033) located in the same gene. 
The robustness of these susceptibility loci, reinforced with replicated results on different 
populations totaling thousands of individuals, contrast with the underpowered and usually 
non-replicated results in the candidate gene studies. 
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Table 1. UCB susceptibility loci reported after GWAS. 
 
 
Study (year) Cases (n): Controls (n) SNPs (n) Locus Gene region SNP ID Risk allele Allelic OR (95% CI) 
Kimeney et al. (2008) 
Discovery: 1803:34,336 
Replication: 2165:3800 
302,140 
10 
8q24.21 MYC rs9642880 T 1.22 (1.15-1.29) 
Kimeney et al. (2008) 
Discovery: 1803:34,336 
Replication: 2165:3800 
302,140 
10 
3q28 TP63 rs710521 A 1.19 (1.12-1.27) 
Rafnar et al. (2009) 
Discovery: 4147:34,998 
Replication: 3699:9076 
1 
1 
5p15.33 TERT rs2736098 A 1.16 (1.08-1.23) 
Rafnar et al. (2009) 
Discovery: 4147:34,998 
Replication: 3699:9076 
1 
1 
5p15.33 CLPTM1L rs401681 C 1.12 (1.06-1.18) 
Wu et al. (2009) 
Discovery: 969:957 
Replication I: 1713:3871 
Replication II: 3985:34,762 
556,429 
50+10 
1 
8q24.3 PSCA rs2294008 T 1.12 (1.06-1.18) 
Kimeney et al. (2010) 
Discovery: 1899:39,310 
Replication: 2691:5959 
304,073 
12 
4p16.3 TACC3/FGFR3 rs798766 T 1.22 (1.15-1.29) 
Rothman et al. (2010) 
Discovery: 3532:5120 
Replication: 8381:48,275 
589,299 
100 
22q13.1 APOBEC3A rs1014971 C 0.88 (0.85-0.91) 
Rothman et al. (2010) 
Discovery: 3532:5120 
Replication: 8381:48,275 
589,299 
100 
19q12 CCNE1 rs8102137 C 1.13 (1.09-1.17) 
Rothman et al. (2010) 
Discovery: 3532:5120 
Replication: 8381:48,275 
589,299 
100 
2q37.1 UGT1A rs11892031 C 0.84 (0.79-0.89) 
Rothman et al. (2010) 
Discovery: 3532:5120 
Replication: 8381:48,275 
589,299 
100 
8p22 NAT2 rs1495741 G 0.87 (0.83-0.91) 
Garcia-Closas et al. (2011) 
Discovery: 4501:6076 
Replication I: 1382:2201 
555,912 
17 
18q12.3 SLC14A1 rs17674580 T 1.16 (1.10-1.22) 
Garcia-Closas et al. (2011) 
Discovery: 4501:6076 
Replication I: 1382:2201 
555,912 
17 
18q12.3 SLC14A1 rs7238033 C 1.20 (1.13-1.28) 
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1.2.5. Genome-wide prognostic studies in the literature 
The optimism regarding the susceptibility loci obtained using GWAS encouraged new 
analyses to discover novel loci that would assess the prognosis of different diseases. The 
pharmacogenomics pioneered the prognostic studies in the genome-wide field trying to 
identify loci that affect either drug toxicity or drug response (Meyer 2004; Daly 2010). As 
in the susceptibility studies, the candidate-gene approaches were the most common in the 
early days and they were mainly focused on drug metabolism, gene-coding drug targets and 
immune response. The availability of variability data on the human genome and its 
application using GWAS, made possible the assessment of differential treatment responses 
using genetic variations. The homogeneity of the patients and the expected large effects 
were considered as a basis to proceed with small sample sizes, thus one of the main 
weaknesses of the GWAS would be dodged. Because of this, a number of studies with 
moderate sample size were performed since 2007. However, problems usually arise when 
the drug responses cannot be quantified, when assessing an independent study to replicate 
the findings or when the effects are smaller that assumed. Despite of this, a bunch of 
pharmacogenomic GWAS have been published with statistically significant results and try 
to find their way into the clinical practice (Daly 2010; Pirmohamed 2011). Other studies 
tried to establish a link between the susceptibility and the prognostic value of replicated 
SNPs in GWAS. However, even in large studies that link remains unconfirmed (Fasching, 
Pharoah et al. 2012). 
At the end of 2012 the number of genome-wide prognostic studies (GWPS) is almost 
anecdotic. Two recent reviews have mentioned the results obtained in four kinds of cancer 
(Gu and Wu 2011; Chang, Gu et al. 2012). An exhaustive search in Pubmed makes possible 
INTRODUCTION. Genome-wide prognostic studies in the literature 
27 
 
to find at least five more studies2. In short, we are aware of nine studies assessing the 
prognosis of non-small-cell lung cancer (NSCLC) (Huang, Heist et al. 2009; Wu, Xu et al. 
2010; Sato, Yamamoto et al. 2011; Wu, Ye et al. 2011), breast cancer (Meyer 2004), 
prostate cancer (Penney, Pyne et al. 2010), pancreatic cancer (Innocenti, Owzar et al. 
2012), chronic lymphocytic leukemia (CLL) (Wade, Di Bernardo et al. 2011) and acute 
lymphoblastic leukemia (ALL) (Yang, Cheng et al. 2012). Prostate and breast cancer 
studies reported no SNP association at the genome-wide level after the replication phase. 
Nevertheless, the studies of NSCLC claim for genuine loci associated with overall survival 
but the borderline significance of most SNPs may suggest a critical evaluation of the 
results. The same claiming is done in the pancreatic cancer study for two SNPs that reach 
the genome-wide threshold of significance. However, the lack of replication in independent 
studies makes difficult to assume it as a genuine result. The study of ALL identifies an 
astonishing number of loci with prognostic value. However, the analysis design of this 
study based on an iterative “discovery vs replication” screening without any independent 
cohort to validate, may lead to an important amount of false positives. No genome-wide 
study designed to assess prognosis in UCB has been published until now. 
The main limitations of these studies lay on the need of large cohorts with similar clinical 
characteristics and exhaustive patient information. Moreover, the common germ line 
variants with prognostic value may depend on the tumor subtype, the disease stage or the 
applied treatment. The lack of well-annotated patient data usually means small sample 
sizes, shortage of available information regarding the possible confounders and survival 
analyses whose only outcome is overall survival (Gu and Wu 2011). 
                                                 
2 Pubmed Search: (genome-wide[Title/Abstract]) AND (cancer[Title/Abstract]) AND (cox[Title/Abstract] 
OR hazard[Title/Abstract]) AND (survival[Title/Abstract]) 
INTRODUCTION. Genome-wide prognostic studies in the literature 
28 
 
Table 2. Published genome-wide studies based on genetic variants assessing for prognosis in several cancers. 
 
 
Study (year) Cancer Cases (N) SNPs (n) Loci* (N) MoI Outcomes 
Huang et al. (2009) NSC lung ǂ 
Discovery: 100 
Replication: 89 
74,666 
50 
5 Additive 
Overall 
survival 
Azzato et al. (2010) Breast 
Discovery: 1145 
Replication: 4335 
262,264 
10 
- Additive 
Overall 
survival 
Penney et al. (2010) Prostate 
Discovery: 637 
Replication: 655 
419,613 
68 
- Additive 
Overall 
survival 
Wu et al. (2010) NSC lung ǂ 
Discovery: 245 
Replication: 305 
265,996 
26 
2 Additive 
Overall 
survival 
Sato et al. (2011) NSC lung ǂ 
Discovery: 105 
Replication: - 
109,365 
- 
3 
Dominant 
Recessive 
Codominant 
Overall 
survival 
Wade et al. (2011) CLL † 
Discovery: 356 
Replication: 380 
346,831 
10 
3 Additive PFS 
Wu et al. (2011) NSC lung ǂ 
Discovery: 327 
Replication I: 315 
Replication II: 420 
307,260 
60 
2 
1 
Dominant 
Recessive 
Additive 
Overall 
survival 
Innocenti et al. (2012) Pancreatic 
Discovery: 294 
Replication: - 
330,690 
- 
2 Additive 
Overall 
survival 
Yang et al. (2012) ALL ‡ 
Discovery: 2532 
Replication: 2532+2532 
444,044 
NA 
134 Additive Relapse 
* Number of SNPs claimed to be statistically significant after multiple comparison adjustment. 
ǂ Non-small cell lung cancer. 
† Chronic lymphocytic leukemia. 
‡ Acute lymphoblastic leukemia. 
MoI, mode of inheritance; PFS, progression-free survival. 
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1.2.6. Gene set analysis in post-genome-wide results 
Over the last decade, the performed GWAS have successfully identified many genetic 
variants associated their susceptibility (Hindorff, Sethupathy et al. 2009). However, the 
individual or even the combined effects of these variants explain just a small proportion of 
the risk associated to the disease (Manolio, Collins et al. 2009; Eichler, Flint et al. 2010). 
The sources of the “missing heritability” may be related (among others such as gene-gene 
interactions, gene-environment interactions, CNVs and rare variants) to the basic design of 
the GWAS: testing for the association between the disease phenotype and each SNP 
individually, even when small effects are expected (Hirschhorn and Daly 2005). It is also 
related with the fact that a large number of tests are performed in the GWAS and genuine, 
but weak, associations are missed after multiple comparison adjustments. Some proposals 
based on testing the joined effects of the SNPs have been suggested to overcome this 
limitation. Probably the most evident one is assessing for epistatic effects, but the number 
of SNP combinations in a genome-wide scenario and its mandatory adjustment for multiple 
comparisons makes the detection of real associations even more difficult. On the other 
hand, gene set analysis (GSA) analyses techniques applied in the assessment of gene-
transcription studies are considered. The aim of the GSA is to increase the power by 
combining the signals from multiple SNPs that can hardly explain any risk on susceptibility 
or prognosis role independently, but explainable when grouped in biologically congruous 
groups (e.g. biological pathways, signaling pathways or protein-protein interaction 
networks). 
The GSA workflow starts taking the SNP genotypes or its p-values obtained after a GWAS 
(or GWPS), assigning this information to the closest gene and running the statistical GSA 
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test itself. There are two families of GSA tests: the competitive tests, which compare 
disease associations for the genes in a gene set with the rest of the genes of the genome; and 
self-contained tests, which test the potential associations for the genes in a particular gene 
set. There is a great number of proposed algorithms for GSA but the statistical techniques 
underlying the most of the methods can be numbered in just a few: direct/modified Fisher’s 
exact test, direct/modified Kolmogorov-Smirnov test, methods based on the Z-statistic or 
Z-score, the adaptive rank truncated product statistic, U-statistics and the SNP ratio test 
(Menashe, Maeder et al. 2010; Wang, Li et al. 2010; Fridley and Biernacka 2011; Wang, 
Jia et al. 2011). 
Post-GWAS analyses using different GSA methods have been performed in a wide range of 
diseases that cover from several cancers to mental diseases (Holmans, Green et al. 2009; 
Medina, Montaner et al. 2009; Menashe, Maeder et al. 2010; Zhang, Cui et al. 2010). The 
application of these techniques to UCB is still in a preliminary phase in the assessment of 
susceptibility. Two gene set methodologies have been successfully applied in the 
assessment of the risk of developing UCB and show alterations in pathways regarding 
metabolic detoxification, clathrin-mediated vesicles and mitosis (Menashe, Figueroa et al. 
2012). To our knowledge, no GSA has been conducted regarding prognosis. 
 
 
 Chapter 2: Hypothesis and objectives 
General hypothesis: 
Common germline variants are associated with clinical outcomes in UCB. 
General objective: 
To assess the role of genetic susceptibility in UCB evolution. 
 
The objective will be accomplished through an agnostic GWPS and additional analyses 
based on the obtained results. In this kind of studies no SNP is thought, a priori, to have a 
higher probability of being associated with the evaluated clinical outcome than any other 
SNP. 
 
Specific objectives: 
1. To identify the independent SNPs associated with UCB clinical outcomes: 
1.1. SNPs independently associated with tumor recurrence, progression and relapse in 
NMIBC. 
1.2. SNPs independently associated with tumor progression, UCB-specific mortality, 
and overall survival in MIBC. 
2. To identify the biological pathways associated with UCB outcomes. 
3. To identify SNP-SNP interactions associated with UCB outcomes. 
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 Chapter 3: Materials and Methods 
A. Population and clinical & follow-up information 
This work has considered different sources of UCB patients. The main sources of 
information are the Spanish Bladder Cancer (SBC)/EPICURO Study and the Texas Bladder 
Cancer (TXBC) Study. Both studies have are involved in the International Consortium of 
Bladder Cancer. They have recruited 1,150 and 1,542 patients with DNA samples, 
respectively. The use of the other sources of patients in validation stages is based upon 
collaborations that differ according to the group who leads the study. While the 
SBC/EPICURO Study leaded the inclusion of 5 retrospective cohorts in Europe and 
Canada (N=918), the TXBC provided a new prospective cohort of cases recruited at the 
same center (N=366). While we had full access to the information collected in the 
retrospective cohorts, only descriptive information and SNP prognostic estimates were 
shared between the two main studies. The full access to the retrospective cohorts’ 
information made possible to perform pooled analyses. On the other hand, the restricted 
information shared with the TXBC Study only made possible to proceed with meta-
analyses. Following is a description of each of the series. 
A.1. Spanish Bladder Cancer (SBC)/EPICURO Study 
Population 
The Spanish Bladder Cancer (SBC)/EPICURO Study is a multicenter hospital-based case-
control study which was conducted between 1997 and 2001. In order to study the prognosis 
of the disease, a nested cohort with the UCB patients (cases, N=1,356) within the 
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mentioned study was considered and followed-up at a yearly basis for more than 10 years. 
All incident UCB patients were treated in 18 hospitals located in 5 Spanish regions 
(Alicante, Asturias, Barcelona, Vallès Occidental/Bages and Tenerife). The participating 
hospitals were general or University-affiliated centers; none of them was a referral hospital 
specialized in urologic oncology. All patients gave written informed consent. The study 
was approved by the local Institutional Ethics Committees of each participating hospital 
and the Institutional Review Boards of the Institut Municipal d’Investigació Mèdica 
(IMIM) and the U.S. National Cancer Institute (NCI). 
Information 
All tumor-containing paraffin-embedded blocks produced at the time of patient's initial 
diagnosis were retrieved from the Department of Pathology of the participating hospitals 
and sent to the Coordinating Center (IMIM). From each block, a section was obtained and 
stained with H&E (hematoxylin and eosin). Diagnostic slides from each case were 
reviewed by a panel of expert study pathologists to confirm diagnosis and ensure 
uniformity of classification criteria across all cases. Tumors were staged and graded 
according to the criteria of the TNM classification and the WHO-ISUP (AJCC 1997; 
Mostofi, Davis et al. 1999). A panel of expert pathologists reviewed all paraffin-embedded 
slides of tumoral blocks in order to avoid heterogeneous classification based on the 
pathological assessment of tumors. They applied the same and most up-dated classification 
available at that time (WHO-ISUP 1999). Thereafter, information on stage, grade, and 
morphology of the tumor was correlated with that from the hospitals and the experts solved 
inconsistencies. Primary tumors from 68 (5.3%) cases could not been evaluated by the 
experts because, for a variety of reasons, it was not possible to obtain sufficient material for 
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pathological evaluation of tumors. As of the rest, 995 were finally classified as NMIBC and 
283 as muscle invasive bladder cancer. Blood and/or saliva were collected in order to 
perform the genotyping. The details in this regard are explained below. 
Clinical data gathering has been described in detail elsewhere (Puente, Malats et al. 2003). 
Briefly, information related to diagnostic procedures, stage, tumor characteristics, and first 
treatment was collected from medical records through reviews conducted by trained 
personnel using a structured questionnaire. Detailed macro- and microscopical tumor 
features were collected, as recorded in the hospital files, including number and location of 
masses, size, gross tumor appearance, mucosal appearance, tumor growth pattern, stage, 
grade, and histology of the largest mass. There was no attempt to treat patients uniformly at 
the various participating centers. Treatment management was categorized according to 
conventional criteria: transurethral resection (TUR) “alone”, TUR+Bacillus Calmette 
Guerin (BCG), TUR+chemotherapy, TUR+BCG+chemotherapy, radical cystectomy, 
radiotherapy, and systemic chemotherapy. Treatment strategies different from those 
specified above were grouped under the “other” category. 
The follow-up of the cases was conducted for more than 10 years. The information related 
to tumor recurrence and/or progression, change of management, and patient’s vital status 
was collected annually from hospital records - using an ad hoc designed questionnaire - and 
through direct telephone interviews. Follow-up rate for NMIBC was 94%. Up to July 2007, 
mean follow-up period for the 995 patients with NMIBC who were “free of disease” was 
82.7 months, ranging from 2.5 to 117.6 months, with a total of 13 (1.3%) deaths due to 
UCB recorded. According to hospital definition, 385 (38.7%) patients suffered at least 1 
recurrence/progression of their tumors. MIBC patients were also followed up to July 2007; 
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mean follow-up period for the 235 patients with MIBC who were “free of disease” was 
83.2 months, ranging from 50 to 105 months, with a total of 108 (46%) deaths due to UCB. 
At the end, 161 (68.5%) patients died due to UCB or any other cause. 
Finally, we proceeded with 1,071 patients (N=836 NMIBC and N=235 MIBC) that had 
completed information for follow-up and genetic data. The relevant clinical and 
pathological variables for further analysis are shown in Supplementary Table 1-3. 
A.2. Texas Bladder Cancer (TXBC) Study 
Population 
All cases were newly diagnosed, histologically confirmed, and previously untreated 
incident UCB cases recruited from The University of Texas MDACC and the Scott 
Department of Urology, Baylor College of Medicine from 1999 until present as previously 
described (Wu, Ye et al. 2009). Written informed consent was obtained from each 
participant before collection of epidemiological and clinical data and blood samples by 
trained MDACC staff interviewers. The response rate for cases was 92%. After diagnosis, 
all NMIBC patients were treated with TUR and followed with periodic cystoscopic 
examinations and intravesical treatment. This treatment consisted of either induction BCG 
(6 weekly instillations) or induction plus maintenance BCG according to Southwest 
Oncology Group (SOWG) protocol (induction BCG followed by instillations at 3, 6, and 
then every 6 months for 3 years). Approximately 90% of the patients in TXBC study were 
Caucasians. To limit the confounding effect of population substructure, we included only 
Caucasians in this study. The study protocols were approved by the Institutional Review 
Boards of MDACC and Baylor College of Medicine. 
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Information 
Trained MDACC interviewers interviewed all cases of the TXBC study. Comprehensive 
epidemiological data on demographics, family history of cancer, and smoking status were 
collected. Blood sample was collected for DNA extraction at the end of the interview. 
Never smokers were patients who never smoked or had smoked less than 100 cigarettes in 
his or her lifetime. Ever smokers were patients who had smoked at least 100 cigarettes in 
their lifetimes. Former smokers were patients who had quit smoking at least 1 year prior to 
diagnosis. Current smokers were patients who were currently smoking or who had stopped 
<1 year prior to being diagnosed. 
The clinical data for TXBC study was collected by trained MDACC chart reviewers on date 
of diagnosis, tumor size, tumor grade, tumor stage, tumor location, presence of Tis, number 
of tumor foci at diagnosis, intravesical therapy, dates of recurrence and progression events, 
systemic chemotherapy, radical cystectomy, pathologic findings at cystectomy, and 
mortality. The relevant clinical and pathological variables for further analysis are shown in 
Supplementary Table 1-3. All patients were followed-up with periodic cystoscopic 
examinations. 
The TXBC study was divided in two subgroups. The data from the first one, known as 
TXBC-1, was used in the Discovery phase of the analyses. The second subgroup, known as 
TXBC-2, was used as a validation cohort in the prognostic assessment for independent 
SNPs performed in the NMIBC patients. 
The validation set of TXBC (TXBC-2) consisted of 366 histologically confirmed NMIBC 
cases. These UCB cases were also obtained from MDACC, including additional cases from 
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our ongoing case-control study. We also included cases that were newly diagnosed 
(diagnosed within 1 year before referral to MDACC) and excluded from the ongoing case-
control study because of previous treatment or recruited prior to the ongoing case-control 
study. The demographic and clinical data was collected as described above. The relevant 
clinical and pathological variables are displayed in and Supplementary Table 2. 
A.3. International Series for NMIBC 
Population 
NMIBC cases from 5 international retrospective studies conducted in the Princess Margaret 
Hospital, Toronto, Canada; Aarhus University Hospital, Denmark; Hôpital Mondor, 
Créteil, France; Erasmus MC, Rotterdam; and the Human Genetics Foundation (HuGeF), 
Turin, Italy, were considered. Cases were recruited in each study according to different 
criteria. Only patients with available demographic and clinical data were included and an 
extensive review was performed to ensure the consistency of variables used in the analysis. 
Characteristics of each population are displayed in Supplementary Table 2. Heterogeneity 
reflects the differences through with patients are managed and treated in each centre. 
Information 
The data from the international series came from hospital-based studies. These studies have 
been conducted during long periods of time (from ~30 to 15 years of follow-up). The 
heterogeneity among them is very important because the main objectives to be 
accomplished for each one were different at the time of the design. 
The cohorts recruited in Hôpital Mondor and HuGeF included only men, in contrast with 
the other series that included ~25% of women. The number of free-of-disease patients in 
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each center is also very different, suggesting heterogeneous kinds of patients. While the 
Prince Margaret Hospital in Toronto has 15% of free-of-disease patient, the other centers 
only have between 33 and 6.4% of these patients. When we explored the number and the 
kind of outcomes in each center, we observed a very low number of relapses in HuGeF, 
compared with all the other centers. This situation is remarkable because the tumoral 
pathology of these patients is not very different from the other centers. Regarding this 
point, we observed that the stage/grade and size and multiplicity of the tumors collected in 
Hôpital Mondor where usually higher than the ones collected in the other centers, 
suggesting a greater level of malignancy. 
 
B. Genotyping 
B.1. Genotyping in SBC/EPICURO GWAS Study 
Blood was fractioned into serum, plasma, leukocytes, lymphocytes and erythrocytes. 
Leukocyte and saliva DNA were obtained as described elsewhere (Garcia-Closas, Malats et 
al. 2005). The initial genotype analysis was done on DNA derived from 2,191 blood 
samples (1,149 cases and 1,042 controls) and 185 buccal samples (42 cases and 143 
controls). Genotyping was performed at the Core Genotyping Facility, National Cancer 
Institute, USA, using the Illumina HumanHap 1M probe BeadChip containing 1,072,820 
markers (Rothman, Garcia-Closas et al. 2010). 
Pre-genotyping quality control measures selected 1,149 blood samples and 42 buccal 
samples for genotyping. Completion rates >98% per individual study were required to 
estimate genotype clusters. SNP assays with locus call rates lower than 95% were excluded. 
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There were 178 duplicated samples (127 duplicates, 11 triplets and 3 quads) that yielded a 
concordance rate of 94%. The final delivered dataset (from both initial and repeat 
genotyping) included 2,424 results for 2,231 distinct individuals; 2,121 derived from blood 
samples, 105 from buccal samples and 5 from both blood and buccal samples. 
We established the significance level threshold at p <1×10
-4 
for a departure from Hardy-
Weinberg equilibrium among controls to excluded SNPs for the prognostic study [R-
package: HardyWeinberg (Weir 1996; Wigginton, Cutler et al. 2005)]. After quality 
control metrics, 998,347 SNPs were available for analysis in a 1,071-patient cohort (N=836 
NMIBC and N=235 MIBC). 
B.2. Genotyping in TXBC GWAS Study 
Genomic DNA was extracted from peripheral blood lymphocytes by proteinase K 
digestion, followed by isopropanol extraction and ethanol precipitation and stored at −80°C 
(Wu, Gu et al. 2006). Genotyping for the TXBC data set was generated using the Illumina 
HumanHap610 chip containing 620,901 markers at MDACC (Wu, Ye et al. 2009). Detailed 
quality control measures were described previously (Wu, Ye et al. 2009). In short, all the 
subjects included in this study were Caucasians and had call rate >95%. Duplicated 
samples and population outliers were removed from the analysis. SNP call rate >95% 
criterion was applied. We further removed markers that deviated from Hardy-Weinberg 
equilibrium in the controls at p <1×10
-4
. In the final analysis, we included 542,953 
autosomal and mitochondrial SNPs for 496 NMIBC and 397 MIBC cases that passed strict 
quality control measures for the SNPs and subjects. 
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B.3. Genotyping in the Validation Phase of NMIBC 
At MDACC, genotyping of the 57 SNPs identified by the discovery phase meta-analysis 
was conducted using TaqMan

 SNP Genotyping assays (Applied Biosystems, Foster City, 
CA) in 366 patients. At CNIO, genotyping of the 47 SNPs for the international series was 
conducted using Taqman SNP Genotyping assays (Applied Biosystems, Foster City, CA), 
genotyping of 9 SNPs was conducted using Fluidigm Dynamic Array in 918 patients. The 
SNP rs4946483 failed both Taqman

 and Fluidigm assay. 
 
C. Endpoints of interest 
After primary tumor diagnosis and treatment, patients may develop new bladder neoplasms 
(called tumor relapses) that can be considered as recurrences or progressions, and they may 
die because of cancer or other causes. For primary diagnosed NMIBC patients, we defined 
recurrence as the reappearance of a NMIBC following a previous negative follow-up 
cytoscopy while progression was defined as the development of a MIBC or metastatic 
disease. As indicated before, tumors relapse indicated the development of either recurrence 
or progression, whichever came first, after treatment of primary tumor and a period of 
improvement, corresponding to disease-free survival. For primary diagnosed MIBC 
patients, progression was defined as the reappearance of an advanced MIBC after a 
negative follow-up medical evaluation, this corresponding to progression-free survival; BC-
specific mortality, when the event of death is caused exclusively by UCB, this 
corresponding to disease-free survival; and overall survival indicated the death by any 
cause. 
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Event-free and disease-free survival time for each endpoint was calculated from date of 
clinical intervention/diagnosis to the date of endpoint event or the date of last follow-up. In 
the SBC/EPICURO Study, it was assumed that any tumor event occurred between the date 
of the last medical visit in which the patient was free-of-disease and the date the event was 
detected. Hence, the intermediate point as interval censoring was used and the total time of 
follow-up from first clinical intervention was computed. Patients who did not present any 
event until the end of study, those lost to follow-up and those who died from other causes 
were censored either at last medical visit or at death. 
At the end of follow-up (7/1/2007) we observed that 44% of the patients with NMIBC and 
25% of patients with MIBC did not show any other event with a mean follow-up time of 
117.6 and 83.2 months, respectively. The considered kinds of events were described before 
and their associated survival times were calculated from date of diagnosis to date of 
endpoint event or date of last follow-up. 
The most intuitive model of UCB evolution would follow a linear sequence from the 
diagnosis of the primary tumor, to possible recurrence/s, followed by possible progression/s 
that may lead to death due to UCB. However, this hypothetical model was not always 
observed in our long-term follow-up where there are patients with NMIBC that recurred 
several times but did not progress and a small group of subjects that progressed so fast that 
no recurrence was reported. In this scenario the mean time to develop recurrences or 
progressions is rather similar, and it may reflect a non-described process of competing risk 
between these events. Patients free-of-disease at the end of study, those lost-to-follow-up, 
and those who died from other causes were censored either at last medical visit or at death. 
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Several survival times have been defined in order to characterize the kind of event. The 
time unit for these survival times was set to months: 
 Recurrence Free Survival (TRFS) for NMIBC: Time from primary diagnosis to first 
recurrence form. 
 Progression Free Survival (TPFS) for NMIBC: Time from primary diagnosis to first 
progression regardless of whether the tumor recurred before or not. 
 Disease/Event Free Survival (TEFS) for NMIBC: Time from primary diagnosis to any 
kind of event. 
 Progression Free Survival (TPFS) for MIBC: Time from primary diagnosis to first 
progression. 
 Disease Specific Survival (TDSS) for MIBC: Time from primary diagnosis to UCB 
death. 
 Overall Survival (TOS) for MIBC: Time from primary diagnosis to death due to any 
cause. 
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3.1. Independent SNPs associated with UCB clinical outcomes 
3.1.1. Independent SNPs associated with NMIBC clinical outcomes 
This analysis followed a design with a Discovery and a Replication phase. In the Discovery 
phase two independent large prospective cohorts of patients with NMIBC with long follow-
up were included: the Texas Bladder Cancer (TXBC-1) and the SBC/EPICURO studies. 
Both studies prospectively followed patients up yearly and applied the same definitions as 
NMIBC patient outcomes.  
Independent SNP analyses were conducted for each study using four genetic modes of 
inheritance (MoI: dominant, recessive, codominant, and additive) and unadjusted and 
adjusted Cox proportional hazard regression analysis (Cox 1972; Therneau and Grambsch 
2000). Hazard ratios (HR), 95% confidence intervals (95% CI), and p-values were 
estimated. Distinct sets of adjusting covariates were used in TXBC-1, TXCB-2, 
SBC/EPICURO, partly due to the availability of these variables. We performed a Discovery 
meta-analysis to cross-validate results between TXBC-1 and SBC/EPICURO. Risk 
estimates (HRma, 95% CI, and p-values) were computed considering individual HR and 
their standard errors for 3,600 SNP models (150 most significant SNPs from each outcome 
x unadjusted/adjusted model x 4 MoI x 2 series) (Cooper and Hedges 1994). It yielded a 
number of 6,059 SNPs for the final combined SNP list for the cross-validation. The results 
of fixed or random effect models were reported as appropriate and displayed jointly with 
the coefficient of heterogeneity (I
2
). A threshold of I
2 
<30% was taken into account for the 
final selection of SNPs. Those with the most significant meta-results were subsequently 
selected for Validation. 
MATERIAL AND METHODS. Independent SNPs associated with UCB clinical outcomes 
45 
 
In the Validation phase, a pooled analysis with the series from PMH, AUH, HM, EMC, and 
HuGeF was conducted using Cox regression with Firth's penalized likelihood for the 
outcomes of interest (Heinze and Dunkler 2008) and a validation meta-analysis was 
performed jointly with the TXBC-2. Finally, a combined meta-analysis resulting from both 
Discovery and Validation data was conducted to summarize all HR and p-values. The 
analysis workflow is summarized below. 
The prognostic value for the resulting SNPs was displayed through Kaplan-Meier product 
limit method for each study (Kaplan and Meier 1958). The differences between categories 
of each variable were assessed using the log-rank test (Therneau and Grambsch 2000). 
Median follow-up time was calculated using reverse Kaplan-Meier estimator.  
The concordance statistic (or c-statistic) was computed for each outcome without and with 
the SNPs for each participating cohort. In this way we can know how well the patients are 
classified in a binary prediction problem. The mentioned statistic is the most usual way to 
establish the discriminative ability of generalized linear regression models. When the 
outcome can be defined as binary variable, the c-statistic is equivalent to the area under the 
receiver operating characteristic (ROC) curve. In this kind of representation the sensitivity 
(true positive rate) is plotted against 1 – specificity (false positive rate). In all the described 
series we obtained the c-statistic through an initial step in which the Somers’ D statistic 
with censored data is calculated (Harell 2001). The c-statistic overestimation in each model 
was controlled using 500 bootstrap samples in a process using the rms R-package. 
Analyses done in TXBC Study applied STATA software (version 10.1, STATA 
Corporation, College Station, TX) and data manipulations were done using the PLINK 
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(version 1.03) and R (version 2.15.0). In the SBC/EPICURO Study, analysis was done 
using R (version 2.11). 
 
Figure 3. Genome-wide prognostic study analysis flowchart. 
3.1.2. Independent SNPs associated with MIBC clinical outcomes 
Similar to NMIBC, in the Discovery phase two independent large prospective cohorts of 
patients with MIBC with long follow-ups were included: the Texas Bladder Cancer 
(TXBC-1) and the SBC/EPICURO studies. 
The statistical analyses were conducted using the same strategy described above for 
NMIBC patients. Overall, 4,412 SNPs remained in the final combined SNP list for the 
cross-validation in the Discovery phase. The results of fixed or random effect models were 
reported as appropriate and displayed jointly with the coefficient of heterogeneity (I
2
). A 
threshold of I
2 
<30% was taken into account for the final selection of SNPs. Finally 108 
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SNPs with the most significant meta-results were subsequently selected for a further the 
ongoing Validation phase that will be finished in the near future. 
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3.2. Biological pathways associated with UCB clinical outcomes 
To detect the genetic pathways playing a role in the prognostic of UCB, we used the 
individual SNP results obtained from the SBC/EPICURO Study Cox regression analysis. 
The analyses were conducted for those NMIBC patients whose outcome was progression or 
recurrence; and the MIBC patients that shown progression or death due to UCB. We 
assigned to each SNP the minimal p-value among the 4 MoI obtained in the multivariate 
survival analysis performed in the SBC/EPICURO Study. Then, we selected a number of 
gene set analysis (GSA) methods that provided us a list of biological pathways significantly 
associated to the UCB outcomes were based on competitive tests. These tests take the list of 
SNPs and their associated p-values obtained in the GWPS and assess for a possible 
overrepresentation of significantly associated SNPs in the GWPS in the predefined gene 
sets (GS). 
 
Figure 4. Gene set analysis flowchart. 
The GSA methods are based on the comparison of the significantly associated SNPs’ 
frequencies in a GS against the ones not present in the set. Several statistical algorithms 
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were studied: ALIGATOR (Holmans, Green et al. 2009) relying on a modified Fisher’s 
exact test, GeSBAP (Medina, Montaner et al. 2009) using a segmentation test based on 
Fisher’s (Al-Shahrour, Arbiza et al. 2007), GSA-SNP (Nam, Kim et al. 2010) based on the 
Z-statistic method, and i-Gsea4gwas (Zhang, Cui et al. 2010) that uses a weighted 
Kolmogorov-Smirnov running-test statistic (Fridley and Biernacka 2011). We also 
evaluated ICSNPathway (Zhang, Chang et al. 2011) because as far as we know, this is the 
only available method available to identify causal SNPs, genes and pathways in the 
genome-wide context. In the last three methods the GS information regarding Gene 
Ontology (GO) and Canonical Pathways (CP) was collected from MSigDB v3.0 
(Subramanian, Tamayo et al. 2005). As a result, 1,454 GS in GO and 880 GS in CP were 
initially considered. In order to reduce the possible multiple test effect and to avoid 
uninformative narrow or wide broad GS, only those with 20-200 genes were used (Wang, 
Li et al. 2007). Applying this criterion 749 GO and 542 CP GS were finally selected. On 
the other hand, ALIGATOR used the predefined 6,723 GS, containing at least three genes 
in each category. 
The complete list of SNPs and two linkage-disequilibrium-pruned (LD-pruned) SNP sets 
with stringent r
2
 thresholds at 0.2 and 0.5 were analyzed. The pruning process was carried 
out taking groups of 1,000 consecutive SNPs in the genome and clustered applying the r
2
 
threshold of interest. In each cluster the most significant SNPs were selected. In the SNP-
gene mapping we considered a scenario in which only the SNPs lying within a gene were 
kept and another one where those SNPs lying within 20 kb (5’ or 3’) of a gene were 
considered. The second criterion is based on the analysis of the location and the role of the 
eQTLs in the genome (Veyrieras, Kudaravalli et al. 2008). 
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ALIGATOR 
The analysis was performed against GO for each of the outcomes. This method only maps 
the most significant SNPs into genes and tests for the putative enrichment within the 
predefined GO categories. In case that a SNP could be mapped within different genes, both 
would be included in the analysis. As far as this method only considers the most significant 
SNPs and the significance threshold is somewhat subjective a priori, three different 
thresholds were studied with p-values lower than 0.01, 0.001 and 0.0001. A fast screening 
analysis was performed with 5,000 gene lists resampling. Then, only the outcomes that 
showed significant overrepresented GO categories were reanalyzed and resampled with 
50,000 gene lists. 
GeSBAP 
Three ranked lists of SNPs and their p-values were supplied for the mentioned LD 
thresholds. In each case, the algorithm only selects the SNPs that map into genes or closer 
than 5 kb to the nearest gene and selects the one with the lowest p-value as a proxy of the 
gene. An additional mapping process for these genes and the GS with 20-200 genes and 3-9 
GO levels is carried out. Finally, a segmentation test based on sequential application of a 
Fisher’s exact test is done in order to find an asymmetric distribution towards the extremes 
of the ranked list of genes generated in the intermediate step of this method (Al-Shahrour, 
Arbiza et al. 2007). The results are corrected by false discovery rate (FDR) (Benjamini and 
Hochberg 1995). 
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GSA-SNP 
We have used an option based on the Z-statistic method. As far as it is based on PAGE 
(Parametric Analysis of Gene Set Enrichment), it uses the normal distribution to assess the 
statistical significance (Kim and Volsky 2005). Then, the p-values obtained for each GS are 
corrected using FDR. Only those GS with 20-200 genes were used in the analysis. In 
addition we used a three-step strategy analysis in order to maximize the false positives 
results removal. In the first step the SNP-gene mapping was performed considering the 
SNP with the second best p-value as the proxy of its gene; then the analysis was done. In 
the second step, the SNP with the best p-value acts as a proxy of the closest gene and the 
analysis is performed again. In the last step we kept only those common results in the 
previous two steps. 
i-Gsea4Gwas 
This method is based on a variation of the Gene Set Enrichment Analysis (GSEA) adapted 
to the GWA studies of complex diseases (Wang, Li et al. 2007). In the first step, all the 
genes were ranked based on their significance. The second step tests whether the genes in a 
GS showed a higher significant rank when compared with the rest of the supplied genes. To 
reduce the possible multiple test effect and to avoid uninformative narrow or wide broad 
gene lists, only those GS with 20-200 genes were used (Wang, Li et al. 2007). The 
improved version of the method (i-GSEA) uses SNP label permutation and introduces the 
concept of significance proportion based enrichment score (SPES). The multiple test 
correction is achieved by applying FDR. The output interface for i-Gsea4Gwas offers the 
list of enriched GS whose FDR is lower than 0.25. The gene sets with FDR <0.05 are 
assumed as highly significant. 
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ICSNPathway 
In the first stage of this method we selected the candidate causal SNPs by LD analysis of 
the most significant SNPs of the genome-wide analysis. We run the analyses using the 
default LD parameters for this method (r
2
 = 0.8 in the HapMap CEU population) and two 
cut-offs for the most significant p-values at 10
-5
 and 10
-4
. In the second stage the GS for the 
candidate causal SNPs are annotated by using the i-GSEA algorithm (Zhang, Cui et al. 
2010). The significant gene sets were obtained after applying the FDR correction. 
Post-analysis pathway evaluation 
In order to have a more systematic view of the results, we checked the similarity or the 
enriched pathways identified. This task was performed through hierarchical clustering 
using the Euclidean distance and the Ward’s minimum variance method (Ward 1963). In 
addition, we grouped the branches obtained in the clusters in order to interpret the results 
keeping into account the overrepresentation of some pathway subparts due to the lack of 
independence between the gene sets. We used the dynamic tree cut and the dynamic hybrid 
cut (Langfelder, Zhang et al. 2008) and the main assessment was done using the latter. The 
similarity was defined as the percentage of overlapping genes in the GS (Menashe, Maeder 
et al. 2010). Additionally, the GO similarities were assessed applying Lin’s pairwise 
similarity and using the GOSim R-package when the GO terms were available (Lin 1998; 
Frohlich, Speer et al. 2007). We also checked whether the most frequent genes among the 
obtained pathways had been mapped to SNPs with significative main effects and the other 
way around; by checking whether the SNPs with the lowest p-values were located in fairly 
common genes in the enriched pathways. 
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3.3. SNP-SNP interactions associated with UCB clinical outcomes 
The vast majority of the strategy and performance of the genome-wide interaction analysis 
(GWIA) was done by Jesús Herranz, the staff statistician of the Genetic and Molecular 
Epidemiology Group at the CNIO from 2010 to 2012. I played an active role in the design 
of the informatics platform to deal with the millions of interactions to be tested, the 
imputation of genotype missing values and the analysis of the results.  
We assessed SNP-SNP interactions associated with UCB prognosis with the genetic and 
follow-up data from SBC/EPICURO Study. The analyses were conducted for those 
NMIBC patients whose outcome was progression or recurrence; and the MIBC patients that 
shown progression or death due to UCB. The Illumina HumanHap 1M platform was used 
in the genotyping tasks and those SNPs with a percentage of missing data >5% were 
removed from the analysis. Missing values of the remaining SNPs in the analysis were 
imputed by random forest algorithm, based in the values of the nearest SNPs. If the 
frequency of variant homozygous was <10 subjects for a given SNP, we considered the 
dominant model, pooling the heterozygous and variant homozygous. Still, if the frequency 
was <10 subjects after pooling the two categories, the SNP was removed from the analysis. 
In the GWIA studies, the reduction of the number of genetic markers is a must for 
computational reasons. To this end, we selected the most representative SNPs for LD 
blocks taking a conservative threshold, r
2
 >0.9, and prioritising the SNPs with less number 
of missing data. After having applied quality control filters and removing SNPs in LD, 
585,220 and 552,220 SNPs were selected for the analysis for non-invasive and invasive 
UCB, respectively. 
MATERIAL AND METHODS. SNP-SNP interactions associated with UCB clinical outcomes 
54 
 
Table 3. Number of events and censored observations for each UCB outcome. 
Outcome Subphenotype Sample size - N Events - N(%) Censored - N(%) 
Recurrence NMIBC 836 275 (32.9) 561 (67.1) 
Progression NMIBC 836 83 (9.9) 753 (90.1) 
Progression MIBC 235 129 (54.9) 106 (45.1) 
BC-specific mortality MIBC 235 108 (46.0) 127 (54.0) 
 
Table 4. Number of SNPs included and interactions performance. 
Subphenotype No. SNPs 
After remove by 
NA count 
After remove by 
LD 
No. interactions 
(millions) 
NMIBC 998,349 682,741 585,220 171,241 
MIBC 998,349 840,558 552,463 152,607 
NA: non-available data 
LD: linkage disequilibrium 
 
The applied analytical strategy considered the following steps: Step 1- Tuning and 
assessment, aiming at defining the best way to analyze survival data with logistic regression 
and making a general assessment of the strategy; Step 2- Screening to select the most 
significant models fitted by logistic regression; Step 3- Cox regression models performed 
with those SNP-SNP interactions selected in step 2; Step 4- Listing the most relevant 
interactions by adjusting the Cox models for confounders, considering all modes of 
inheritance. 
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Figure 5. SNP-SNP interaction analysis flowchart. 
Step 1 - Tuning and Assessment 
It was capital to define the binary response variable (Y) in the logistic model using the 
follow-up time and to assess if the definition applied work reasonably well in our dataset. 
The simplest way to define the binary response variable is to assign 1 to the observations 
when the event occurred, and 0 if not. However, another more general definition of the 
binary response variable Y, depending on a survival time cut-off point was used in order to 
avoid situations in which the number of censored observations is small: 
Y = 0 if status = 0     
Y = 0 if status = 1 and the survival time > cut-off –point  (Formula 1) 
Y = 1 if status = 1 and the survival time ≤ cut-off point 
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In each survival dataset, different factors may affect the selection of the best cut-off point: 
sample size, percentage of censored observations and the distribution of the survival time. 
This study made possible to know if the approach based on logistic regression correlates 
with the results we would get with Cox regression. 
In order to evaluate the interaction, we fitted two Cox regression models. The first model 
contained the main effects of the two SNPs, X1 and X2, and had the following formula: 
     (Formula 2a) 
The second Cox regression model included both the main effects and the interaction terms 
as follows: 
   (Formula 2b) 
Let LM and LI be the log-partial-likelihoods of the main effect model and the interaction 
model, respectively. Then, we compared these models to evaluate the interaction, based on 
the difference LI - LM. 
Similarly, two logistic regression models were proposed. First, the model with only the 
main effects of the two SNPs, X1 and X2: 
     (Formula 3a) 
The second logistic regression model included both the main effects and the interaction 
terms with the following formulation: 
   (Formula 3b) 
)XXexp()t()X/t( 22110 
)XXXXexp()t()X/t( 211222110 
22110 XX)X/1Y(itlog 
211222110 XXXX)X/1Y(itlog 
MATERIAL AND METHODS. SNP-SNP interactions associated with UCB clinical outcomes 
57 
 
Let LM and LI be the log likelihoods of the main effect model and the interaction model, 
respectively. Again, we compared these two models to evaluate the interaction, based in the 
difference LI - LM. 
We randomly selected a specific number of pairs of interactions from all the possible pairs 
and fitted the two Cox regression models and the two logistic regression models for each of 
these pairs. Then, we obtain two p-values from the two ratio likelihood tests, evaluating the 
interaction term with each regression technique. In order to compare the p-values, we 
changed them as log10 scale to check if the models with the lowest p-values from the two 
techniques were similar.  
The relation between the p-values, as -log10 values, of the tests of the logistic and Cox 
regression was evaluated with the Pearson correlation coefficient. This analysis was 
repeated for different cut-off points of the survival time, defining different binary response 
variables in the logistic model. The cut-off point that had the highest correlation was then 
selected, since it is the best way to reproduce the results obtained by Cox regression with 
logistic regression. Finally, when the definition of the binary response variable was 
established, we performed a study selecting between up to 5 millions of random 
interactions. 
Step 2: Screening with logistic regression 
In the screening step, pair-wise interactions with all SNPs were analyzed by logistic 
regression applying the definition of the outcome binary variable as mentioned above. 
BOOST (Wan, Yang et al. 2010) was used to this end. BOOST uses a non-iterative method 
to approximate the likelihood ratio statistics (Formula 3a and 3b) by evaluating all pairs of 
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SNPs. It selects those pairs that reach a specific threshold according to the likelihood ratio 
statistics, or equivalently, a threshold for the p-value of the tests. From a practical point of 
view, the choice of this threshold depends on the number of SNPs, and the computational 
availability in the posterior stages of the analysis. We could estimate roughly the number of 
selected models by logistic regression by multiplying the threshold by the total number of 
pair-wise interactions involved in our dataset. We suggest to select a small significant level 
to screen pair-wise interactions, for p-values between <10
-4
 and <10
-6
.  
BOOST analyzes categorical variables coding in 2 or 3 categories meaning that it allows 
the analysis of either dominant, recessive or co-dominant mode of inheritance. We 
considered the latter to explore SNP-SNP interactions. Thus, SNPs were coded as 0, 1 and 
2 for the common homozygous, the heterozygous, and the variant homozygous genotypes, 
respectively. It is worth noting that BOOST does not permit to include confounder 
variables in the analysis to adjust it for. 
Step 3: Cox regression 
It was used to evaluate the interactions identified in Step 2 using the co-dominant mode of 
inheritance. The p-value for the partial log-likelihood ratio test was estimated to evaluate 
the interactions and was obtained from two Cox regression models, one with the main 
effects (Formula 2a) and the other including both the main effects and the interaction term 
(Formula 2b). We ended up with a list of the most important interactions using unadjusted 
Cox regression techniques to detect them. 
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In this step we also evaluated the potential interactions missed in the screening step (false 
negative results), those with significant interactions identified by Cox regression but not 
detected by logistic regression. 
Step 4: Listing the most relevant interactions identified by Cox regression and 
confounder adjustment 
We performed additional analyses assessing SNP-SNP interactions by adjusting for 
potential confounders/prognosticators and considering the recessive, dominant, additive and 
co-dominant modes of inheritance. It meant that both SNPs could be introduced in the 
model with any of the 4 modes of inheritance, making possible up to 16 combinations 
between a pair of SNPs. 
Multiple Test 
In order to avoid false positive results the level of statistical significance needed to be 
lowered. Among strategies allowing for multiple test correction, the Bonferroni correction 
assumes that the tests are independent. However, the presence of LD among the SNPs 
makes that many interactions tests may be highly correlated. In the context of GWAS with 
LD, this approach is accepted to be very conservative. The permutation test is an extended 
option to assess significance while allowing multiple test and correlations but we have 
discarded them because this approach is computationally prohibitive when analyzing 
several thousands of millions of interactions. 
Only a few of strategies have been proposed to deal with the threshold of statistical 
significance in the GWIA studies. We referred to two of them, providing quite 
approximated results. The first one (Gao, Starmer et al. 2008) used the principal component 
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analysis (PCA) with a genotyped dataset to define the number of independent comparisons 
as the number of principal components explaining a large portion of the variance, usually 
99.5%. This value is known as the “number of informative SNPs”. The second one (Becker 
and Knapp 2004) suggested the use of the Bonferroni correction, adding a correction factor 
over the total number of interactions. Based in simulation studies in case-control studies for 
testing for allelic interaction, they propose a roughly approximation by dividing the original 
type I error obtained in the Bonferroni correction by a 0.4 factor. Becker indicated this 
correction factor is difficult to obtain when testing co-dominant models and he suggested 
that stronger correction factors could be appropriate.  
The analysis of all modes of inheritance for the 2 SNPs introduces an additional correction 
in the multiple tests, because the tests analyzing different modes are not independent. Based 
on simulation studies, a 2.2 correction factor in the significant level has been suggested in 
order to calculate the effective number of tests (Gonzalez, Carrasco et al. 2008). Analyzing 
SNP-SNP interactions, the natural extension of this correction factor would be 4.84 
(2.2×2.2) when all the combinations between the modes of inheritance for a pair of SNPs 
are explored. 
 
 
 Chapter 4: Results 
4.1. Independent SNPs associated with UCB clinical outcomes 
4.1.1. Independent SNPs associated with NMIBC clinical outcomes 
A total of 2,616 patients with NMIBC were considered in this study. Characteristics of 
cases are summarized in Supplementary Table 1 and Supplementary Table 2. Discovery 
population included 1,332 patients and Validation included 1,284 patients. In the TXBC, 
patients in the Discovery phase were recruited from 7/19/1999 to 3/6/2008 and the date of 
last follow-up was 10/24/2008. Out of 496 patients, 213 patients were free-of-disease and 
their median follow-up was 75.6 months. 57 patients were lost-to-follow-up 
(Supplementary Table 1). In the SBC/EPICURO Study, patients were recruited from 
6/13/1998 to 6/28/2001 and the date of last follow-up was 7/1/2007. Out of 836 patients, 
504 patients were free-of-disease and their median follow-up was 77.5 months. Only 9 
patients were lost-to-follow-up (Supplementary Table 1). For the combined validation 
cohorts, patients were recruited from 1/1/1979 to 5/19/2010 and the date of last follow-up 
was 7/18/2011. Out of 1,284 patients, 486 were free-of-disease and the median follow-up 
was ranged from 26.3 to 113.0 months. The number of patients lost-to-follow-up was not 
available (Supplementary Table 1 and Supplementary Table 2). 
We observed similar distribution of main patient characteristics between TXBC-1 and 
TXBC-2 populations. Patients recruited in TXBC tend to have more aggressive disease 
than those from SBC/EPICURO because MDACC is a tertiary referral centre. Both studies 
had a low rate of progression ranging from 9.9%-17%. The international studies presented 
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heterogeneity in grade, multiplicity, tumor size, treatment variables, and rate of events 
(Supplementary Table 1). Among a total of 2,616 patients, 1,170 (44.7%) presented tumor 
recurrences, 380 (14.5%) tumor progressions, and 1,376 (52.6%) tumor relapses. 
From now on, I am going to present and discuss the results obtained for the multivariate 
survival analyses. The univariate survival analysis will be considered only in the 
complementary assessment of SNPs using the Kaplan-Meier estimator. Supplementary 
Figure 6 displays the Manhattan plots for the two Discovery studies for the three outcomes 
of interest with the p-values from the adjusted Cox regression models. In the Discovery 
phase, the meta-analysis of the combined TXBC-1 and SBC/EPICURO identified 57 SNPs 
significantly and independently associated with clinical outcome with meta p-values lower 
than 2.24×10
-4
 and no heterogeneity between studies (Supplementary Table 4). Among the 
57 SNPs, 12 were associated with recurrence alone, 24 with progression alone, and 18 with 
relapse alone, 2 were associated with both recurrence and relapse, and one was associated 
with both progression and relapse. The distribution of these SNPs across the genome was 
uniform (Figure 6). These 57 SNPs were further followed-up in the Validation phase 
through genotyping 1,284 additional NMIBC cases from the TXBC-2 and 5 International 
series. 
Risk of non-muscle invasive bladder cancer recurrence 
Out of the 14 SNPs identified in the Discovery meta-analysis, SNP rs754799 (19p13.3, 
Supplementary Figure 5a) was replicated and significantly associated with recurrence in all 
the series (Supplementary Table 4). Patients with the homozygous genotype had a 
significantly increased risk of recurrence in the TXBC (HR= 3.00; 95% CI=1.51-5.93, 
p=1.6310-3), SBC/EPICURO (HR= 2.68; 95% CI=1.63-4.42, p=1.0210-4), and the 
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Validation series (HR=1.51; 95% CI=1.00-2.27, p=4.7610-2). The combined estimates 
with Discovery and Validation series provided a HR=2.06 (95% CI=1.55-2.75, p=7.4510-
7
) showing no significant heterogeneity among studies (p-value for heterogeneity = 0.21). 
The median recurrence-free survival time for individuals with the common allele was 
longer than for those carrying the rare homozygous genotype in TXBC (not computable 
versus vs. 4.41 months, logrank p=0.003) and in SBC/EPICURO (not computable vs. 17.1 
months, logrank p=5.54×10
-6
) (Supplementary Figure 6). The c-statistics without and with 
the SNPs were 0.64 and 0.65 in TXBC, 0.64 and 0.64 in the SBC/EPICURO, 0.68 and 0.68 
in TXBC-2, and 0.67 and 0.66 in the International cohorts, respectively (Supplementary 
Table 5). 
Risk of non-muscle invasive bladder cancer progression 
SNP rs4246835 (Supplementary Figure 5b) was showed to be significantly associated with 
progression in all the series. Compared to the common homozygous genotype, patients 
carrying heterozygous genotype of rs4246835 had significantly reduced risk of progression: 
TXBC (HR=0.41, 95% CI=0.25-0.69, p=6.85×10
-4
), SBC/EPICURO (HR=0.34, 95% 
CI=0.19-0.59, p=1.36×10
-4
), and combined Validation data (HR=0.64, 95% CI=0.43-0.94, 
p=2.36×10
-2
). The combined Discovery and Validation data yielded a HR=0.49 (95% 
CI=0.37-0.64, p=1.77×10
-7
). Compared to the common homozygous genotype, subjects 
with the rare homozygous genotype had relative longer median progression-free survival 
time in TXBC and SBC/EPICURO (Supplementary Figure 6). 
Five additional SNPs showed similar association with progression in the Discovery and in 
some of the Validation studies, although the Validation meta-analysis did not yield 
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significant results (Table 6). Of notice, all 6 SNPs had remarkable HR (>2 or ≤0.5) for the 
combined estimates from Discovery and Validation data and we observed no significant 
heterogeneity between studies for these SNPs in the combined estimates for Discovery and 
Validation data (p for heterogeineity >0.05). The c-statistics without and with these SNPs 
were 0.70 and 0.75 in TXBC, 0.77 and 0.84 for the SBC/EPICURO, 0.81 and 0.82 in 
TXBC-2, and 0.80 and 0.79 in the International cohorts (Supplementary Table 5). 
Risk of non-muscle invasive bladder cancer relapse 
SNP rs754799 was also replicated and significantly associated with relapse in the 
Validation data (Supplementary Table 2, Supplementary Figure 5a). Analyses of combined 
estimates from Discovery and Validation data indicated that patients harboring the rare 
homozygous genotype showed an increased risk of relapse compared to patients having the 
common allele (HR=1.89, 95% CI=1.43-2.49, p=5.89×10
-6
). rs754799 also showed the 
strongest association with recurrence and was the only SNP validated for both events. The 
median disease-free survival time was shorter for patients with the rare genotype in 
comparison to those harboring the common allele in the TXBC (4.41 months vs. 13.9 
months, logrank p=0.0293) and in the SBC/EPICURO (17.1 months vs. not computable, 
logrank p=1.13×10
-5
) (Supplementary Figure 6). 
Two additional SNPs, rs4946483 and rs11615759, also exhibited similar association with 
the risk of relapse in both Discovery and Validation data. The c-statistics without and with 
these SNPs were 0.63 and 0.64 in the TXBC, 0.62 and 0.63 in the SBC/EPICURO, 0.71 
and 0.72 in the TXBC-2, and 0.67 and 0.67 in the International cohorts (Supplementary 
Table 5). 
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Figure 6. Chromosomal representation with the genomic location of the closest genes to the SNPs associated with non-muscle invasive UCB 
outcome (Recurrence, red; Progression, blue; and relapse, green) in Discovery analysis. Boxed are those SNPs that were replicated in Validation 
phase. The idiograms were plotted with the R/Biconductor package quantsmooth version 1.24. 
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Table 5. SNPs with lowest p-values associated with clinical outcome for non-muscle invasive UCB patients. 
Marker [Alleles]         
Chr location   Genotype      
gene* Model Study Count HR(95% CI) P P het 
Recurrence         
rs754799[A/C] recessive TXBC 306/129/12 3.00 1.51 5.93 1.63×10-3  
19p13.3  SBC/EPICURO 549/257/29 2.68 1.63 4.42 1.02×10-4  
SCAMP4, ADAT3  Discovery 855/386/41 2.79 1.86 4.17 5.87×10-7 0.798 
  Validation 787/350/44 1.51 1.00 2.27 4.76×10-2 0.840 
  Combined 1642/736/85 2.06 1.55 2.75 7.45×10-7 0.213 
Progression         
rs4246835[G/A] codom.het TXBC 150/221/79 0.41 0.25 0.69 6.85×10-4  
9p22-p13  SBC/EPICURO 312/372/152 0.34 0.19 0.59 1.36×10-4  
SLC24A2, MLLT3  Discovery 462/593/231 0.38 0.26 0.55 3.72×10-7 0.621 
  Validation 441/538/196 0.64 0.43 0.94 2.36×10-2 0.051 
  Combined 903/1131/427 0.49 0.37 0.64 1.77×10-7 0.052 
rs6100810[A/G] recessive TXBC 303/134/13 2.95 1.03 8.48 4.46×10-2  
20q13  SBC/EPICURO 554/252/30 5.65 2.62 12.2 9.73×10-6  
C20orf197, CDH26  Discovery 857/386/43 4.51 2.43 8.40 1.95×10-6 0.329 
  Validation 843/305/37 1.55 0.70 3.47 2.83×10-1 0.640 
  Combined 1700/691/80 3.03 1.85 4.95 9.76×10-6 0.144 
rs7572970[G/A] recessive TXBC 221/195/35 3.78 1.98 7.23 5.65×10-5  
2q24  SBC/EPICURO 434/334/67 2.28 1.18 4.38 1.35×10-2  
RBMS1  Discovery 655/529/102 2.94 1.86 4.66 4.27×10-6 0.279 
  Validation 595/493/93 1.27 0.65 2.47 4.78×10-1 0.689 
  Combined 1250/1022/195 2.24 1.54 3.27 2.88×10-5 0.140 
rs12294567[A/G] codom.hom TXBC 355/88/8 4.08 1.08 15.4 3.83×10-2  
11q14.3  SBC/EPICURO 632/183/21 6.14 2.68 14.1 1.79×10-5  
FAT3  Discovery 987/271/29 5.48 2.71 11.1 2.17×10-6 0.609 
  Validation 907/259/19 0.56 0.10 3.07 5.06×10-1 0.768 
  Combined 1894/530/48 3.92 2.05 7.52 3.76×10-5 0.100 
rs17218455[G/A] codom.hom TXBC 325/110/16 5.03 2.30 11.0 5.25×10-5  
 67 
 
12q32  SBC/EPICURO 572/243/21 2.91 1.17 7.22 2.11×10-2  
TCP11L2  Discovery 897/353/37 3.98 2.20 7.20 4.89×10-6 0.372 
  Validation 818/326/40 1.32 0.57 3.04 5.19×10-1 0.519 
  Combined 1715/679/77 2.75 1.70 4.47 4.08×10-5 0.128 
rs3797725[A/G] codom.hom TXBC 305/131/15 2.77 1.02 7.54 4.57×10-2  
5q22.1  SBC/EPICURO 497/294/45 3.38 1.82 6.28 1.16×10-4  
C5orf13  Discovery 802/425/60 3.20 1.89 5.42 1.49×10-5 0.741 
  Validation 758/369/48 1.06 0.46 2.47 8.91×10-1 0.329 
  Combined 1560/794/108 2.35 1.50 3.67 1.80×10-4 0.122 
Relapse         
rs754799[A/C] recessive TXBC 307/130/12 2.31 1.17 4,54 1.56×10-2  
19p13.3  SBC/EPICURO 549/257/29 2.43 1.52 3.88 2.15×10-4  
SCAMP4, ADAT3  Discovery 856/387/41 2.39 1.62 3.51 9.92×10-6 0.903 
  Validation 787/350/44 1.48 1.00 2.20 4.91×10-2 0.743 
  Combined 1643/737/85 1.89 1.43 2.49 5.89×10-6 0.392 
rs4946483[G/A] additive TXBC 127/226/96 1.25 1.03 1.52 2.08×10-2  
6q22  SBC/EPICURO 325/392/119 1.35 1.16 1.58 1.37×10-4  
COX6A1P3  Discovery 452/618/215 1.31 1.16 1.48 1.00×10-5 0.538 
  Validation 102/122/65 1.16 0.91 1.49 2.29×10-1 NA 
  Combined 554/740/280 1.28 1.15 1.43 6.89×10-6 0.573 
rs11615759[A/G] recessive TXBC 331/110/8 2.51 1.13 5.56 2.32×10-2  
12p12  SBC/EPICURO 589/219/28 2.66 1.64 4.33 7.47×10-5  
SOX5  Discovery 920/329/36 262 1.73 3.96 5.02×10-6 0.900 
  Validation 887/284/13 1.06 0.52 2.15 8.77×10-1 NA 
  Combined 1807/613/49 2.08 1.46 2.98 5.83×10-5 0.095 
*Nearest gene to the SNP; NA: not available; Chr – Chromosome; P-het: p-value for test of heterogeneity; HR: hazard ratio; 95% CI: 95% confidence interval; Codom.hom: 
codominant.homozygote; Codom.het: codominant.heterozygote  
TXBC: Texas Bladder Cancer Study; SBC/EPICURO: Spanish Bladder Cancer/EPICURO Study 
Genotype Count: number of patients with homozygous common genotypes/heterozygous genotypes/homozygous rare genotypes 
Discovery: combined analysis of Discovery populations from TXBC and SBC/EPICURO; Validation: combined analysis of Validation populations from TXBC-2, the Princess 
Margaret Hospital (PMH), Toronto; Aarhus University Hospital (AUH), Denmark; Hôpital Henri Mondor (HM), Créteil, France; Erasmus MC (EMC), Rotterdam; and the Human 
Genetics Foundation (HuGeF), Turin, Italy 
 
RESULTS. Independent SNPs associated with MIBC clinical outcomes 
68 
 
4.1.2. Independent SNPs associated with MIBC clinical outcomes 
A total of 632 patients with MIBC were considered in this study in the Discovery phase. 
The complementary analyses will be performed in the near future for the Validation phase. 
Characteristics of cases are summarized in Supplementary Table 3. In the TXBC, patients 
in the Discovery phase were recruited from 12/31/1997 to 4/25/2001; the date of last 
follow-up was 02/05/2009. Out of 397 patients, 200 patients were free-of-disease and their 
median follow-up was 43.7 months. 5 patients were lost-to-follow-up. In the 
SBC/EPICURO, patients were recruited from 4/25/1998 to 6/28/2001; the date of last 
follow-up was 7/1/2007. Out of 235 patients, 66 patients were free-of-disease and their 
median follow-up was 26 months. Only 3 patients were lost-to-follow-up. 
The Manhattan plots for the two Discovery studies for the three outcomes of interest with 
the p-values from the adjusted Cox regression models are displayed in Supplementary 
Figure 4. In the Discovery phase, the meta-analysis of the combined TXBC-1 and 
SBC/EPICURO identified 57 SNPs significantly and independently associated with clinical 
outcome with meta p-values lower than 9.69×10
-5
 and no heterogeneity between studies 
(Supplementary Table 7). Among the 57 SNPs, 18 were associated with progression, 23 
with death due to UCB, and 19 with overall survival; and 3 of them (rs2646727, rs2565721 
and rs783145) were associated with both progression and BC-specific mortality. There was 
not any region with an overrepresentation of SNPs across the genome. These 57 SNPs are 
going to be validated in the same cohorts as the NMIBC part of the study. The details of the 
SNPs reaching or close to the Bonferroni multiple test correction threshold (p-value <10
-8
) 
are described below. 
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Risk of muscle invasive bladder cancer progression 
Out of the 18 SNPs identified in the Discovery phase meta-analysis, SNP rs16927851 
(12p12.1) had the lowest p-value for the recessive MoI. The combined estimates in the 
Discovery series provided a HR=3.48 (95% CI=2.25-5.39, p=2.0810-8). Patients with the 
homozygous genotype had a significantly increased risk of progression in the 
SBC/EPICURO (HR=2.79; 95% CI=1.58-4.94, p=3.9510-4) and in the TXBC (HR= 4.75; 
95% CI=2.41-9.37, p=6.8310-6) (Table 6). No significant heterogeneity between the 
studies was detected (p-value for heterogeneity = 0.21). The median progression-free 
survival time for individuals with the common allele was longer than for those carrying the 
rare homozygous genotype in TXBC (not computable vs 30.8 months, logrank p=4.92×10
-
5
) and in SBC/EPICURO (25.46 vs. 5.67 months, logrank p=0.004) (Supplementary Figure 
7). The c-statistics without and with the SNPs were 0.67 and 0.71 in TXBC; and 0.69 and 
0.76 in the SBC/EPICURO, respectively (Supplementary Table 8). 
Risk of muscle invasive BC-specific mortality 
Out of the 23 SNPs identified in the Discovery phase meta-analysis, SNP rs1015267 
(11p14.2) had the lowest p-value for the codominant MoI. The combined estimates in the 
Discovery series provided a HR=3.96 (95% CI=2.51-6.23, p=2.9110-9) showing no 
significant heterogeneity among studies (p-value for heterogeneity = 0.96). Patients with 
the homozygous genotype had a significantly increased risk of progression in the 
SBC/EPICURO (HR=3.91; 95% CI=2.03-7.54, p=4.6610-5) and in the TXBC (HR= 4.00; 
95% CI=2.13-7.51, p=1.5610-5). The median survival time for individuals with the 
common allele was longer than for those carrying the rare homozygous genotype in TXBC 
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(not computable vs not computable vs 27.3 months, logrank p=0.013) and in 
SBC/EPICURO (not computable vs 33.9 vs. 23 months, logrank p=3.6×10
-3
) 
(Supplementary Figure 7). The same SNP appeared as significantly associated to BC-
specific mortality for the recessive MoI; more information can be found in Table 6 and in 
Supplementary Figure 7. 
Four additional SNPs showed similar association with the risk of dying because of UCB in 
the Discovery studies, although the Discovery phase meta-analysis did not yield 
statistically significant results using the strict Bonferroni multiple test correction (Table 6). 
Of notice, all 4 SNPs had remarkable HR (between 2.50 and 3.86) for the combined 
estimates from Discovery data and no significant heterogeneity between studies for these 
SNPs was observed in the combined estimates for Discovery data (p for heterogeineity 
>0.05). The c-statistics without and with these SNPs were 0.73 and 0.76 in TXBC; and 0.76 
and 0.77 for the SBC/EPICURO (Supplementary Table 8). 
Risk of muscle invasive bladder cancer overall survival 
Out of the 19 SNPs identified in the Discovery phase meta-analysis, none of them reached 
the stringent threshold to satisfy the multiple test correction. The most relevant SNPs were 
rs10437447 (10q26.2) and rs2565721 (6q26) for the dominant and the additive MoI, 
respectively. Nevertheless, we describe the details for these SNPs below. 
The combined estimates for rs10437447 in the Discovery series provided a HR=1.88 (95% 
CI=1.47-2.41, p=4.5910-7) (Table 6). No significant heterogeneity between the studies 
was detected (p-value for heterogeneity = 0.59). Patients with the homozygous genotype 
had a significantly increased risk of progression in the SBC/EPICURO (HR=2.02; 95% 
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CI=1.42-2.88, p=1.0310-4) and in the TXBC (HR= 1.76; 95% CI=1.25-2.48, p=1.1110-3). 
The median survival time for individuals with the common allele was longer than for those 
carrying the rare homozygous genotype in TXBC (60 vs 26.5 months, logrank p=5.6710-3) 
and in SBC/EPICURO (30.1 vs 22.9 months, logrank p=0.02). The combined estimates for 
rs2565721 in the Discovery series provided a HR=0.66 (95% CI=0.56-0.78, p=9.6010-7) 
(Table 6). No significant heterogeneity between the studies was detected (p-value for 
heterogeneity = 0.60). Patients with the homozygous genotype had a significantly increased 
risk of progression in the SBC/EPICURO (HR=0.69; 95% CI=0.54-0.89, p=3.5710-3) and 
in the TXBC (HR= 0.63; 95% CI=0.51-0.79, p=3.5710-5). In the Supplementary Figure 7 
we observe that the median survival time for individuals with the common allele was 
shorter than for those carrying the rare homozygous genotype in TXBC (20.1 vs 74.8 vs 
85.1 months, logrank p=7.8310-4) and in SBC/EPICURO (18.4 vs 27.6 vs 36.9 months, 
logrank p=0.18). 
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Figure 7. Chromosomal representation with the genomic location of the closest genes to the SNPs associated with muscle invasive bladder cancer 
outcome (BC-specific mortality, red; Progression, blue; and Overall survival, green) in Discovery analysis. The idiograms were plotted with the 
R/Biconductor package quantsmooth version 1.2. 
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Table 6. SNPs with lowest p-values associated with clinical outcome for muscle invasive bladder cancer patients. 
Marker [Alleles]         
Chr location   Genotype      
gene* Model Study Count HR(95% CI) P P het 
Progression         
rs16927851 [A/G] recessive TXBC 231/131/22 4.75 2.41 9.37 6.83×10-6  
12p12.1  SBC/EPICURO 125/87/22 2.79 1.58 4.94 3.95×10-4  
BCAT1  Discovery 356/218/44 3.48 2.25 5.39 2.08×10-8 0.24 
         
rs9849682 [A/C] recessive TXBC 118/197/69 2.57 1.51 4.39 5.38×10-4  
3q25.31  SBC/EPICURO 75/109/51 2.19 1.43 3.36 3.42×10-4  
PLCL3  Discovery 193/306/120 2.33 1.67 3.25 7.08×10-7 0.64 
         
rs11732628 [A/G] recessive TXBC 141/182/60 2.19 1.21 3.97 9.91×10-3  
4q26  SBC/EPICURO 93/110/32 2.92 1.78 4.79 2.04×10-5  
SYNPO2  Discovery 234/292/92 2.60 1.78 3.80 8.41×10-7 0.46 
BC-specific mortality         
rs1015267 [A/G] codom.hom TXBC 182/169/32 4.00 2.13 7.51 1.56×10-5  
11p14.2  SBC/EPICURO 96/114/24 3.91 2.03 7.54 4.66×10-5  
TMEM16C  Discovery 278/283/56 3.96 2.51 6.23 2.91×10-9 0.96 
         
rs1015267 [A/G] recessive TXBC 182/169/32 3.66 2.04 6.59 1.41×10-5  
11p14.2  SBC/EPICURO 96/114/24 3.16 1.73 5.78 1.76×10-4  
TMEM16C  Discovery 278/283/56 3.41 2.24 5.19 1.01×10-8 0.73 
         
rs1008954 [A/G] dominant TXBC 344/38/1 2.78 1.60 4.83 2.79×10-4  
11q24.3  SBC/EPICURO 201/33/1 2.72 1.62 4.59 1.65×10-4  
APLP2  Discovery 545/71/2 2.75 1.88 4.02 1.65×10-7 0.96 
         
rs11221970 [A/G] dominant TXBC 346/36/1 2.77 1.57 4.87 4.18×10-4  
11q24.3  SBC/EPICURO 203/31/1 2.78 1.64 4.71 1.54×10-4  
APLP2  Discovery 549/67/2 2.77 1.88 4.08 2.28×10-7 0.99 
         
rs17603887 [G/A] dominant TXBC 313/63/6 2.09 1.28 3.40 3.14×10-5  
 74 
 
10q26.13  SBC/EPICURO 194/38/3 3.02 1.83 4.98 1.54×10-5  
GPR26  Discovery 507/91/9 2.50 1.76 3.54 6.39×10-7 0.30 
         
rs1537010 [A/G] dominant TXBC 365/18/0 3.52 1.70 7.30 7.21×10-4  
9q33.3  SBC/EPICURO 217/16/1 4.25 2.04 8.87 1.17×10-4  
C9orf28  Discovery 582/34/1 3.86 2.30 6.49 3.15×10-7 0.72 
Overall survival         
rs10437447 [G/A] dominant TXBC 284/97/3 1.76 1.25 2.48 1.11×10-3  
10q26.2  SBC/EPICURO 168/61/5 2.02 1.42 2.88 1.03×10-4  
TMEM12  Discovery 452/158/8 1.88 1.47 2.41 4.59×10-7 0.59 
         
rs2565721 [G/A] additive TXBC 106/189/89 0.63 0.51 0.79 3.57×10-5  
6q26  SBC/EPICURO 74/108/53 0.69 0.54 0.89 3.57×10-3  
PLG  Discovery 180/297/142 0.66 0.56 0.78 9.60×10-7 0.60 
*Nearest gene to the SNP; NA: not available; Chr – Chromosome; P het: p-value for test of heterogeneity; HR: hazard ratio; 95% CI: 95% confidence interval; 
Codom.hom: codominant homozygote; Codom.het: codominant.heterozygote  
TXBC: Texas Bladder Cancer Study; SBC/EPICURO: Spanish Bladder Cancer/EPICURO Study 
Genotype Count: number of patients with homozygous common genotypes/heterozygous genotypes/homozygous rare genotypes 
Discovery: combined analysis of Discovery populations from TXBC and SBC/EPICURO 
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4.2. Biological pathways associated with UCB clinical outcomes 
ALIGATOR results 
In an initial fast screening process with 5,000 gene lists, three LD scenarios with two 
window sizes for the SNP-gene mapping and three p-value thresholds were considered. 
ALIGATOR offers the number of overrepresented GO categories reaching several levels of 
significance for overrepresentation, together with p-values that informs whether this 
number is greater than expected by chance. The lowest p-values were obtained in the 
NMIBC patients when the outcome was progression and the p <0.001. For this outcome, 
we found significantly more enriched GO categories in the simulated gene lists. Thus, we 
focused on this outcome and the number of simulated gene lists was increased to 50,000 in 
order to get more accurate category-specific p-values. The enhanced results related the 
overrepresentation for this outcome is shown in the Table 7. 
An excess of enrichment was observed in one of the most stringent scenarios by 
considering only the SNPs that lie within the genes with very low LD between them (r
2
 
<0.2). In the Table 7 is shown that in the mentioned scenario we obtained 54 categories 
with p <0.01, based upon 569 autosomal genes with some SNP with independent predictive 
value with p <0.001. We noticed that different LD thresholds cause a slight variation in the 
results. Nevertheless, a similar pattern of results was observed with more inclusive LD 
thresholds. However, the higher was the number of SNPs included in the analysis the lower 
was the observed significance. It would suggest that the performed analyses were at least 
mildly sensitive to random variation. The results were considered by joining all the 
significantly enriched categories, ignoring the fact that we dealt with different LD 
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thresholds. We got more putative enriched categories involved in the prognosis of the 
disease at the cost of including probable false positives. 
We kept the enriched categories that had p <0.01 in these three different LD scenarios 
because the results obtained with less restrictive enriched p-value thresholds (e.g. p <0.05) 
showed a lack of statistical significance. The results obtained with LD r
2
 <0.2 and LD r
2
< 
0.5 were very similar (the first one involved 54 categories, the second one 51 and they 
share 37) but when compared with the non-LD pruned list of SNPs (53 categories) there 
were 27 common enriched categories. When all the enriched categories obtained in the 
three LD situations were joined, we obtain 89 different sets. The most significant enriched 
categories revealed similarities between them after the clustering analysis. When those 
categories were analyzed in detail, a clear implication of several elements related to the 
inflammatory and the immunological response arose. 
Table 7. ALIGATOR results for NMIBC patients with progression. The analyses were performed 
with 50,000 simulated gene lists for the SNPs that lie within the genes. 
  Count p < 0.05 p <0.01 p <0.001 
LD GWPS p Significant genes No. cat p No. cat p No. cat p 
         
LD 0.2 
0.001 175 135 0.82 34 0.10 2 0.45 
0.01 569 166 0.15 54 0.03 10 0.03 
0.1 2,232 183 0.26 30 0.38 2 0.54 
         
         
LD 0.5 
0.001 142 218 0.13 28 0.45 3 0.39 
0.01 483 162 0.12 51 0.04 7 0.07 
0.1 2,065 114 0.10 22 0.26 0 1.00 
         
         
Non-LD 
0.001 211 152 0.06 33 0.14 5 0.15 
0.01 741 190 0.15 53 0.06 3 0.39 
0.1 2,936 255 0.06 53 0.08 3 0.43 
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The most frequent genes among the obtained categories after joining the results of the 
different LD scenarios were SYK, CD74, IL6 and CD24. SYK and CD74 appeared in 35 and 
30 enriched categories respectively. Meanwhile, IL6 and CD24 both appeared in 28 
categories. None of them were related to SNPs with significant predictive values, therefore 
their putative role in the prognosis of the disease would be ignored in the preliminary SNP-
independent genome-wide analysis. When all the SNPs in the obtained GS were evaluated, 
ITGA4 came up with the lowest p-value (rs2305586 in the recessive MoI with p=6.1×10
-11
) 
and appeared in 5 categories associated with hematopoietic or lymphoid processes. 
Additionally, we obtained enriched results close to the significance level in NMIBC 
patients when the outcome was recurrence when a LD r
2
 <0.5 threshold was defined using 
a 20 kb window in the SNP-gene assignation. However, further analyses were not 
considered because the significance of the number of overrepresented categories was 
greatly decreased when different LD and SNP mapping criteria were evaluated. 
GeSBAP results 
The analyses were carried out using the three LD mentioned criteria for all the outcomes. 
The effect of the SNP mapped to a specific gene is not evaluable if the SNP is not within 
the gene or 5 kb apart from it. When the SNPs were evaluated without any LD restriction, 
we obtained a single enriched GS for “protein export” for the patients that die due to BC. 
With more restrictive LD values we observed enriched GS for almost all the possible 
outcomes. The most obvious observation is the lack of outcome specificity for the most 
significative enriched GO categories that were obtained. In most of the outcomes the role of 
small GTPase mediated signal transduction, calcium ion transport, cell adhesion molecules 
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and neuronal development seemed to be important. Despite of this, protein glycosylation 
categories in NMIBC appeared as distinctive GS for this outcome. 
In NMIBC patients with progression, TSC1 was the most frequent among all the 
significantly enriched GO categories, as far as it appeared in 6 of 9 GO categories. The 
most frequent genes in the other outcomes appeared in one third of the cases, at most. In 
this scenario we had a calcium channel subunit (CACNA1B) and a cholinergic receptor 
(CHRNA7) in MIBC, whose outcome was death, and B4GALT1 for NMIBC with 
recurrences. None of the SNPs lying within these genes came up to statistical significance. 
When we looked for the SNPs with the lowest p-values in the GS that reached significance, 
a pair of SNPs for progression in MIBC and NMIBC came up. In the MIBC outcome were 
rs683004 (p=4.2×10
-8
 in the dominant MoI) and rs620508 (p = 6.4×10
-8
 in the dominant 
MoI), both mapped to CDH6. However, this gene appears only in one GS regarding cell 
junction organization. In the NMIBC outcome were rs2305586 (p=6.1×10
-11
 in the 
recessive MoI) and rs2036268 (p=2.5×10
-8
 in the recessive MoI), mapping to ITGA4 and 
the RhoGEF and PH domain containing 4 (FGD4) respectively. The first one appeared only 
once in the CAMs pathway and the second one appeared in 4 GS associated with signal 
transduction in Rho/Ras GTPases. 
GSA-SNP results 
In this method we found remarkable the high number of statistically significant gene sets 
obtained after the analyses as well as the similarities among the outcomes. The role of the 
different LD (without restriction, r
2
 <0.2 and 0.5) and the SNP-gene distance mapping 
(SNPs within the gene and those extended to 20 kb in the up-downstream) were evaluated. 
We obtained 34 common GS when the results for all the outcomes where compared. That 
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meant about 1/4 of the results for NMIBC with progression and 1/3 in MIBC and NMIBC 
with recurrence. The results trended towards the same kind of results obtained using the 
GeSBAP method. Only a few general differences arose: those GS regarding 
cardiomyopathies, the protein tyrosine kinase activity, the role of platelet activation, a more 
marked effect of neurogenesis and axonogenesis and the regulation of GLP-1, free fatty 
acids or acetylcholine. 
The most frequent genes in all the outcomes were calcium channel, voltage-dependent 
subunits, especially CACNA1C and CACNA1D. They appeared in approximately 25% of 
the GS; except in NMBC cases with progressions where its presence dropped to 20%. 
Interestingly KCNIP2 came out in the outcomes with progression with the same frequency 
as the other two mentioned genes. None of the SNPs located in those genes behaved as a 
putative allele risk.  
The SNPs with significant main effects were associated with pathways regarding the MIBC 
and NMIBC patients that suffered progression. In the MIBC outcome came up the same 2 
SNPs observed for this event in GeSBAP. On the other hand, 8 SNPs arose in the NMIBC 
scenario. The most significant one was rs2305586 mapped to ITGA4 and it was involved 
with 8 pathways regarding cell-cell interactions and cardiomyopathy (rs2305586, as 
described in GeSBAP). A similar putative risk was observed for rs34050907 and 
rs12761617 in the dominant MoI (p=7.1×10
-10
 and p=9.84×10
-10
 respectively) assigned to 
RHOBTB1. However, this gene was obtained just for the Rho GTPase cycle. Regarding 
FGD4, the same SNP and GS were obtained, when compared with the GeSBAP analysis. 
And an additional SNP (rs17036321, associated with PPARG, with p=8.7×10
-8
 in the 
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dominant MoI) suggests a putative association of nuclear receptor transcription with 
progression in NMIBC. 
i-Gsea4Gwas results 
We performed the analyses evaluating all the BC outcomes against the GO and CP gene 
sets. The effects of the LD (r
2
 <0.2 and 0.5) and the SNP-gene distance mapping (SNPs 
within the gene and within 20 kb in the up-downstream of the closest gene) were also 
inspected in this method. After the SNP-gene assignation, we observed that only around 
11k and 13k genes (LD r
2
 <0.2 and 0.5, respectively) were considered in the different LD 
scenarios. That probably leads to an important loss of power, but the LD bias and the 
important background noise is minimized at this cost. When the GSA results were 
evaluated, we realized that this method may be quite sensitive to the considered LD 
thresholds and the SNP-gene distance association. The method offered high confidence 
results when we analyzed the data from the NMIBC and MIBC patients whose outcome 
was recurrence. They suggested possible alterations in the regulation of the lymphocytes 
and T cells, the biosynthesis of cytokines and effects on tumor suppressor genes such as 
CDH1 and p53. Much milder effects were observed in NMIBC with progression regarding 
oncogenic pathways in which FGFR and PI3K are involved. The results seemed to go in 
another direction when the MIBC patients that show progression were evaluated. In this 
outcome the nuclear membrane transport seemed to be altered together with the NOD like 
receptor signaling pathway. However, these last results had far less statistical significance 
than the ones relevant to the NMIBC outcomes. 
The most frequent element in the GS that show overrepresentation of risk alleles in NMIBC 
with recurrence was IL12B. It appeared in 11 of the 39 enriched GS associated to this 
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event; however none of the SNPs mapping this gene had high predictive values. Other 
genes related to the immune system such as B7-H3, CD28 and EBI3 appeared in 10 of 
those GS in the mentioned outcome and the lack of predictive values of their SNPs was 
also observed. In the MIBC with progression we saw that 21 genes appeared in 5 of 11 GS. 
These genes are part of the nucleoporin (NUP) family. None of the mentioned genes were 
associated with SNPs acting as putative risk alleles. The SNP with the lowest p-value 
mapping any gene involved in the enriched pathways was located in ITGA4. It was 
rs2305586 (p=6.1×10
-11
 for NMIBC in progression for the recessive MoI) and it appeared 
in the leishmania infection pathway. 
In addition, this method makes possible to avoid the possible bias due to the major 
histocompatibility complex (MHC) inclusion in the analyses. A new round of analyses 
were performed masking the genes of this region (Horton, Wilming et al. 2004). When the 
results of with and without the MHC region were compared, we found out a decrease in the 
number of enriched GS (from 56 to 43) when the MHC region is masked. In most of the 
outcomes the enriched GS obtained in the MHC-masked analyses, were also obtained 
without that restriction. The only exception happens when this region is masked in the 
patients with MIBC whose outcome is progression, the LD r
2
 threshold is 0.2 and the SNP-
gene mapping distance is 20k using the GO categories. We obtained 4 low significant new 
GS related to intracellular transport and signal transduction when the MHC region was 
masked. 
ICSNPathway results 
Highly significant GS were obtained in patients with NMIBC and milder effects were 
observed in MIBC patients that die due to BC. When the different scenarios for LD, 
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genome-wide significance threshold, SNP-gene mapping and FDR levels of correction 
were considered we obtained 16 gene sets for the NMIBC patients in progression, 4 for 
those enduring recurrences and 10 for the deceased patients. Only two gene sets arose when 
the most restrictive threshold for genome-wide analysis and FDR were considered (p-value 
<10
-5
 and FDR <0.05): the GTP binding and the vasopressin regulated water reabsorption 
in NMIBC patients that suffered progressions. When the threshold of genome-wide 
significance was loosen to <10
-4
 and the FDR was kept at <0.05, a remarkable 
overrepresentation for GS regarding structural organization, tissue development and 
vasopressin regulated water reabsorption was obtained for patients with NMIBC that 
experienced progressions. 
The most frequent gene in the obtained GS for the NMIBC patients that showed 
progression was LIMA1. It appears in 5 of the 28 enriched GS and it is present in GS 
regarding structural cell organization. None of the genotyped SNPs in this gene reached 
significance in the initial genome-wide analysis. Once we selected the most significant 
SNPs included in the obtained GS, we observed 2 SNPs that may act as risk alleles in those 
patients with progression in NMIBC. The first one (rs7113416 with p=1.5×10
-13
 in the 
recessive MoI) was mapped to FANCF in the DNA reparation pathway.  The second one 
was associated to ITGA4 (rs2305586 with p=6.1×10
-11
 in the recessive MoI), which is 
related to focal adhesion and the ECM receptor interaction. 
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Table 8. Summary of the enriched and most representative gene sets in the NMIBC cases developing recurrences 
(corrected p-value at 0.05). The gene sets were grouped in several modules according to the hierarchical cluster 
trees and the modules defined by dynamic tree cut method. ALIGATOR did not offer any significant result. 
 
  
i-Gsea4Gwas GeSBAP GSA-SNP ICSNPathway 
Module A 
- CDC20 phospho APC 
mediated degradation of 
cyclinA 
- Autodegradation of 
CDH1 by CDH1 APC 
Module B 
- Regulation of cytokine 
biosynthesis 
- Cytokine metabolic 
process 
Module C 
- Regulation of T cell 
activation 
- Regulation of 
lymphocyte activation 
- T-cell activation 
Module D 
- G protein coupled 
receptor binding 
 
Module A 
- Di-, tri- valent 
inorganic cation 
transport 
- Calcium ion transport 
Module B 
- Response to UV 
- Response to light 
stimulus 
Module C 
- Protein amino acid N-
linked glycosylation 
- Glycoprotein 
biosynthetic process 
Module D 
- Phosphatidylinositol 
signaling system 
- Calcium signaling 
pathway 
Module E 
- Regulation of small 
GTPase mediated 
signal transduction 
- Exocytosis 
- Cell-cell adhesion 
- Axon guidance 
- Long-term 
depression** 
- Neurotransmitter 
transport** 
 
Module A 
- Calcium channel activity 
- Voltage gated potassium channel 
complex 
- Voltage gated channel activity 
- Voltage gated cation channel 
activity 
- Gated channel activity 
- Substrate specific channel activity 
- Ion channel activity 
- Cation channel activity 
- Cation transmembrane transporter 
- Metal ion transmembrane 
transporter activity 
Module B 
- Neurogenesis 
- Generation of neurons 
- Neuron differentiation 
- Axon guidance 
- Axonogenesis 
- Cellular morphogenesis during 
differentiation 
- Neurite development 
- Neuron development 
Module C 
- PTK activity 
- Transmembrane receptor PK 
activity 
- Transmembrane receptor PTK 
activity 
Module D  
- Hematopoietin interferon 
classD200 domain cytokine 
receptor activity 
- IL binding 
- Cytokine binding 
 
Module E 
-Neurotransmitter receptor 
binding and downstream 
transmission in the 
postsynaptic cell 
- Transmission across 
chemical synapses 
- Glutamate receptor activity 
- Synaptic transmission 
Module F 
- Enzyme linked receptor 
protein signaling 
- Transmembrane receptor 
PTK signaling 
Module G 
- NRAGE signals death 
through JNK 
- Rho GTPase cycle 
- Focal adhesion 
- ECM receptor interaction 
- Cell migration 
- Central nervous system 
development 
- Synapse 
- Axon guidance 
- Calcium signaling 
- Vascular smooth muscle 
contraction 
- Integrin binding 
- CAMs 
- Structural constituent of 
muscle 
- Muscle cell differentiation 
- Membrane organization 
and biogenesis 
Module H 
- Dilated cardiomyopathy 
- Hypertrophic 
cardiomyopathy 
- Arrhythmogenic right 
ventricular cardiomyopathy 
Module I 
- Axon guidance 
- NCAM1 interactions 
- NCAM signaling for 
neurite out growth 
 
Module A 
- Carbohydrate binding 
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Table 9. Summary of the enriched and most representative gene sets in the NMIBC cases developing progression 
events (corrected p-value at 0.05). The gene sets were grouped in several modules according to the hierarchical 
cluster trees and the modules defined by dynamic tree cut method i-Gsea4GWAS did not offer any significant result. 
 
  
ALIGATOR GeSBAP GSA-SNP ICSNPathway 
Module A 
- Hemopoiesis 
- Leukocyte 
differentiation 
Module B 
- Lymphocyte 
activation 
- Lymphocyte 
proliferation 
- Regulation 
immune system 
Module C 
- Unsaturated fatty 
acid metabolism 
- Leukotriene 
biosynthesis 
- Icosanoid 
metabolism 
Module D 
- Aspartic-type 
peptidase activity 
- IL1 binding 
- IP3 kinase activity 
- Potassium channel 
activity 
- Wnt-protein 
binding 
Module E 
- Histone H2A 
acetylation 
- Alkene 
biosynthesis 
- Glucan 
metabolism 
- cAMP metabolism 
- PLC activity by G-
protein 
- Telomerase 
regulation 
Module F 
- Filopodium 
assembly 
- Collagen 
metabolism 
- Negative 
regulation of DNA 
replication 
- Negative 
regulation of 
inflammatory 
response 
 
Module A 
- Regulation of 
small GTPase 
mediated signal 
transduction 
- Rho protein 
signal 
transduction 
- Regulation of 
Rho protein 
signal 
transduction 
- Regulation of 
Ras protein signal 
transduction 
Module B 
- Calcium ion 
transport 
- Calcium 
signaling pathway 
- Pl signaling 
system 
Module C 
- CAMs 
- Regulation of 
neurotransmitter 
levels 
- Cell recognition 
- Cell-cell 
adhesion 
 
Module A 
- Voltage gated channel 
- Voltage gated cation channel 
- Gated channel 
- Substrate specific channel 
- Ion channel 
- Cation transmembrane transporter 
- Cation channel 
- Metal ion transmembrane transporter 
Module B 
- Monovalent inorganic cation transport 
- Metail ion transport 
- Cation transport 
- Ion transport 
- Potassium ion transport 
- Voltage gated potassium channel 
complex 
- Voltage gated potassium channel 
activity 
- Potassium channel activity 
Module C 
- Neurogenesis 
- Neuron differentiation 
- Axon guidance 
- Axonogenesis 
- Cellular morphogenesis during 
differentiation 
- Neurite development 
- Neuron development 
Module D 
- NRAGE signals death JNK 
- Rho GTPase cycle 
- Signaling by NGF 
- G-alpha 12 13 signaling events 
- Cell death via NRAGE NRIF NADE 
Module E 
- PTK activity 
- Transmembrane receptor PK 
- Transmembrane receptor PTK 
Module F 
- TCR downstream signaling 
- PD1 signaling 
- Phosphorylation of CD3 and TCR 
zeta chains 
- CAMs 
- Type I diabetes mellitus 
Module G 
- Dilated cardiomyopathy 
- Arrythmogenic right ventricular 
cardiomyopathy 
- Sodium ion transport 
- Calcium channel activity 
 
Module H 
- Transmission of nerve impulse 
- Transmembrane receptor PTK 
signaling 
- Muscle cell differentiation 
- Cytoskeletal protein binding 
- Sensory perception 
- PTP activity 
- ABC transporters 
- O-glycan biosynthesis 
- Nuclear receptor transcription 
- Guanyl nucleotide exchange factor  
- Cell projection 
- Synapse 
- Axon guidance 
- Cell migration 
- Brain development 
- Extracellular matrix part 
- Basement membrane 
- Focal adhesion 
- ECM interactions 
- Integrin interactions 
- Tight junction 
- Adherence junction 
- Leukocyte transendothelial migration 
Module I 
- CREB phosphorilation of RAS 
- Post NMDA receptor activation events 
- Neurotransmitter receptor binding and 
downstream transmission in the 
postsynaptic cell 
- Transmission across chemical synapses 
Module J 
- Platelet activation triggers 
- Formation of platelet plug 
- Platelet activation 
Module K 
- Opioid signaling 
- PLC beta mediated events 
- CAMs 
- PLC gamma1 signaling 
- GAP junction 
- Vascular smooth muscle contraction 
- GNRH signaling pathway 
- Calcium signaling pathway 
- Long term potentiation 
- Melanogenesis 
- ST myocyte  AD pathway 
- Regulation of insulin secretion by 
glucagon-like petide1 
- Regulation of insulin secretion by free 
fatty acids 
- NO1 pathway 
- G-alpha S signaling events 
 
Module A 
- GTP binding 
Module B 
- Actin filament 
organization 
- Actin filament 
binding 
Module C 
- Tissue development 
- Anatomical 
structure formation 
Module D 
- Vasopressin 
regulated water 
reabsorption 
Module E 
- ECM receptor 
interaction 
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Table 10. Summary of the enriched and most representative gene sets in the MIBC cases 
developing progression events (corrected p-value at 0.05). The gene sets were grouped in several 
modules according to the hierarchical cluster trees and the modules defined by dynamic tree cut 
method. Results were obtained only when GeSBAP and GSA-SNP were applied. 
GeSBAP GSA-SNP 
Module A 
- Regulation of Rho protein signal 
transduction 
- Rho protein signal transduction 
- Regulation of Ras protein signal 
transduction 
- Regulation of small GTPase 
mediated signal transduction 
Module B 
- Bone remodeling 
- Tissue remodeling 
Module C 
- Di- , trivalent inorganic cation 
transport 
- Calcium ion transport 
Module D 
- Regulation of neurotransmitter levels 
- Neurotransmitter secretion 
Module E 
- Brain development 
- Central nervous system development 
Module F 
- Cell junction organization 
- Homophilic adhesion 
- Cell-cell adhesion 
Module G 
- Anion transport 
- Phosphate transmembrane 
transporter activity 
- Axon guidance 
- Transmembrane receptor PTK 
signaling 
- Calcium signaling 
- Muscle development 
- Phospholipid transporter activity 
 
Module A 
- Voltage gated channel activity 
- Voltage gated cation channel 
activity 
- Gated channel activity 
- Substrate specific channel 
activity 
- Ion channel activity 
- Cation transmembrane 
transporter activity 
- Cation channel activity 
- Metal ion transmembrane 
transporter activity 
Module B 
- Voltage gated potassium channel 
activity 
- Potassium channel activity 
- Metal ion transport 
- Cation transport 
- Ion transport 
- Monovalent inorganic cation 
transport 
- Potassium ion transport 
Module C 
- Neurogenesis 
- Generation of neurons 
- Neuron differentiation 
- Axonogenesis 
- Cellular morphogenesis during 
differentiation 
- Neurite development 
- Neuron development 
Module D 
- Collagen 
- Extracellular matrix part 
- Proteinaceous extracellular 
matrix 
- Extracellular matrix 
Module E 
- PTK activity 
- Transmembrane receptor PK 
activity 
- Transmembrane receptor PTK 
activity 
Module F 
- Axon guidance 
- NCAM signaling for neurite out 
growth 
- NCAM1 interactions 
 
Module G 
- Calcium channel activity 
- Arrhythmogenic right ventricular cardiomyopathy 
- Hypertrophic cardiomyopathy 
- Dilated cardiomyopathy 
Module H 
- Trafficking of AMPA receptors 
- Transmission across chemical synapses 
- Neurotransmitter receptor binding and downstream 
transmission in the postsynaptic cell 
Module I 
- Formation of platelet plug 
- Platelet activation 
- Enzyme linked receptor protein signaling  
- Brain development 
- Central nervous system development 
- GTPase regulator activity 
- GTPase activator activity 
- Focal adhesion 
- ECM receptor interaction 
- CAMs 
- Type I diabetes mellitus 
- Viral myocarditis 
- Regulation of insulin secretion by glucagon like 
peptide1 
- Glutamate receptor activity 
- Phosphoric diester hydrolase activity 
- Calcium signaling 
- Cell-cell adhesion 
- Cell junction organization 
- Hematopoietin interferon classD200 domain cytokine 
receptor activity 
- Regulation of neurotransmitter levels 
- Embryonic development 
- PTP activity 
- Adherens junction 
- Axon guidance 
- Rho GTPase cycle 
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Table 11. Summary of the enriched and most representative gene sets in the in the MIBC cases 
dying due to BC (corrected p-value at 0.05). The gene sets were grouped in several modules 
according to the hierarchical cluster trees and the modules defined by dynamic tree cut method. 
Results were obtained only when GeSBAP and GSA-SNP were applied. 
GeSBAP GSA-SNP 
Module A 
- Rho protein signal transduction 
- Regulation of Rho protein signal 
transduction 
- Regulation of Ras protein signal 
transduction 
- Regulation of small GTPase mediated 
signal transduction 
Module B 
- Synaptic transmission 
- Regulation of neurotransmistter levels 
- Neurotransmitter secretion 
Module C 
- Di-, trivalent inorganic cation 
transport 
- Calcium ion transport 
Module D 
- Homophilic cell adhesion 
- Cell-cell adhesion 
Module E 
- Sodium ion transport 
- Phosphate transmembrate transporter 
activity 
- Transmembrane receptor PTK 
signaling 
- Adherens junction 
- Phospholipid transporter activity 
- Protein export 
 
Module A 
- Neurogenesis 
- Generation of neurons 
- Neuron differentiation 
- Axonogenesis 
- Cellular morphogenesis during 
differentiation 
- Neurite development 
- Neuron development 
Module B 
- Cation transport 
- Voltage gated channel activity 
- Voltage gated cation channel 
activity 
- Gated cannel activity 
- Ion channel activity 
- Cation Transmembrane 
transporter activity 
- Cation channel activity 
- Metal ion transmembrane 
transporter activity 
Module C 
- Collagen 
- Basement membrane 
- Extracellular matrix part 
- Proteinaceous extracellular 
matrix 
- Extracellular matrix 
Module D 
- PTK activity 
- Transmembrane receptor PK 
activity 
- Transmembrane receptor PTK 
activity 
Module E 
- Axon guidance 
- NCAM1 interactions 
- NCAM signaling for neurite out 
growth 
Module F  
- Arrythmogenic right ventricular 
cardiomyopathy 
- Hypertrophic cardiomyopathy 
- Dilated cardiomyopathy 
Module G 
- Regulation of actin cytoskeleton 
- Focal adhesion 
- ECM receptor interaction 
- Integrin-cell surface interactions 
 
Module H 
- Guanyl nucleotide exchange factor activity 
- Signaling by NGF 
- Rho GTPase cycle 
- NRAGE signals death through JNK 
- G-alpha 12 13 signaling events 
Module I 
- Adherens junction interactions 
- Cell-cell adhesion system 
- Cell junction organization 
Modules J 
- Collagen mediated activation cascade 
- Reactome formation of platelet plug 
- Platelet activation 
Modules K 
- Enzyme linked receptor protein signaling 
- Transmembrane receptor PTK signaling 
Modules L 
- Neurotransmitter receptor binding and downstream 
transmission in the postsynaptic cell 
- Transmission across chemical synapses 
Modules M 
- Glutamate receptor activity 
- Neurotransmitter levels 
- Synaptic transmission 
Modules N 
- Brain development 
- Central nervous system development 
Module O 
- Axon guidance 
- Semaphorin interactions 
- Viral myocarditis 
- Cell-cell adhesion 
- Adherens junction 
- Tight junction 
- Type II diabetes mellitus 
- Calcium signaling pathway 
- Regulation of insulin secretion by glucagon like 
peptide1 
- Synapse 
- Hematopoietin interferon classD200 domain cytokine 
receptor activity 
- Amine compound SLC transporters 
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4.3. SNP-SNP interactions associated with UCB clinical outcomes 
We studied prediction of tumour recurrence and progression in 836 UCB cases with 
NMIBC and progression and mortality in 235 MIBC. In the Materials and Methods Section 
was pointed the number of events and censored observations for each clinical outcome and 
the number of SNPs included in the analyses. 
In the step of tuning and assessment of this new methodology, we explored different cut-off 
points of the survival time to define binary response variables: 30, 40, 50, 60, 70, and 80 
months, considering to the Formula 1, the distributions of the survival and follow-up times 
for each event, and taking into account that the number of censored observations was quite 
high for the NMIBC clinical outcomes. We selected 10,000 random SNP pairs and 
estimated, for each pair, the partial likelihood ratio test based on the two fitted Cox 
regression models (Formula 2a and 2b). For each one of these selected pairs and for each 
of the 6 possible definition of the binary response variable given by the different cut-off 
points in the survival time, we calculated the likelihood ratio test based on the two fitted 
logistic regression models (Formulas 3a and 3b) and the Pearson correlation coefficient 
between the p-values of the Cox models and each of the 6 different logistic models, as -
log10 values. These correlation coefficients are shown in the Table 12, where we can 
observe in all scenarios that the correlations increase with the cut-off point. The highest 
correlation was reached when the cut-off point coincided with the maximum survival time 
(i.e., 80 months). 
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Table 12. Correlation coefficients (r) between the p-values obtained by the logistic and the Cox 
regressions for 10,000 random SNP pairs. 
 NMIBC MIBC 
 Recurrence Progression Progression Recurrence 
Cutpoints r 
Censored 
n(%) 
r 
Censored 
n(%) 
r 
Censored 
n(%) 
r 
Censored 
n(%) 
30 0.816 607 (72.6) 0.669 782 (93.5) 0.79 116 (49.4) 0.721 147 (62.2) 
40 0.869 586 (70.1) 0.743 776 (92.8) 0.807 112 (47.7) 0.793 136 (57.9) 
50 0.913 573 (68.8) 0.637 768 (91.9) 0.829 107 (45.5) 0.826 132 (56.2) 
60 0.932 566 (67.7) 0.891 762 (91.1) 0.836 106 (45.1) 0.842 129 (54.9) 
70 0.936 564 (67.5) 0.954 756 (90.4) 0.836 106 (45.1) 0.848 127 (54.0) 
80 0.946 561 (67.1) 0.995 753 (90.1) 0.836 106 (45.1) 0.848 127 (54.0) 
In order to compare the results between logistic and Cox regression models and analyze the 
scenario for SNP interactions associated with low p-values, 5 million pairs were randomly 
selected and the four regression models run (Formulas 2a, 2b, 3a and 3b). Then, we 
calculated the p-values from the two ratio likelihood tests evaluating the interaction term, 
and the Pearson correlation coefficient and showed a good relationship among them. 
However, we observed that the sample size influenced the correlation. In NMIBC patients 
(836 individuals), we obtained a very high correlation (r=0.944) for the analysis of 
recurrence, and a moderate correlation (r=0.944) for progressions. Analysing BC-specific 
mortality and progression in the MIBC (235 individuals), we obtained lower correlations, r 
= 0.858 and r = 0.840, respectively (Supplementary Figure 10). The number of models with 
a strong discrepancy between both kinds of regression is very low. Similar to the 
correlation coefficients, the number of discrepancies decreases with increasing the sample 
size. 
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In the second step of the analyses, we executed BOOST in order to detect the potential 
interactions between all the pairs of SNPs. We selected thr interactions that reached P <10
-4
 
or lower. At last, we obtained around 22 millions of SNP-SNP interactions detected by 
logistic regression for each of the four outcomes considered. We also observed that the 
likelihood reported by BOOST was similar to that obtained directly fitting the two logistic 
regression models. 
In the third step, two Cox regression models (Formulas 2a and 2b) were fitted for all the 
pair-wise SNP-SNP interactions selected by BOOST and we estimated the p-values of the 
partial ratio likelihood tests. The models were not adjusted by potential confounding 
factors. Similarly to the logistic analysis performed using BOOST, we fitted unadjusted 
Cox regression using the co-dominant mode of inheritance. We set a conservative 
significance threshold at P <10
-5
 to select SNP-SNP interactions that may be of interest in 
the prognostic assessment of the disease. Using this criterion, around 1.5 million of 
interactions were select for further analyses. 
In the last step we finally adjusted Cox regression models including confounder variables 
and combining the different inheritance models for the pairs of SNPs. We fitted the Cox 
regression models using the 16 possible combinations between the 4 modes of inheritance 
(additive, recessive, dominant and co-dominant) for each pair of SNPs. 
Correction for multiple testing was needed at this stage and we applied the two approaches 
explained in the Materials and Methods Section. First, by applying the method based on the 
principal components and the informative SNPs, we set the threshold at 8.60×10
-14
 and 
9.46×10
-14
 for the NMIBC and the MIBC subsample. The thresholds obtained by the 
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second of the methods, based on the 0.4 correction factor over the total number of 
interactions gave two similar thresholds, 1.06×10
-13
 and 1.17×10
-13
 for the NMIBC and 
MIBC subsamples, respectively. In the Table 13, we included the most significant models 
for each of our four outcomes, some of them with p-values smaller than the significant 
thresholds calculated by the 2 methods. 
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Table 13. SNP-SNP interactions with potential prognostic value in UCB. 
Subphenotype Outcome SNP ID Chr 
Closest gene 
(SNP location) 
MoI SNP ID Chr 
Closest gene 
(SNP location) 
MoI P 
Threshold 
Informative-
SNPs 
Threshold 
0.4-Factor 
NMIBC Recurrence rs7498329 16 
LAT 
(flanking 3UTR) 
A rs909010 19 
TRPM4 
(intron) 
A 5.53×10-14 Significative Significative 
NMIBC Recurrence rs941586 14 
CHGA 
(intron) 
R rs6093059 20 
CDH4 
(flanking 5UTR) 
A 7.31×10-14 Significative Significative 
NMIBC Recurrence rs668204 11 
NCAM1 
(flanking 3UTR) 
D rs7141930 14 
SEL1L 
(flanking 5UTR) 
C 1.91×10-13 Non-significative 
Non-
significative 
NMIBC Recurrence rs2169685 10 
SLC16A9 
(flanking 3UTR) 
D rs17004695 21 
C21orf29 
(flanking 3UTR) 
D 1.94×10-13 Non-significative 
Non-
significative 
NMIBC Progression rs253235 5 
FLJ46010 
(intron) 
R rs10148938 14 
CDCA4 
(flanking 5UTR) 
D 8.43×10-14 Non-significative 
Non-
significative 
MIBC Progression rs3750272 2 
HTLF 
(flanking 5UTR) 
D rs2126337 16 
SALL1 
(flanking 5UTR) 
R 1.66×10-13 Non-significative 
Non-
significative 
MIBC BC-related surv rs10110883 8 
MSR1 
(flanking 5UTR) 
D rs10847791 12 
KIAA1944 
(intron) 
D 4.11×10-14 Significative Significative 
MIBC BC-related surv rs11977984 7 
LHFPL3 
(intron) 
C rs4394757 10 
IPMK 
(flanking 3UTR) 
C 7.24×10-14 Significative Significative 
MIBC BC-related surv rs11588107 1 
PROX1 
(flanking 5UTR) 
D rs6439470 3 
RYK 
(flanking 5UTR) 
D 1.56×10-13 Non-significative 
Non-
significative 
MIBC BC-related surv rs2066713 17 
SLC6A4 
(intron) 
C rs2015823 22 
CARD10 
(intron) 
D 2.03×10-13 Non-significative 
Non-
significative 
MoI includes: A for additive; R for recessive; D for dominant; C for co-dominant. 
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 Chapter 5: Discussion 
The search of new and robust prognostic markers for UCB is, in fact, the driving force of 
this study that is unique in providing new clues on the involvement of inherited factors in 
UCB outcome, beyond the studies on cancer risk. It is highly unlikely that only one 
factor/marker will be able to discriminate those individuals presenting an outcome or not. 
Rather, it is highly probable that prognosis models need to consider several independent 
factors/markers. This reasoning is even more certain when considering genetic variables 
because of the relatively small effect of each of them individually. 
5.1. Independent SNPs associated with UCB clinical outcomes 
We have conducted a comprehensive genome-wide prognosis scan in patients with UCB 
and have identified distinct loci associated with the risk of tumor recurrence, progression, 
relapse and BC-specific/overall mortality. Our notable findings include: 1) the consistency 
of results between the two genome-wide studies; 2) the inclusion of independent 
populations for Validation when NMIBC is considered; and 3) the identification of several 
significant loci with relatively high estimates, especially when compared with those found 
in GWAS for cancer risk. The identified SNPs lie in genetic regions that have not been 
previously related to any UCB outcome. As in GWAS of cancer risk, most of the SNPs 
associated with prognosis are located in intergenic or intronic regions, suggesting that they 
may tag other SNPs directly associated with the outcomes of interest. Alternatively, they 
could influence gene expression, splicing, or other events at distance. A genetic enrichment 
analysis using Ingenuity
®
 indicated that most of the genes harboring these significant SNPs 
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associated with the NMIBC outcomes were involved in cellular death and development, 
drug and lipid metabolism, and molecular transport. Regarding MIBC, enrichment was 
detected for infectious disease response, molecular transport and cell signaling, and 
hematological system development. 
rs754799, showing the strongest association with risk of recurrence and of relapse localizes 
to 19p13.3 and lies less than 1kb 5’ from SCAMP4 and ADAT3, two genes that share 
common sequence but are alternatively transcribed. SCAMP4 encodes a member of the 
secretory carrier membrane protein family (SCAMP) that has been implicated in membrane 
trafficking and vesicular transport and is ubiquitously expressed (Castle and Castle 2005). 
ADAT3 encodes an adenosine deaminase that is involved in tRNA editing. The association 
of either of these genes with cancer has not been previously reported.  
One SNP was significantly associated with progression in both the Discovery and 
Validation phases and 5 exhibited similar associations in both phases as well, three of 
which are located in introns. The strongest association was for rs4246835, which is located 
in a “gene desert” region on 9p22-p13, ~246kb from the nearest gene, SLC24A2. This gene 
encodes a sodium, potassium, and calcium ion exchanger and is implicated in retinal 
photoreceptor signaling (Sharon, Yamamoto et al. 2002). Centromeric to this SNP lies 
MLL3 (also known as AF9, at ~312 Kb distance), a Drosophila Trithorax homolog gene 
that regulates cell differentiation, is often translocated in mixed lineage leukemia, and has 
been found to be somatically mutated in some tumors (COSMIC database, 
http://www.sanger.ac.uk) (Pina, May et al. 2008). It is possible that rs4246835 tags this 
gene in the variant’s association with NMIBC progression, although further fine-mapping 
of this region is necessary to identify the causal SNP. 
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In addition to rs754799 described above, two SNPs showed similar association with relapse 
in both Discovery and Validation phases although results were not significant in the latter 
phase: rs4946483, a non-genic SNP on chromosome 6q22, and rs11615759, an intronic 
variant of SOX5. Chromosome 6q22 deletions in tumors correlate with malignant and 
metastatic progression in sporadic endocrine pancreatic tumors and are associated with 
shorter survival in primary central nervous system lymphoma patients, suggesting the 
presence of tumor suppressor gene(s) in this region (Barghorn, Speel et al. 2001; 
Nakamura, Kishi et al. 2003; McPhail, Law et al. 2011). SOX5 is a member of the sex 
determining region Y (SRY)-related high mobility group (HMG)-box family of 
transcription factors involved in embryonic development and cell fate determination. SOX5 
amplification has been found in testicular seminomas (Zafarana, Gillis et al. 2002). 
Some of the SNPs identified in the Discovery phase of the MIBC studies are statistically 
significant even with the most stringent scenarios of multiple test correction. The SNP 
rs1015267 shows the strongest association with risk of death due to UCB for the recessive 
and codominant modes of inheritance (p-value < 1×10
-8
). It is located in the intronic region 
of TMEM16C in the chromosome region 11p14.2. This gene encodes a member of 
TMEM16 family of transmembrane proteins, which regulates calcium activated chloride 
channels (Hartzell, Yu et al. 2009). The members of this family are cell-surface proteins 
that are up-regulated in cancer (Galindo and Vacquier 2005). In addition, it seems that 
mutations described in one of the most relevant members of this family (ANO1) is not 
associated carcinogenesis, but cell proliferation or tumor progression (Miwa, Nakajima et 
al. 2008). 
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When the progression was evaluated in MIBC, another statistically significant recessive 
SNP arose (rs16927851). This SNP is located in the 3’ flanking region of BCAT1 (~ 
100kb), which is located in 12p12.1. This gene encodes the cytosolic form of the enzyme 
branched-chain amino acid transaminase. It catalyzes the reversible transamination of 
branched-chain alpha-keto acids to branched-chain L-amino acids, essential for cell growth. 
Two different clinical disorders have been attributed to a defect of branched-chain amino 
acid transamination: hypervalinemia and hyperleucine-isoleucinemia. Within the BCAT1 
gene there is a functional c-Myc binding site located 3’ of its transcription initiation site, 
and has been shown to be a direct target for c-Myc activity in both mice and humans 
(Benvenisty, Leder et al. 1992). It was pointed that BCAT1 is expressed at significantly 
higher levels in tumor tissues with distant metastases, compared to those without them. It 
makes possible to suggest the use of this gene expression as a highly reliable predictive 
factor for distant metastasis in patients with advanced colorectal cancer (Yoshikawa, 
Yanagi et al. 2006). Additional studies on the association between cancer susceptibility and 
this gene overexpression suggest its involvement in epithelial ovarian cancer (Ju, Yoo et al. 
2009), nasopharyngeal carcinoma (Zhou, Feng et al. 2007) and testicular germ cell tumors 
(Rodriguez, Jafer et al. 2003). On the other hand, there is also some evidence regarding the 
prognostic role of the mRNA levels of BCAT1 in medulloblastoma patients with metastases 
compared with those without (de Bont, Kros et al. 2008). 
Resequencing, searching for causal variants, and functional analyses should shed light on 
the mechanisms through which these SNPs associate with UCB outcomes. The application 
of high throughput genotyping to the identification of genetic variants associated with 
outcome poses major challenges. One of them is the heterogeneity of case series. In our 
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work, Discovery phase was performed with prospective studies and the Validation for 
NMIBC consisted mostly of retrospective studies having different aims and applying 
variable designs as well as classifications and therapeutic criteria. We made outstanding 
efforts to identify them and ensure data exhaustiveness and homogeneity. Their variability 
has likely resulted in the Validation of a smaller number of NMIBC SNPs through effect 
dilution, suggesting that the SNPs identified are robust to such variability and that 
additional prospective studies may identify new genetic markers. Even with this constraint, 
our study has identified several novel independent genetic markers associated with 
prognosis, most of them in proximity or within biologically plausible gene candidates. 
Several of these genes are implicated in cellular signaling or tissue/organ development, 
suggesting a link between these processes and tumor progression. A notable finding was 
the greater magnitude of the HR associated with the outcomes of interest in comparison to 
the risks observed in genetic risk association studies. 
Importantly, in the NMIBC series there were no consistent significant associations of the 
SNPs with baseline tumor characteristics in the four series (Supplementary Table 6). None 
of the NMIBC SNP p-values reached significance after Bonferroni correction. In addition, 
the correlation coefficient was relatively small with the largest rho coefficient being 0.17. 
In the MIBC series no significant association was observed after correcting for multiple 
testing (Supplementary Table 9). Therefore, these SNPs were not highly correlated with 
baseline tumor stage, grade, or size and their association with the outcome was independent 
from the effects of other prognostic factors since those were included as covariates in the 
adjusted models. 
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UCB is a complex disease regarding both etiology and prognosis and the prognosticators 
that are used in standard practice discriminate poorly cases according to their tumor 
evolution. This complexity is shown when comparing the discrimination ability (c-
statistics) of the identified SNPs with that of the used and most important prognosticators 
(stage-grade-TG, multiplicity, and size). For progression, the added value of the SNPs was 
5%-6%, while neither multiplicity nor size adds any value yet they are generally used by 
urologists to prognosticate UCB progression. The c-statistics of the SNPs in discriminating 
recurrence is smaller, similar to most prognosticators and biomarkers for this outcome. We 
suspect the occurrence of recurrence is mainly driven by the skills of the surgeon rather 
than the biology of the tumor or the patient because there are no robust biological markers 
of associated with recurrence. Therefore, we believe that the study provides evidence of the 
potential clinical usefulness of inherited factors in UCB prognosis. 
While two NMIBC subphenotypes are well recognized (low-risk and high-risk), this study 
aimed at identifying SNPs associated - as main effects - with outcome in overall UCB as 
evidence of the important role of the host factors in tumor evolution, similarly to what has 
been evidenced in cancer susceptibility assessments. Furthermore, the subphenotype 
analysis would require larger studies with a common pathological assessment to avoid 
misclassification. Furthermore, the study did not set out to assess the predictive value of the 
markers for treatment response, this requiring of specific study design and analysis. 
This study has several major strengths, among them the agnostic comprehensive 
exploration of the genome, the large sample size and large number of events with several 
independent series for the Discovery and Validation (when available), the quality of the 
clinical and the prospective follow-up in Discovery studies, the long follow-up of all 
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patients, and the inclusion of all stages representative of the disease seen in a wide range of 
clinical settings. Although this project included patients from American and European 
cohorts, the analysis was restricted to Caucasian patients of European descent. In addition, 
genotyping for the Spanish series was performed at the Core Genotyping Facility, National 
Cancer Institute, USA. The stringent quality control measures applied to the NCI GWAS 
(Rothman, Garcia-Closas et al. 2010) did not show population substructure in the Spanish 
study with the other US studies. Therefore, our patient population is rather homogeneous: 
only the patients recruited in Tenerife shown slight population differences in a substructure-
population test performed by principal component analysis. The genomic control inflation 
factor derived from the individual SNP analysis indicated that the effect of population 
substructure was minimal. The long follow-up (> 10 years) of the patients in almost all 
series made possible to have sufficient events in all the considered outcomes. Given the 
number of cases and events, we have 80% power to detect hazard ratios of about 1.5-1.6 or 
greater for homozygous rare genotype with frequencies of 0.10 and 0.08 for recurrence and 
relapse, respectively, at the unadjusted p-value of 1×10
-4
. The results are robust for tumor 
progression in NMIBC patients when HR >1.8 for homozygous rare genotype with 
frequencies >0.20. When we considered the MIBC cases, the statistical power was 
diminished due to the lower sample size available for these patients. Nevertheless, we have 
80% power to detect HR around 2 for homozygous genotypes with frequencies of >0.3 
(Supplementary Figure 8). In addition, initial genome-wide scans were done in parallel in 
the Discovery phase and the main results were cross-validated in both series. The most 
significant results were further replicated in additional NMIBC series to minimize false 
discovery. 
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A further strength of the study is that it involved both a referral center and a wide range of 
non-referral centers in the discovery phase, indicating that the findings are robust and could 
be applied in a broad range of community-University hospital settings. While this study 
represents an important advance in the discovery of inherited susceptibility genetic factors 
involved in UCB outcome, the translation of such results into the clinics, both as prognostic 
and predictive markers in UCB, requires additional confirmation in homogeneously 
conducted follow-up studies. 
In summary, we have identified genetic variants independently associated with outcome in 
patient with UCB through a cross-validation of two genome-wide scans performed in 
independent Caucasian populations and a further Validation for NMIBC patients with 6 
independent series of different geographical location and urological practice. These 
findings highlight the important role of inherited genetic factors in tumor progression. The 
ease of analyzing germline SNPs and the robustness of the assays used are important assets 
of this strategy. Next steps would include efforts to extend these studies to larger series, 
combine independent SNPs, and dissect the biological underpinnings of inherited genetic 
factors in the clinical evolution of UCB. The lack of large clinical series with germline 
DNA, exhaustive and reliable clinical data, and enough follow-up is a major challenge for 
the Validation of genome-wide prognostic studies. 
 
5.2. Biological pathways associated with UCB outcomes 
In this study, we used an approach based on prior biological knowledge from public 
databases in order to detect gene sets that display an overrepresentation of SNPs 
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significantly associated with UCB outcomes. The main motivation of this approach is to 
increase the power to discover new genetic relations with a particular GS, when compared 
with the single-SNP strategy based in its main effects. We decided to proceed using 
different statistical approaches because it is known that even using the same set of data the 
results can vary substantially under different gene set analysis (GSA) scenarios (Wang, Li 
et al. 2007; Hong, Pawitan et al. 2009; Cantor, Lange et al. 2010). 
The great amount of GS detected associated with the different outcomes made necessary to 
interpret the results using the clustering and similarity methods described in the Materials 
and Methods Section. According to the results obtained for NMIBC series – indistinctively 
for recurrence or progression – there is an important overrepresentation of GS associated 
with the signaling of G protein, small GTPase and Rho protein, which were obtained using 
i-Gsea4Gwas, ICSNPathway, GSA-SNP or GeSBAP. The association of alterations in 
these regulator GS with cancer development and their clinical importance have been 
discussed in multiple publications (Oxford and Theodorescu 2003; Gur, Kadowitz et al. 
2011; Fujita, Shida et al. 2012; Smith, Baras et al. 2012). The alterations of key pieces in 
the inflammatory response seem to be also important because the regulation of T-
cell/lymphocytes is also modified in recurrence and progression according to the results 
obtained in ALIGATOR/GSA-SNP and i-Gsea4Gwas respectively. There is plenty of 
literature associating the T-cell/lymphocyte activity with the prognosis after treatments 
based on BCG instillation (Hoffmann, Roumeguere et al. 2006; Takeuchi, Dejima et al. 
2011); even its use as a prognostic factor was suggested in the past (Mizutani, Okada et al. 
1996; Saint, Patard et al. 2002). Furthermore, GS regarding membrane cell transport based 
on cation transport or voltage-gated channel activity – obtained in GeSBAP and GSA-SNP 
DISCUSSION 
102 
 
– also arose in the GSA. Interestingly, the more specific calcium ion transport channel 
appeared in both methods. Multiple GS associated to neuronal/axon signaling and 
proliferation; and synaptic processes appeared in recurrence and progression NMIBC series 
when GeSBAP and GSA-SNP were used. There are evidences regarding neuron-associated 
protein expression with the prognosis of NMIBC (Mhawech-Fauceglia, Ali et al. 2009). 
On the other hand, we have observed that some groups of GS are more common in one of 
the NMIBC outcomes. Altered gene sets regarding cell-cell junctions (general CAMs, GAP 
junction, integrins and extracellular matrix) are very common in progression – when 
GeSBAP and GSA-SNP are used – but they are much scarce in recurrence and they are 
obtained only in GSA-SNP in last outcome. Probably these results were obtained because 
of the cell proliferation and reorganization in the context of cancer invasiveness (Zhong, 
Chen et al. 2010; Reis, Leite et al. 2012). In addition, alterations in the actin filament 
organization related pathways were detected in NMIBC progression when ALIGATOR 
and ICSNPathway were applied. These pathways, in addition to small GTP-binding protein 
Rho, have been described as a potential prognostic factor for UCB invasiveness (Kamai, 
Tsujii et al. 2003). 
The results obtained for the MIBC series are much less rich than those obtained in the 
NMIBC series because of the modest statistical power available for this UCB subtype. 
Furthermore, we obtained significant results only when GSA-SNP and GesBAP were 
applied; and as it was pointed above, these methods have multiple important biases. Thus, 
the results and conclusions for the MIBC series should be accepted with caution. Probably 
the most significant aspect of the results is the extremely high concordance between the 
MIBC outcomes. However, there is one general difference: the presence of structural 
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tissue-development pathways in MIBC progression (e.g. bone remodeling, tissue 
remodeling and muscle development). 
In the MIBC series we found again the GS regarding small GTPase signalling, cell-
membrane transporters and neuronal/axon, which appeared also in the NMIBC series. It 
would suggest an action along the time that affects the prognosis of the disease from the 
reappearance of the tumor to the patient’s death. It may be very interesting to evaluate the 
overlapping of the enriched GS between the progression outcomes in NMIBC and MIBC in 
order to detect some shared pathway that would lead us from NMIBC to the MIBC. 
Unfortunately we are limited by the modest statistical power in the MIBC series. Apart 
from the mentioned common GS found in all the analyzed outcomes, we could not find any 
significant block of similar pathways in the different progression outcomes. On the other 
hand, we observed that immune and inflammatory pathways such as the T-cell/lymphocyte 
regulation or the production of leukotrienes/icosanoids are specific of NMIBC progression. 
A priori unexpected results aroused in some of the methods in all the analyzed outcomes, 
such as the groups of pathways related to cardiomyopathy. However, even in this case a 
possible link with UCB can be established through the action of some members of the S100 
gene family, whose over-expression is associated with poor prognosis in UCB (Yao, 
Davidson et al. 2007). 
The number of GSA procedures is increasing every few months trying to overcome the 
known limitations in these methodologies. However, the vast majority of these methods 
have been designed with the aim of being applied on studies based on a case-control 
strategy ant it leaves a rather reduced list of options for a prognostic study. Despite of this, 
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several GSA methods based on competitive tests (those which compare test statistics for 
SNP/genes in the pathway to a background defined by the remaining pathways) and the p-
values obtained in the GWPS are available. It is difficult to give more credibility to one 
statistical approach because no much is known in terms of comparative power between the 
algorithms and even there are some contradictions establishing the most reliable method 
when some of them have been compared (Chen, Hutter et al. 2010; Jia, Wang et al. 2011; 
Kwon, Kim et al. 2012). Most of the previous studies showed lack of power in unfavorable 
scenarios such as small sample size and makers with low association with the disease. 
One of the critical points in the SNP/gene strategies is the lack of common criteria in the 
reduction of the SNP information within each gene. In all the studied algorithms the SNP 
with the lowest p-value acts as a proxy of its closest gene. However this approach may lead 
to a loss of power because when multiple markers with risks of different directions map one 
single gene, their combined effect may be lost. 
The presence of LD between the SNPs is a potential source of bias. It invalidates the 
assumption of independence between the SNPs and ignores that multiple signals from one 
single genuine marker may appear. Algorithms such as ALIGATOR claim to control this 
effect and we have seen that it is basically certain in our dataset; others based on i-GSEA 
request the use of LD-pruned before the GSA and those based on the Z-statistic method 
ignore the LD structure. Despite of this, the preservation of the LD patterns in the dataset is 
important but they are usually disrupted in SNP-label permutation procedures inherent in 
the assessment of the statistical significance. At the gene level we can establish potential 
biases regarding the gene length and their overlapping. The former means that larger genes 
will be more prone to have more disease-associated signal within them and inflate the 
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significance for those GS with many long genes. The latter implies that one single SNP 
may be mapped to several overlapping genes and will lead to an overrepresentation of its 
signal. The correction for gene size is accomplished in ALIGATOR and i-GSEA using 
resampling strategies, but no correction is performed neither in GSA-SNP nor GeSBAP. 
The authors of ALIGATOR and GSA-SNP mention that in case that a SNP could be 
mapped within different genes, both would be included in the analysis; nothing in this 
regard is mentioned in i-GSEA but the overlapping problem is issued (Jia, Wang et al. 
2010; Wang, Jia et al. 2011). 
The GSA methods have an inherent source of bias: the GS themselves. There is still an 
important gap in the knowledge of the biological function of all the genes in genome, so the 
genes with no functional evidence are lost. On the other hand, the well studied genes and 
biological functions are overrepresented in the GS. It may be an important issue in the 
competitive test strategies because an unrealistic background of analysis is constructed. An 
additional non-negligible factor emerges when the different GS sources are compared and 
reveal a lack of consensus in the common GS. Despite of this, considerable efforts are done 
in trying to compile different sources of information that overcome these problems by 
initiatives such as MSigDB (Subramanian, Tamayo et al. 2005). The different statistical 
methods underneath the GSA algorithms demand a collection of independent GS to be 
analyzed. Unfortunately this request is difficult to fulfill because a great number of genes 
play diverse roles in different pathways; not to mention the hierarchical structure of GO. In 
our study we used the provided GS lists in ALIGATOR and GeSBAP. On the other hand, 
we used the GS available in MSigDB in the other methods because it claims to keep only 
GS with a certain level of non-redundancy. Nonetheless, it may cause over-conservative 
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results because the higher is the number of GS, the more strict needs to be the multiple test 
correction. The differences in GS size can lead to biased results (in a similar way as we see 
in the gene-size issue) but it can be controlled by resampling (ALIGATOR) or 
permutations (i-GSEA) (Efron and Tibshirani 2007). 
According to recent reviews on this issue (Cantor, Lange et al. 2010; Wang, Li et al. 2010; 
Fridley and Biernacka 2011; Wang, Jia et al. 2011), we selected four of the most popular 
and user-friendly tools to perform our analysis that were based on different statistical 
backgrounds. In addition, we added ICSNPathway as far as it claims to be the only tool 
able to obtain functional results. All these tools but GeSBAP rely on gene-based 
methodologies that need a two-step process from SNP to genes prior to the statistical 
analysis. It has been observed that this approach is more powerful than the direct SNP-
based methods (Wang, Li et al. 2007; Yu, Li et al. 2009). The possibility of using directly 
the p-values obtained in GWPS makes feasible the study of prognostic data in a rather 
simple way. The main advantage of the p-value-methods choice relies on the possibility of 
reducing the genomic inflation and controlling the confounding factors. This task represents 
a challenge for the raw genotype-based methodologies but little has been done to deal with 
it. 
In summary, an extensive list of gene sets has been found to be associated with specific 
UCB outcomes in the SBC/EPICURO Study. The obtained results highlight some of the 
most known biological pathways related to UCB prognosis. In addition, the great number 
of identified pathways and understanding their interactions is challenging because it 
suggests that a regulatory system underlying the genetic architecture of UCB needs to be 
accurately described. This kind of pathway-based approaches have provided a wider 
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biological perspective if compared with the single-marker analysis. The development of 
high-throughput sequencing techniques - and their functional interpretation - may provide 
in the close future a statistically powerful source of data suitable to be used with these 
pathway-based techniques and allow us to exploit the most of the GWAS data. 
 
5.3. SNP-SNP interactions associated with UCB clinical outcomes 
Restricted interaction assessments in case-control studies have been proposed, considering 
only the SNPs showing significant main effects and analyzing pair-wise interactions among 
them. While this approach could be easily extended to survival data, it would miss 
interesting interactions between SNPs without significant main effects. We went through 
this issue and shown that the SNPs participating in some of the most interesting interactions 
identified with the proposed approach did not show significant main effects. 
From a practical point of view, the exhaustive search of genetic interactions requires large 
computational efforts, this being a limiting factor of this analysis. Therefore, at the genome-
wide setting, only two-way interactions can be considered at present since a further search 
does not scale up to analyse higher-order interactions. Methodological papers about the 
available statistical and data mining techniques available for the gene-gene interactions 
assessment in case-control studies have been published (Cordell 2009), but again, only a 
few of these techniques have a natural extension to the time-to-event data, among them, 
classification trees (Breiman, Freidman et al. 1984), random forest (Ishwaran, Kogalur et 
al. 2008), and logic regression (Ruczinskie, Kooperberg et al. 2003) can be used to detect 
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high-order genetic interactions with time-to-event data. However, they are limited to 
manage a genome-wide size number of SNPs. 
The key point of our strategy was determining the relationship between the p-values 
assessing the interactions of the logistic and Cox regression models. Genome-wide 
interaction analyses (GWIA) studies require testing thousands of millions of pairs, and the 
p-values for ensuring significance level need be extremely small. The multiple comparisons 
topic was also revised and two approaches were selected. 
The use of simulated datasets could provide us a better understanding of the conditions in 
which this strategy could be applied and what is the best way to proceed. However, the high 
computational cost makes this process prohibitive because of the computational time 
needed to perform it. We preferred to illustrate the strategy with a particular case using the 
SBC/EPICURO Study and developing a methodology to assess the comparison between p-
values in the two mentioned kinds of regression tests. In addition, we determined the 
limitations of the strategy, when survival data is analyzed with logistic regression. 
We selected BOOST to analyse all the pairs of interactions for several reasons. From the 
technical point of view, BOOST is a very fast, flexible tool with freely available source 
code; and from the statistical point of view, it is based in the widely extended definition of 
interaction based in logistic regression models. Our first step of the strategy was to take 
advantage of the similarity between the fit of the logistic and Cox regression models. 
BOOST is very fast because uses an approximation to the logistic regression using 
contingency tables, based on the equivalence between logistic regression and log-linear 
model. Unfortunately, this approach based in contingency tables cannot be extended to Cox 
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regression with survival data because it is not possible to add survival time information to 
the contingency tables. Despite of the BOOST advantages, it has a modest statistical power 
because in situations with low minor allele frequencies, the contingency tables can be too 
sparse. It has some additional limitations such as the need of imputed missing values. 
The SNP-SNP interactions with potential prognostic value in UCB are presented in the 
Results Section. SNP combinations were analyzed with STRING (Search Tool for the 
Retrieval of Interacting Genes/Proteins) (Franceschini, Szklarczyk et al. 2013) and 
Ingenuity
®
 in order to identify known pairwise associations. None of them have been 
described either in the existing interaction databases or in the Pubmed-based textmining 
analyses. In addition, we used all the single enrichment analysis tools contained in 
Babelomics (Medina, Carbonell et al. 2010) (FatiGO, Marmite and Snow) but no direct 
association between these pairs of SNPs were identified. 
We also wanted to analyze the results from a broader point of view and we run the analyses 
using the complete list of SNP/genes altogether. When we used STRING, we observed that, 
in the NMIBC series, NCAM1 and CHGA are mentioned in the same context in at least 50 
published papers. However this occurrence is just because they are fairly common 
neuroendocrine biomarkers that are usually evaluated in all kinds of cancer-based studies. 
On the other hand, Snow provided us a potential MIBC association between SALL1 and 
PROX1, using SUMO1 as a link node between them. Despite of this, it seems that there is 
no published study associating these elements because they don’t appear in the textmining 
tools we used (STRING and Marmite). 
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To date, very few GWAS have gone beyond the single-marker analysis and have 
incorporated the interaction testing. To our knowledge, the methodology and the results we 
have presented are the first ones to be applied to a real dataset in which the survival 
analyses have been taken into account in the assessment of cancer susceptibility. Novel 
pairwise interactions were identified in our dataset, even applying the most stringent 
criteria to avoid the multiple test effect. Despite of this, an independent study is needed to 
validate the reported results. 
In the last two years the so-called genome-wide interaction-based association (GWIBA) 
studies have been developed and applied in order to identify novel susceptibility loci, 
whose effects were lost in the regular GWAS approach. There is a common effort trying to 
reduce de dimensionality of the analyses and a growing list of solutions is being 
established: methods based on Bayesian models (Zhang 2012), methods based on ranking 
scores calculated from the difference in marker dependencies between cases/control groups 
(Piriyapongsa, Ngamphiw et al. 2012), methods based on multidimensionality reduction 
(Oh, Lee et al. 2012) or methods based on clustering (Xie, Li et al. 2012). The important 
number of GWAS performed during the last decade and the naïve approach applied until 
now makes us think that evaluation the genome elements interactions will be the logical 
next step after the single-locus testing. 
In summary, we confirmed that common germline variants are associated with clinical 
outcomes in UCB. In addition, we identified and validated independent genetic variants 
associated with NMIBC. Additional markers identified in MIBC patients were also 
identified and they are waiting to be validated in independent cohorts in the near future. A 
novel approach has been designed in order to identify pairwise SNP interactions. Technical 
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and statistical challenges have been solved in this regard and a list of potential SNP pairs 
has been identified for the first time in a real UCB dataset. The synergistic role of SNPs 
was also assessed using a complete list of GSA approaches and we have obtained a wide 
view of the biology underlying the disease. New technologies and challenges are emerging 
in the assessment of UCB prognosis and the study of germline variants will play an 
important role from now on. 
 
5.4. Future plans and directions in the prognostic study of UCB 
The data gathering from the MIBC patients Validation cohorts is being performed at the 
time of writing this Thesis. The genetic, pathological and clinical information will be used 
in order to validate the prognostic value of the SNPs obtained in the Discovery phase. 
Once the most significant SNPs in the survival analyses have been identified it may be 
necessary to perform additional analyses in the chromosomal regions containing these 
variants. The reason to proceed in this way is because a particular SNP identified in the 
genome-wide analysis may just be one variant that is linkage disequilibrium with the causal 
maker. The imputation of the known SNPs contained in the region of interest (but not 
present in the genotyping platform) provides a source of information to study those regions 
in deeper detail. Custom genotyping platforms such as Fluidigm Dynamic Array would 
be useful to genotype few hundreds of SNPs restricted to areas of interest at an interesting 
cost-benefit scenario. However, the desirable option would be the use of Next Generation 
Sequencing (NGS) techniques and evaluate the presence of multiple genetic variants close 
to the studied loci. In this moment the SBC/EPICURO Study has gone into this field by 
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sequencing germline DNA from an initial group of 20 patients and another set of 72 
patients are waiting to be sequenced in the future. 
The assessment of copy-number variants (CNV) in genotyping platforms and its association 
with UCB susceptibility has been studied in detail in the SBC/EPICURO Study (Marenne, 
Rodriguez-Santiago et al. 2011; Marenne, Real et al. 2012). The extension to the 
assessment of UCB prognosis has been performed in exploratory univariate analyses taking 
into account the Log R Ratio (LRR) for each CNV but no statistically significant results 
were obtained. Our next efforts will be focused on assessing the potential CNV prognostic 
value in multivariate survival models. 
New statistical approaches have been started to be applied in the study of complex diseases 
such as UCB. These techniques make possible to deal with the great number of variant 
candidates and create multifactorial models. Bayesian approaches in combination with 
shrinkage and selection methods for linear regressions, such as LASSO (Tibshirani 1996), 
have been started to be applied with promising results in the context of the UCB 
susceptibility in the Molecular and Epidemiology group at the CNIO. The great-scale study 
of epistatic biomarkers in cancer was limited because of the computational power needed to 
perform this task. However, the development of multifactor dimensionalityl reduction 
methods (MDR) has been around for more than one decade (Ritchie, Hahn et al. 2001) and 
it has been improved in order to run analyses based on particular statistical models. A MDR 
variant technique called mb-MDR (Calle, Urrea et al. 2008) has been developed to assess 
for the disease susceptibility of genetic biomarkers. Moreover, an alternative version that 
assess for survival is has been developed at the Molecular and Epidemiology group at the 
CNIO and is ready to be applied on the SBC/EPICURO dataset. 
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The effort to create genetic scores of germline biomarkers and combine them with the 
somatic ones into multifactorial models is on the way. In addition, the great amount of 
information available in the context of “-omics” studies (i.e., transcriptomics, genomics, 
epigenomics) makes interesting its integration into models that take into account the diverse 
biological aspects of the disease (Hamid, Hu et al. 2009; Bell, Pai et al. 2011). 
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 Conclusions 
I. Through a genome-wide prognostic scan of SNPs covering all autosomal 
chromosomes and by applying a tiered design (discovery cross-validation and 
validation phase) that tested each individual SNP, we found that common germline 
variants are associated with clinical outcomes of UCB. 
II. The SNPs rs754799 and rs4246835, which were identified and validated in 
independent cohorts, were found to be independently associated with the risk of 
tumor recurrence and progression in NMIBC, respectively. 
III. The SNPs rs16927851 and rs1015267, which were identified in independent 
cohorts, were found to be potentially independently associated with the risk of 
tumor progression and UCB-specific mortality in MIBC. The validation of these 
results will be assessed in independent cohorts in the near future. 
IV. The application of five gene set analysis algorithms (ALIGATOR, GeSBAP, i-
Gsea4Gwas, ICSNPathway and GSA-SNP), provided a set of biological pathways 
associated with UCB outcomes. Specific results were obtained for NMIBC 
regarding the inflammatory system and the immune response. Moreover, in all the 
UCB outcomes we identified SNP enrichment in pathways in which the GTPases, 
the membrane transport systems, neuro/axonogenesis and angiogenesis play 
important roles. 
V. The pairwise survival analysis of the non-correlated SNPs genotyped through 
Illumina Infinium HumanHap 1M probe Beadchip in the SBC/EPICURO Study, let 
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us to identify pairs of SNPs whose combined effect was associated with the UCB 
prognosis. We identified four pairs of SNPs that reached the level of statistical 
significance among NMIBC patients who develop recurrence (rs7498329/rs909010 
and rs941586/rs6093059) and MIBC patients who died due to the disease 
(rs10110883/rs10847791 and rs11977984/rs4394757). 
 
 
 Conclusiones 
I. Mediante un análisis pronóstico pan-genómico de SNPs localizados en los 
cromosomas autosómicos y aplicando un diseño gradual (validación cruzada en la 
fase de cribado y validación posterior) que analizó cada SNP individualmente, 
identificamos variantes comunes de línea germinal asociadas con el pronóstico del 
carcinoma urotelial de vejiga. 
II. Los SNPs rs754799 y rs4246835, identificados y validados en cohortes 
independientes, están independientemente asociados con el riesgo de padecer 
recurrencia y progresión tumoral de cáncer de vejiga no-invasivo del músculo, 
respectivamente. 
III. Los SNPs rs16927851 y rs1015267, identificados en dos cohortes independientes de 
la fase de cribado, están potencialmente independientemente asociados con el riesgo 
de padecer progresión tumoral y a la supervivencia relacionada con el cáncer de 
vejiga invasivo del músculo. La validación de estos resultados se llevará a cabo en 
cohortes independientes en un futuro próximo. 
IV. La aplicación de cinco algoritmos de análisis de enriquecimiento génico 
(ALIGATOR, GeSBAP, i-Gsea4Gwas, ICSNPathway y GSA-SNP) han 
proporcionado una lista de procesos biológicos potencialmente alterados en relación 
al pronóstico del carcinoma urotelial de vejiga. Se obtuvieron resultados específicos 
del cáncer de vejiga no-invasivo en relación al sistema inflamatorio y la respuesta 
inmune. Además, al estudiar los eventos propios de la enfermedad se observó una 
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sobrerrepresentación de SNPs en rutas biológicas en las que las GTPasas, los 
sistemas de transporte de membrana, la neuro/axonogenesis y la angiogénesis 
desempeñan papeles importantes. 
V. El análisis de supervivencia de parejas de SNP no correlacionados genotipados 
mediante Illumina Infinium HumanHap 1M probe BeadChip en el estudio 
SBC/EPICURO identificó interacciones en dos parejas de SNPs que alcanzaron el 
nivel de significación estadística para su asociación con recurrencia: 
rs7498329/rs909010 y rs941586/rs6093059. Además, se identificaron las parejas 
rs10110883/rs10847791 y rs11977984/rs4394757 asociados a mortalidad cáncer-
específica en pacientes con cáncer de vejiga invasivo del músculo. 
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Supplementary Table 1. Demographic, clinical and pathological characteristics, and follow-up 
of the NMIBC patients included in Discovery and Validation phases. 
Characteristics 
Discovery Validation 
TXBC-1 
N (%) 
SBC/EPICURO 
N (%) 
All Series 
N (%) 
Total number 496 836 1284 
Sex    
Men 415 (83.7) 732 (87.6) 1036(80.7) 
Women 81 (16.3) 104 (12.4) 248(19.3) 
Age    
Mean (sd) –years- 63.8 (11.4) 65.5 (10.21) - 
Mínimum - Maximum 19 - 89 22 - 80 18-97 
Smoking status    
Non-smoker 142 (28.6) 146 (17.5) 104(8.1) 
Former smoker 244 (49.2) 337 (40.3) 189(14.7) 
Current smoker 110 (22.2) 346 (41.4) 65(5.1) 
Missing 0 (0.0) 7 (0.8) 8(0.6) 
Stage    
Ta 229 (46.2) 698 (83.5) 740(57.6) 
T1 237 (47.8) 132 (15.8) 486(37.9) 
Tis 28 (5.6) 6 (0.7) 52(4.0) 
Missing 2 (0.4) 0 (0.0) 6(0.4) 
Grade    
G1 20 (4.0) 352 (42.1) 342(26.6) 
G2 168 (33.9) 286 (34.2) 317(24.7) 
G3 289 (58.3) 198 (23.7) 610(47.6) 
Missing 19 (3.8) 0 (0.0) 15(1.2) 
Stage-Grade    
TaG1* 19 (3.8) 352 (42.1) 323(25.2) 
TaG2 136 (27.4) 265 (31.7) 246(19.2) 
TaG3** 72 (14.5) 81 (9.7) 170(13.2) 
T1G1/T1Low   16(1.2) 
T1G2 32 (6.5) 20 (2.4) 70(5.46) 
T1G3*** 201 (40.5) 112 (13.4) 399(31.1) 
CIS 28 (5.6) 6 (0.7) 52(4.0) 
Missing 8 (1.6) 0 (0.0) 8(0.6) 
CIS    
Yes 161 (32.5) - 114(8.9) 
No 311 (62.7) - 199(15.5) 
Missing 24 (4.8) - 53(4.1) 
Number of bladder tumors    
1 tumor 191 (38.5) 554 (66.3) 697(54.3) 
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> 1 tumor 159 (32.1) 238 (28.5) 422(32.9) 
Missing 146 (29.4) 44 (5.3) 165(12.9) 
Tumor location    
1 localization 193 (38.9) 552 (66.0) 165(12.9) 
Trigone 27 (5.4) 75 (9.0) 11(0.8) 
Others 166 (33.5) 477 (57.1) 154(12.0) 
>1 localization 190 (38.3) 261 (31.2) 118(9.2) 
Missing 113 (22.8) 23 (2.8) 83(6.5) 
Size of the largest tumor    
>=2cm 65 (13.1) - 92(7.1) 
>2-5cm 109 (22.0) - 68(5.3) 
>5cm 38 (7.7) - 25(1.9) 
< 3 cm - 487 (58.3) 635(49.5) 
> 3 cm - 113 (13.5) 252(29.6) 
Missing 284 (57.3) 236 (28.2) 31(2.4) 
Treatment    
No BCG 248 (50.0) 566 (67.7) - 
iBCG 145 (29.2) 269 (32.2) - 
mBCG 103 (20.8) 0 (0.0) - 
TUR ‘alone’ 168 (33.9) 356 (42.6) 590(46.0) 
TUR+BCG 207 (41.7) 248 (29.7) 436(34.0) 
TUR+Chemother (Intravesical) 23 (4.6) 181 (21.7) 105(8.2) 
TUR+BCG+ChemoT (Intravesical) 19 (3.8) 21 (2.5) 41(3.2) 
TUR+BCG+IFN (Intravesical) 15 (3.0) 0 (0.0) 7(0.5) 
Others 56 (11.3) 29 (3.5) 95(7.4) 
Missing 8 (1.6) 1 (0.1) 10(0.8) 
Follow-up    
Date 1st diagnosis 19/7/1999 6/13/1998 1/1/1979 
Date last diagnosis 3/6/2008 6/28/2001 5/19/2010 
Date last control 10/24/2008 7/1/2007 7/18/2011 
Free-of-disease patients 213 (42.9) 504 (60.3) 486 (37.9) 
Median follow-up (months) 75.6 77.5 26.3 – 113.0 
Lost to follow-up 57 (11.5) 9 (2.7) NA 
Bladder cancer outcomes    
No. of patients with at least one tumor relapse 258 (52.0) 332 (39.7) 786(61.2) 
No. of patients with at least one tumor 
recurrence 
213 (42.9) 275 (32.9) 682(53.1) 
No. of patients with tumor progression 85 (17.1) 83 (9.9) 212(16.5) 
TXBC- Texas Bladder Cancer Study; SBC/EPICURO- Spanish Bladder Cancer Study; PMH - Princess Margaret Hospital; AUH - 
Aarhus University Hospital; HM - Hôpital Henri Mondor; EMC - Erasmus MC; HuGeF - Human Genetics Foundation.   
*TaG1 includes TaLow and TaPUNLMP; **TaG3 includes TaHigh; ***T1G3 includes T1High; sd: standard deviation; NA: non-
available; CIS: carcinoma in situ;  iBCG: induction BCG; mBCG: maintanace BCG 
Other treatments include: Cystectomy / Cystectomy+Radiotherapy, Cystectomy+Chemotherapy / 
Cystectomy+Chemotherapy+Radiotherapy / Chemotherapy+Radiotherapy, and Radiotherapy alone 
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Supplementary Table 2. Demographic, clinical, pathological, and follow-up characteristics of 
the NMIBC patients included in Stage II – Validation for each participating study. 
Characteristics 
Validation Studies 
 
TXBC-2 
N (%) 
International Cohorts 
POOL 
N (%) 
PMH 
N (%) 
AUH 
N (%) 
HM 
N (%) 
EMC 
N (%) 
HuGeF 
N (%) 
Total number 366 918 333 291 109 105 80 
Sex        
Men 285(77.9) 751(81.8) 257(77.2) 227(78.0) 109(100.0) 78(74.3) 80(100.0) 
Women 81(22.1) 167(18.2) 76(22.8) 64(22.0) - 27(25.7) - 
Age        
Mean (sd) -years- 65.4(10.8) 67.6(11.1) 71.35(11.6) 66.9(9.9) 63.5(9.5) 64.6(12.2) 64.3(8.4) 
Minimum - Maximum 18-93 22-97 22-97 27-86 28-79 23-88 40-75 
Smoking status        
Non-smoker 104(28.4) - - - - - - 
Former smoker 189(51.6) - - - - - - 
Current smoker 65(17.8) - - - - - - 
Missing 8(2.2) - - - - - - 
Stage        
Ta 167(45.6) 573(62.4) 206(61.9) 178(61.2) 63(57.8) 72(68.6) 54(67.5) 
T1 177(48.4) 309(33.7) 98(29.4) 107(36.8) 46(42.2) 33(31.4) 25(31.3) 
Tis 16(4.4) 36(3.9) 29(8.7) 6(2.1) - - 1(1.3) 
Missing 6(1.6) - - - - - - 
Grade        
G1 14(3.8) 328(35.7) 133(39.9) 90(30.9) 15(13.8) 35(33.3) 55(68.8) 
G2 117(32.0) 200(21.8) 36(10.8) 73(25.1) 48(44.0) 43(41.0) - 
G3 220(60.1) 390(42.5) 164(49.2) 128(44.0) 46(42.2) 27(25.7) 25(31.3) 
Missing 15(4.1) - - - - - - 
Stage-Grade        
TaG1* 14(3.8) 309(33.7) 129(38.7) 87(29.9) 15(13.8) 35(33.3) 43(53.8) 
TaG2 92(25.1) 154(16.8) 30(9.0) 57(19.6) 38(34.9) 29(27.6) - 
TaG3** 60(16.4) 110(12.0) 47(14.1) 34(11.6) 10(9.2) 8(7.6) 11(13.8) 
T1G1/T1Low  16(1.7) 4(1.2) 1(0.3) - - 11(13.8) 
T1G2 23(6.3) 47(5.1) 6(1.8) 17(5.8) 10(9.2) 14(17.5) - 
T1G3*** 153(41.8) 246(26.8) 88(26.4) 89(30.6) 36(36.0) 19(18.1) 14(17.5) 
CIS 16(4.4) 36(3.9) 29(8.7) 6(2.0) - - 1(1.3) 
Missing 8(2.2) - - - - - - 
CIS        
Yes 114(31.1) - - - - - - 
No 199(54.4) - - - - - - 
Missing 53(14.5) - - - - - - 
Number of bladder tumors        
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1 tumor 121(33.1) 576(68.0) 180(54.1) 167(75.9) 84(77.1) 68(64.8) 77(96.3) 
> 1 tumor 151(41.3) 271(32.0) 153(45.9) 53(24.1) 25(22.9) 37(35.2) 3(3.7) 
Missing 94(25.7) 71(7.7) - 71(24.4) - - - 
Tumor location        
1 localization 165(45.1) - - - - - - 
Trigone 11(3.0) - - - - - - 
Others 154(42.1) - - - - - - 
>1 localization 118(32.2) - - - - - - 
Missing 83(22.7) - - - - - - 
Size of the largest tumor  -      
>=2cm 92(25.1) - - - - - - 
>2-5cm 68(18.6) - - - - - - 
>5cm 25(6.8) - - - - - - 
< 3 cm. - 635(71.6) 266(79.9) 187(71.1) 58(53.2) 68(66.7) 56(70.0) 
> 3 cm. - 252(28.4) 67(20.1) 76(28.9) 51(46.8) 34(33.3) 24(30.0) 
Missing 181(49.5) 31(3.4) - 28(9.6) - 3(2.9) - 
Treatment        
No BCG 186(50.8) 585(63.7) 191(57.4) 232(79.7) 57(52.3) 59(56.2) 46(57.5) 
iBCG 93(25.4) 333(36.3) 142(42.7) 59(20.3) 52(47.7) 46(43.8) 34(42.5) 
mBCG 77(21.0) 0 0 0 0 0 0 
TUR ‘alone’ 105(28.7) 485(52.8) 165(49.5) 226(77.7) 37(33.9) 50(47.6) 7(8.8) 
TUR+BCG 128(35.0) 308(33.6) 138(41.4) 58(19.9) 52(47.7) 34(32.4) 26(32.5) 
TUR+Chemother (Intravesical) 27(7.4) 78(8.5) 21(6.3) 1(0.3) 12(11.1) 9(8.6) 35(43.8) 
TUR+BCG +ChemoT (Intravesical) 16(4.4) 25(2.7) 4(1.2) 1(0.3) 0(0.0) 12(11.4) 8(10.0) 
TUR+BCG+IFN (Intravesical) 7(1.9) - - - - - - 
Others 73(19.9) 22(2.4) 5(1.5) 5(1.7) 8(7.3) - 4(5.0) 
Missing 10(2.7) - - - - - - 
Follow-up        
Date 1st diagnosis 25/2/1982 1/1/1979 2/21/1980 1/1/1979 5/3/1995 1/13/1983 10/4/1999 
Date last diagnosis 12/29/2009 5/19/2010 5/19/2010 8/22/2007 8/21/2006 3/23/2007 6/4/2009 
Date last control 6/11/2010 7/18/2011 3/28/2011 1/14/2009 7/18/2011 7/28/2010 3/25/2010 
Free-of-disease patients 174(47.5) 312(34.0) 138(15.0) 30(3.3) 59(6.4) 32(3.5) 53(5.8) 
Median follow-up (m) 43.7 58.8 55.1 26.3 69.5 113.0 36.3 
Lost to follow-up 17 (4.6) NA NA NA NA NA NA 
Bladder cancer outcomes        
No. of patients with at least one tumor relapse 180(49.2) 606(66.0) 195(58.9) 261(89.7) 50(45.9) 73(69.5) 27(33.7) 
No. of patients with at least one tumor 
recurrence 
142(38.8) 540(58.8) 180(54.5) 223(76.6) 45(41.2) 71(67.6) 21(26.2) 
No. of patients with tumor progression 71(19.4) 141(15.3) 17(5.1) 90(30.9) 8(7.3) 18(17.1) 8(10.0) 
TXBC-2- Texas Bladder Cancer Study for Validation; PMH - Princess Margaret Hospital; AUH - Aarhus University Hospital; HM - Hôpital Henri Mondor; 
EMC - Erasmus MC; HuGeF - Human Genetics Foundation.   
*TaG1 includes TaLow and TaPUNLMP; **TaG3 includes TaHigh; ***T1G3 includes T1High; sd: standard deviation; NA: non-available; CIS: carcinoma 
in situ;  iBCG: induction BCG; mBCG: maintanace BCG 
Other treatments include: Cystectomy / Cystectomy+Radiotherapy, Cystectomy+Chemotherapy / Cystectomy+Chemotherapy+Radiotherapy / 
Chemotherapy+Radiotherapy, and Radiotherapy alone 
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Supplementary Table 3. Demographic, clinical and pathological characteristics, and follow-up 
of the MIBC patients included in Discovery phase. 
Characteristics 
Discovery 
TXBC-1 
N (%) 
SBC/EPICURO 
N (%) 
Total number 397 235 
Sex   
Men 311 (78.3) 209 (88.9) 
Women 86 (21.7) 26 (11.1) 
Age   
Mean (sd) –years- 66.4 (10.7) 66.9 (8.9) 
Mínimum - Maximum 39-89 36 - 80 
Smoking status   
Non-smoker 94 (23.7) 30 (12.8) 
Former smoker 202 (50.9) 78 (33.2) 
Current smoker 101 (25.4) 127 (54.0) 
Missing 0 (0.0) 0 (0.0) 
Stage   
T1 4 (1.0) 0 (0.0) 
T2 300 (75.6) 129 (54.9) 
T3 57 (14.4) 54 (23.0) 
T4 32 (8.1) 52 (22.1) 
Missing 4 (1.0) 0 (0.0) 
Grade   
G2 11 (2.8) 22 (9.4) 
G3 375 (94.5) 213 (90.6) 
Missing 11 (2.8) 0 (0.0) 
Stage-Grade   
T1G2 0 (0.0) 0 (0.0) 
T1G3 4 (1.0) 0 (0.0) 
T2G2 10 (2.5) 10 (4.3) 
T2G3 282 (71.0) 119 (50.6) 
T3G2 0 (0.0) 6 (2.6) 
T3G3 55 (13.9) 48 (20.4) 
T4G2 1 (0.3) 6 (2.6) 
T4G3 30 (7.6) 46 (19.6) 
Missing 15 (3.8) 0 (0.0) 
Number of bladder tumors   
1 tumor 220 (55.4) 163 (69.4) 
> 1 tumor 79 (19.9) 53 (22.5) 
Missing 98 (24.7) 19 (8.1) 
Tumor location   
Trigone 34 (8.6) 28 (11.9) 
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Others 139 (35.0) 84 (35.7) 
>1 localization 193 (48.6) 118 (50.2) 
Missing 31 (7.8) 5 (2.1) 
Size of the largest tumor   
>=2cm 15 (3.8) - 
>2-5cm 182 (45.8) - 
>5cm 62 (15.6) - 
< 3 cm - 63 (26.8) 
> 3 cm - 68 (28.9) 
Missing 138 (34.8) 104 (44.3) 
Metastasis (M)   
M0 370 (93.2) 188 (80.0) 
M1 20 (5.0) 27 (11.5) 
Mx 7 (1.8) 20 (8.5) 
Affected ganglia (N)   
N0 349 (87.9) 162 (68.9) 
N1-N3 38 (9.6) 47 (20.0) 
Nx 10 (2.5) 26 (11.1) 
Treatment   
TUR+Cystectomy 116 (29.2) 82 (34.9) 
TUR+Cystectomy+Chemotherapy 116 (29.2) 32 (13.6) 
TUR+Chemothearpy (alone) 55 (13.9) 23 (9.8) 
TUR+Radiotherapy+Chemotherapy 11 (2.8) 24 (10.2) 
NMIBC treatment 42 (10.6) 18 (7.7) 
Others 53 (13.4) 56 (23.8) 
Missing 4 (1.0) 0 (0.0) 
Follow-up   
Date 1st diagnosis 12/31/1997 6/28/1998 
Date last diagnosis 9/24/2007 4/25/2001 
Date last control 02/05/2009 7/1/2007 
Free-of-disease patients 200(50.3) 66 (28.1) 
Median follow-up (months) 43.7 26 
Lost to follow-up 5 3 
Bladder cancer outcomes   
No. of patients with tumor progression 74(18.6) 129 (54.9) 
No. of patients dead by bladder cancer 97(24.4) 108 (46.0) 
No. of patients dead by any cause 161(40.6) 161 (68.5) 
TXBC- Texas Bladder Cancer Study; SBC/EPICURO- Spanish Bladder Cancer Study 
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Supplementary Table 4. NMIBC associations of SNPs identified in Stage I analysis with risk of recurrence, progression, and relapse: Meta-analysis for 
Stage I, Stage II, and All studies combined, Chromosome and gene location, minor allele, mode-of inheritance, and statistical model are also displayed. 
SNP 
Model Discovery Meta-analysis results 
Outcome MoI Alleles MAF SBC/EPICURO MAF TXBC-1 HR(95% CI) fixed P fixed HR(95% CI) random P random P het I2 
rs754799 Recurrence recessive A/C 0.19 0.17 2.79(1.86-4.17) 5.87E-07 2.79(1.86-4.17) 5.87E-07 7.98E-01 0.00 
rs12988804 Recurrence codom.het G/A 0.25 0.28 1.60(1.32-1.94) 1.45E-06 1.60(1.32-1.94) 1.45E-06 4.94E-01 0.00 
rs489770 Recurrence recessive A/G 0.18 0.20 2.55(1.72-3.77) 2.68E-06 2.55(1.72-3.77) 2.68E-06 7.23E-01 0.00 
rs980761 Recurrence codom.het A/G 0.38 0.37 1.62(1.32-2.00) 4.24E-06 1.62(1.32-2.00) 4.24E-06 5.07E-01 0.00 
rs3736994 Recurrence dominant A/G 0.31 0.33 0.65(0.54-0.78) 4.61E-06 0.65(0.54-0.78) 4.61E-06 3.84E-01 0.00 
rs7930624 Recurrence additive C/A 0.24 0.23 1.39(1.20-1.61) 9.67E-06 1.39(1.20-1.61) 9.67E-06 7.36E-01 0.00 
rs12681007 Recurrence recessive G/A 0.40 0.46 1.65(1.31-2.07) 1.56E-05 1.65(1.31-2.07) 1.56E-05 3.23E-01 0.00 
rs6443819 Recurrence additive A/G 0.27 0.23 1.37(1.19-1.59) 1.56E-05 1.37(1.19-1.59) 1.56E-05 3.85E-01 0.00 
rs10867878 Recurrence recessive G/A 0.22 0.19 2.28(1.56-3.34) 2.09E-05 2.28(1.56-3.34) 2.09E-05 8.58E-01 0.00 
rs9504361 Recurrence codom.het G/A 0.47 0.46 0.63(0.50-0.78) 2.92E-05 0.63(0.50-0.78) 2.92E-05 4.94E-01 0.00 
rs6512003 Recurrence recessive C/A 0.42 0.40 1.63(1.29-2.04) 3.00E-05 1.63(1.29-2.04) 3.00E-05 5.46E-01 0.00 
rs6505263 Recurrence additive G/A 0.27 0.25 0.71(0.61-0.84) 3.73E-05 0.71(0.61-0.84) 3.73E-05 5.87E-01 0.00 
rs2943313 Recurrence dominant G/A 0.03 0.03 2.00(1.45-2.76) 2.37E-05 2.00(1.44-2.79) 3.76E-05 3.05E-01 0.05 
rs2191031 Recurrence dominant G/A 0.16 0.18 0.63(0.51-0.78) 3.10E-05 0.63(0.50-0.80) 1.05E-04 2.85E-01 0.13 
rs1421776 Progression codom.hom A/G 0.13 0.12 7.63(3.64-15.96) 6.96E-08 7.63(3.64-15.96) 6.96E-08 8.95E-01 0.00 
rs4246835 Progression codom.het G/A 0.40 0.42 0.38(0.26-0.55) 3.72E-07 0.38(0.26-0.55) 3.72E-07 6.21E-01 0.00 
rs10167220 Progression dominant G/A 0.11 0.11 2.34(1.68-3.28) 6.70E-07 2.34(1.68-3.28) 6.70E-07 6.58E-01 0.00 
rs526509 Progression additive C/A 0.42 0.39 1.77(1.41-2.23) 7.61E-07 1.77(1.41-2.23) 7.61E-07 5.18E-01 0.00 
rs6100810 Progression recessive A/G 0.19 0.18 4.51(2.43-8.40) 1.95E-06 4.51(2.43-8.40) 1.95E-06 3.29E-01 0.00 
rs12294567 Progression codom.hom A/G 0.13 0.12 5.48(2.71-11.08) 2.17E-06 5.48(2.71-11.08) 2.17E-06 6.09E-01 0.00 
rs4246835 Progression dominant G/A 0.40 0.42 0.46(0.33-0.63) 3.07E-06 0.46(0.33-0.63) 3.07E-06 6.84E-01 0.00 
rs17218455 Progression codom.hom G/A 0.17 0.16 3.98(2.20-7.20) 4.89E-06 3.98(2.20-7.20) 4.89E-06 3.72E-01 0.00 
rs6752816 Progression dominant G/A 0.06 0.07 2.52(1.69-3.75) 5.26E-06 2.52(1.69-3.75) 5.26E-06 4.90E-01 0.00 
rs2950650 Progression codom.hom A/G 0.13 0.15 4.58(2.38-8.82) 5.35E-06 4.58(2.38-8.82) 5.35E-06 5.76E-01 0.00 
rs9891348 Progression codom.het A/G 0.43 0.42 0.38(0.26-0.56) 6.72E-07 0.38(0.25-0.58) 5.42E-06 2.75E-01 0.16 
rs5027573 Progression dominant G/A 0.05 0.03 2.72(1.77-4.19) 5.49E-06 2.72(1.77-4.19) 5.49E-06 4.76E-01 0.00 
rs17831395 Progression dominant A/G 0.02 0.02 3.40(2.01-5.77) 5.50E-06 3.40(2.01-5.77) 5.50E-06 3.77E-01 0.00 
rs1568519 Progression dominant A/C 0.06 0.07 2.57(1.71-3.87) 5.75E-06 2.57(1.71-3.87) 5.75E-06 4.10E-01 0.00 
rs7721273 Progression codom.hom A/G 0.19 0.21 4.41(2.32-8.38) 5.76E-06 4.41(2.32-8.38) 5.76E-06 4.39E-01 0.00 
rs7588481 Progression dominant A/C 0.18 0.14 2.13(1.52-2.97) 9.41E-06 2.13(1.52-2.97) 9.41E-06 4.83E-01 0.00 
rs6531449 Progression additive A/G 0.31 0.27 1.71(1.34-2.17) 1.22E-05 1.71(1.34-2.17) 1.22E-05 7.60E-01 0.00 
  
128 
SNP 
Model Discovery Meta-analysis results 
Outcome MoI Alleles MAF SBC/EPICURO MAF TXBC-1 HR(95% CI) fixed P fixed HR(95% CI) random P random P het I2 
rs7936809 Progression dominant G/A 0.21 0.25 2.08(1.50-2.89) 1.30E-05 2.08(1.50-2.89) 1.30E-05 5.22E-01 0.00 
rs3797725 Progression codom.hom A/G 0.23 0.18 3.20(1.89-5.42) 1.49E-05 3.20(1.89-5.42) 1.49E-05 7.41E-01 0.00 
rs7572970 Progression recessive G/A 0.28 0.29 2.94(1.86-4.66) 4.27E-06 2.94(1.79-4.84) 2.16E-05 2.79E-01 0.15 
rs10437619 Progression additive A/G 0.38 0.40 1.60(1.28-2.00) 3.31E-05 1.60(1.28-2.00) 3.31E-05 4.87E-01 0.00 
rs1035856 Progression dominant G/A 0.02 0.02 3.36(1.96-5.76) 1.11E-05 3.35(1.88-5.97) 4.22E-05 2.84E-01 0.13 
rs1847325 Progression additive G/A 0.47 0.48 0.59(0.45-0.76) 5.69E-05 0.59(0.45-0.76) 5.69E-05 3.68E-01 0.00 
rs1432374 Progression additive G/A 0.36 0.33 1.56(1.25-1.95) 7.44E-05 1.56(1.25-1.95) 7.44E-05 3.21E-01 0.00 
rs10783528 Progression additive G/A 0.38 0.33 1.62(1.29-2.04) 3.79E-05 1.62(1.27-2.06) 1.04E-04 2.88E-01 0.11 
rs6757412 Progression codom.hom A/C 0.28 0.25 3.07(1.81-5.23) 3.45E-05 3.06(1.69-5.54) 2.24E-04 2.64E-01 0.20 
rs3772337 Relapse recessive A/G 0.14 0.14 3.71(2.26-6.08) 2.01E-07 3.71(2.26-6.08) 2.01E-07 8.65E-01 0.00 
rs11604069 Relapse dominant G/A 0.45 0.43 0.65(0.54-0.78) 1.67E-06 0.65(0.54-0.78) 1.67E-06 4.39E-01 0.00 
rs446027 Relapse codom.hom A/G 0.36 0.32 1.84(1.43-2.36) 1.85E-06 1.84(1.43-2.36) 1.85E-06 6.52E-01 0.00 
rs2694787 Relapse codom.hom G/A 0.19 0.20 2.53(1.71-3.75) 3.57E-06 2.53(1.71-3.75) 3.57E-06 7.27E-01 0.00 
rs2834651 Relapse codom.het A/G 0.34 0.34 1.60(1.33-1.93) 4.36E-07 1.61(1.31-1.97) 3.74E-06 2.74E-01 0.16 
rs11615759 Relapse recessive A/G 0.16 0.14 2.62(1.73-3.96) 5.02E-06 2.62(1.73-3.96) 5.02E-06 9.00E-01 0.00 
rs3736994 Relapse dominant A/G 0.31 0.33 0.68(0.57-0.80) 5.79E-06 0.68(0.57-0.80) 5.79E-06 3.99E-01 0.00 
rs4920993 Relapse recessive A/G 0.27 0.29 1.84(1.41-2.40) 6.41E-06 1.84(1.41-2.40) 6.41E-06 8.62E-01 0.00 
rs8111608 Relapse additive G/A 0.34 0.33 0.74(0.65-0.84) 6.59E-06 0.74(0.65-0.84) 6.59E-06 8.10E-01 0.00 
rs7572970 Relapse recessive G/A 0.28 0.30 1.85(1.41-2.43) 8.45E-06 1.85(1.41-2.43) 8.45E-06 4.68E-01 0.00 
rs962312 Relapse dominant G/A 0.48 0.47 1.66(1.33-2.07) 8.56E-06 1.66(1.33-2.07) 8.56E-06 7.35E-01 0.00 
rs754799 Relapse recessive A/C 0.19 0.17 2.39(1.62-3.51) 9.92E-06 2.39(1.62-3.51) 9.92E-06 9.03E-01 0.00 
rs4946483 Relapse additive G/A 0.38 0.47 1.31(1.16-1.48) 1.00E-05 1.31(1.16-1.48) 1.00E-05 5.38E-01 0.00 
rs9533040 Relapse codom.hom A/G 0.15 0.14 2.64(1.75-3.98) 4.10E-06 2.64(1.72-4.07) 1.03E-05 2.96E-01 0.09 
rs846978 Relapse dominant G/A 0.11 0.08 1.58(1.29-1.94) 1.15E-05 1.58(1.29-1.94) 1.15E-05 7.97E-01 0.00 
rs923435 Relapse codom.het A/C 0.28 0.29 0.66(0.55-0.80) 1.16E-05 0.66(0.55-0.80) 1.16E-05 5.22E-01 0.00 
rs3917265 Relapse dominant G/A 0.46 0.47 1.55(1.27-1.89) 1.41E-05 1.55(1.27-1.89) 1.41E-05 4.44E-01 0.00 
rs12435167 Relapse dominant G/A 0.29 0.31 0.69(0.58-0.81) 1.43E-05 0.69(0.58-0.82) 1.71E-05 3.13E-01 0.02 
rs2028008 Relapse dominant A/G 0.29 0.30 1.44(1.22-1.71) 2.21E-05 1.44(1.22-1.71) 2.21E-05 4.33E-01 0.00 
rs10888205 Relapse recessive G/A 0.23 0.23 1.95(1.43-2.67) 2.35E-05 1.95(1.43-2.67) 2.35E-05 3.66E-01 0.00 
rs1036332 Relapse additive C/A 0.27 0.27 0.72(0.63-0.83) 6.29E-06 0.72(0.62-0.84) 5.01E-05 2.64E-01 0.20 
  
  
129 
SNP 
Model Validation Meta-analysis results 
Outcome MoI Alleles HR(95% CI) fixed P fixed HR(95% CI) random P random P het I2 
rs754799 Recurrence recessive A/C 1.51( 1.00-2.27) 4.76E-02 1.51( 1.00-2.27) 4.76E-02 8.40E-01 0.0 
rs12988804 Recurrence codom.het G/A 1.08( 0.90-1.28) 4.08E-01 1.01( 0.73-1.41) 9.41E-01 1.36E-01 55.0 
rs489770 Recurrence recessive A/G 0.85( 0.55-1.31) 4.68E-01 0.75( 0.36-1.59) 4.52E-01 1.58E-01 49.8 
rs980761 Recurrence codom.het A/G 1.06( 0.89-1.27) 5.27E-01 1.00( 0.73-1.37) 9.91E-01 1.52E-01 51.4 
rs3736994 Recurrence dominant A/G 1.02( 0.86-1.21) 8.30E-01 0.98( 0.76-1.28) 8.96E-01 2.02E-01 38.5 
rs7930624 Recurrence additive C/A 1.00( 0.86-1.16) 9.97E-01 1.00( 0.86-1.16) 9.97E-01 7.24E-01 0.0 
rs12681007 Recurrence recessive G/A 1.15( 0.94-1.40) 1.76E-01 1.18( 0.89-1.57) 2.38E-01 2.28E-01 31.1 
rs6443819 Recurrence additive A/G 1.06( 0.92-1.21) 4.29E-01 1.14( 0.82-1.58) 4.24E-01 6.42E-02 70.8 
rs10867878 Recurrence recessive G/A 0.81( 0.53-1.23) 3.21E-01 0.81( 0.53-1.23) 3.21E-01 9.57E-01 0.0 
rs9504361 Recurrence codom.het G/A 1.00( 0.82-1.22) 9.94E-01 0.93( 0.65-1.35) 7.18E-01 1.86E-01 42.8 
rs6512003 Recurrence recessive C/A 0.99( 0.80-1.24) 9.43E-01 0.94( 0.66-1.34) 7.34E-01 2.04E-01 38.1 
rs6505263 Recurrence additive G/A 0.99( 0.86-1.13) 8.35E-01 0.96( 0.79-1.17) 7.03E-01 2.27E-01 31.3 
rs2943313 Recurrence dominant G/A 0.97( 0.70-1.34) 8.47E-01 0.97( 0.70-1.34) 8.47E-01 7.31E-01 0.0 
rs2191031 Recurrence dominant G/A 0.94( 0.79-1.13) 5.12E-01 0.88( 0.62-1.24) 4.66E-01 1.28E-01 56.7 
rs1421776 Progression codom.hom A/G 0.96( 0.23-3.97) 9.57E-01 0.96( 0.23-3.97) 9.57E-01 NA NA 
rs4246835 Progression codom.het G/A 0.64( 0.43-0.94) 2.36E-02 0.57( 0.25-1.28) 1.72E-01 5.14E-02 73.7 
rs10167220 Progression dominant G/A 0.49( 0.29-0.84) 8.86E-03 0.49( 0.29-0.84) 8.86E-03 3.22E-01 0.0 
rs526509 Progression additive C/A 1.09( 0.86-1.38) 4.67E-01 1.09( 0.86-1.38) 4.67E-01 6.36E-01 0.0 
rs6100810 Progression recessive A/G 1.55( 0.70-3.47) 2.83E-01 1.55( 0.70-3.47) 2.83E-01 6.40E-01 0.0 
rs12294567 Progression codom.hom A/G 0.56( 0.10-3.07) 5.06E-01 0.56( 0.10-3.07) 5.06E-01 7.68E-01 0.0 
rs4246835 Progression dominant G/A 0.74( 0.52-1.05) 8.71E-02 0.66( 0.30-1.42) 2.85E-01 4.24E-02 75.7 
rs17218455 Progression codom.hom G/A 1.32( 0.57-3.04) 5.19E-01 1.32( 0.57-3.04) 5.19E-01 5.19E-01 0.0 
rs6752816 Progression dominant G/A 0.96( 0.58-1.58) 8.58E-01 0.92( 0.51-1.67) 7.94E-01 2.67E-01 19.0 
rs2950650 Progression codom.hom A/G 0.76( 0.10-5.52) 7.86E-01 0.76( 0.10-5.52) 7.86E-01 NA NA 
rs9891348 Progression codom.het A/G 1.44( 0.96-2.17) 7.70E-02 1.44( 0.96-2.17) 7.70E-02 3.66E-01 0.0 
rs5027573 Progression dominant G/A 0.64( 0.29-1.40) 2.63E-01 0.64( 0.29-1.40) 2.63E-01 5.32E-01 0.0 
rs17831395 Progression dominant A/G 0.26( 0.04-1.92) 1.88E-01 0.26( 0.04-1.92) 1.88E-01 NA NA 
rs1568519 Progression dominant A/C 0.98( 0.56-1.71) 9.33E-01 1.01( 0.44-2.31) 9.76E-01 1.44E-01 53.2 
rs7721273 Progression codom.hom A/G 0.86( 0.34-2.20) 7.61E-01 0.86( 0.34-2.20) 7.61E-01 8.96E-01 0.0 
rs7588481 Progression dominant A/C 1.01( 0.69-1.48) 9.40E-01 1.01( 0.69-1.48) 9.40E-01 3.47E-01 0.0 
rs6531449 Progression additive A/G 0.80( 0.61-1.04) 9.55E-02 0.80( 0.61-1.04) 9.55E-02 9.30E-01 0.0 
rs7936809 Progression dominant G/A 0.82( 0.58-1.15) 2.51E-01 0.91( 0.41-2.05) 8.24E-01 2.55E-02 80.0 
rs3797725 Progression codom.hom A/G 1.06( 0.46-2.47) 8.91E-01 1.06( 0.46-2.47) 8.91E-01 3.29E-01 0.0 
rs7572970 Progression recessive G/A 1.27( 0.65-2.47) 4.78E-01 1.27( 0.65-2.47) 4.78E-01 6.89E-01 0.0 
  
130 
SNP 
Model Validation Meta-analysis results 
Outcome MoI Alleles HR(95% CI) fixed P fixed HR(95% CI) random P random P het I2 
rs10437619 Progression additive A/G 0.92( 0.73-1.17) 5.09E-01 0.88( 0.59-1.32) 5.33E-01 1.11E-01 60.6 
rs1035856 Progression dominant G/A 1.43( 0.69-2.98) 3.36E-01 1.43( 0.69-2.98) 3.36E-01 NA NA 
rs1847325 Progression additive G/A 1.16( 0.91-1.48) 2.38E-01 1.16( 0.91-1.48) 2.38E-01 6.87E-01 0.0 
rs1432374 Progression additive G/A 0.75( 0.58-0.98) 3.56E-02 0.75( 0.58-0.98) 3.56E-02 4.02E-01 0.0 
rs10783528 Progression additive G/A 0.94( 0.73-1.21) 6.29E-01 0.91( 0.64-1.30) 5.99E-01 1.84E-01 43.2 
rs6757412 Progression codom.hom A/C 0.65( 0.32-1.34) 2.47E-01 0.65( 0.32-1.34) 2.47E-01 8.90E-01 0.0 
rs3772337 Relapse recessive A/G 1.06( 0.66-1.69) 8.18E-01 1.21( 0.49-2.97) 6.85E-01 7.73E-02 67.9 
rs11604069 Relapse dominant G/A 1.12( 0.94-1.34) 2.16E-01 1.12( 0.94-1.34) 2.16E-01 8.55E-01 0.0 
rs446027 Relapse codom.hom A/G 0.93( 0.73-1.19) 5.52E-01 0.93( 0.73-1.19) 5.52E-01 5.23E-01 0.0 
rs2694787 Relapse codom.hom G/A 0.95( 0.59-1.53) 8.35E-01 0.95( 0.59-1.53) 8.35E-01 6.29E-01 0.0 
rs2834651 Relapse codom.het A/G 0.99( 0.84-1.17) 8.92E-01 1.08( 0.73-1.61) 6.99E-01 5.38E-02 73.1 
rs11615759 Relapse recessive A/G 1.06( 0.52-2.15) 8.77E-01 1.06( 0.52-2.15) 8.77E-01 NA NA 
rs3736994 Relapse dominant A/G 1.07( 0.91-1.26) 3.99E-01 1.07( 0.91-1.26) 3.99E-01 7.25E-01 0.0 
rs4920993 Relapse recessive A/G 1.18( 0.87-1.60) 2.99E-01 0.97( 0.45-2.07) 9.37E-01 7.52E-02 68.4 
rs8111608 Relapse additive G/A 0.97( 0.86-1.09) 5.75E-01 0.97( 0.86-1.09) 5.75E-01 7.56E-01 0.0 
rs7572970 Relapse recessive G/A 0.80( 0.58-1.11) 1.87E-01 0.66( 0.29-1.48) 3.09E-01 1.48E-01 52.3 
rs962312 Relapse dominant G/A 1.08( 0.91-1.29) 3.83E-01 1.08( 0.91-1.29) 3.83E-01 4.37E-01 0.0 
rs754799 Relapse recessive A/C 1.48( 1.00-2.20) 4.91E-02 1.48( 1.00-2.20) 4.91E-02 7.43E-01 0.0 
rs4946483 Relapse additive G/A 1.16( 0.91-1.49) 2.29E-01 1.16( 0.91-1.49) 2.29E-01 NA NA 
rs9533040 Relapse codom.hom A/G 0.64( 0.09-4.70) 6.61E-01 0.64( 0.09-4.70) 6.61E-01 NA NA 
rs846978 Relapse dominant G/A 0.97( 0.77-1.22) 8.02E-01 0.97( 0.77-1.22) 8.02E-01 6.86E-01 0.0 
rs923435 Relapse codom.het A/C 1.01( 0.86-1.19) 8.93E-01 1.01( 0.86-1.19) 8.93E-01 6.77E-01 0.0 
rs3917265 Relapse dominant G/A 0.87( 0.73-1.03) 9.79E-02 0.87( 0.73-1.03) 9.79E-02 9.14E-01 0.0 
rs12435167 Relapse dominant G/A 1.08( 0.93-1.27) 3.19E-01 1.15( 0.85-1.56) 3.75E-01 1.07E-01 61.4 
rs2028008 Relapse dominant A/G 1.02( 0.87-1.20) 7.92E-01 1.00( 0.82-1.23) 9.62E-01 2.51E-01 24.0 
rs10888205 Relapse recessive G/A 0.70( 0.48-1.02) 6.02E-02 0.70( 0.48-1.02) 6.02E-02 7.82E-01 0.0 
rs1036332 Relapse additive C/A 1.00( 0.88-1.13) 9.84E-01 1.00( 0.88-1.13) 9.84E-01 8.63E-01 0.0 
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SNP 
Model All Combined Meta-analysis results 
Outcome MoI Alleles HR(95% CI) fixed P fixed HR(95% CI) random P random P het I2 
rs754799 Recurrence recessive A/C 2.06( 1.55- 2.75) 7.45E-07 2.10( 1.46- 3.04) 7.71E-05 2.13E-01 33.2 
rs12988804 Recurrence codom.het G/A 1.29( 1.13- 1.47) 1.08E-04 1.27( 0.96- 1.66) 8.90E-02 8.90E-03 74.1 
rs489770 Recurrence recessive A/G 1.56( 1.17- 2.09) 2.68E-03 1.39( 0.69- 2.80) 3.50E-01 1.33E-03 80.8 
rs980761 Recurrence codom.het A/G 1.27( 1.11- 1.45) 5.05E-04 1.26( 0.95- 1.68) 1.14E-01 7.55E-03 74.9 
rs3736994 Recurrence dominant A/G 0.83( 0.73- 0.94) 3.35E-03 0.79( 0.58- 1.06) 1.10E-01 1.98E-03 79.7 
rs7930624 Recurrence additive C/A 1.18( 1.06- 1.30) 1.81E-03 1.20( 0.98- 1.46) 8.05E-02 1.79E-02 70.2 
rs12681007 Recurrence recessive G/A 1.34( 1.16- 1.56) 1.14E-04 1.42( 1.09- 1.84) 8.55E-03 4.54E-02 62.6 
rs6443819 Recurrence additive A/G 1.20( 1.08- 1.32) 3.89E-04 1.25( 1.03- 1.53) 2.60E-02 1.24E-02 72.4 
rs10867878 Recurrence recessive G/A 1.44( 1.08- 1.91) 1.18E-02 1.42( 0.75- 2.68) 2.86E-01 5.13E-03 76.5 
rs9504361 Recurrence codom.het G/A 0.81( 0.69- 0.94) 4.48E-03 0.75( 0.55- 1.04) 8.34E-02 8.86E-03 74.2 
rs6512003 Recurrence recessive C/A 1.26( 1.08- 1.48) 4.33E-03 1.23( 0.88- 1.71) 2.28E-01 1.04E-02 73.4 
rs6505263 Recurrence additive G/A 0.86( 0.78- 0.96) 5.44E-03 0.82( 0.66- 1.02) 7.00E-02 1.14E-02 72.9 
rs2943313 Recurrence dominant G/A 1.39( 1.11- 1.75) 4.25E-03 1.41( 0.89- 2.22) 1.42E-01 1.23E-02 72.5 
rs2191031 Recurrence dominant G/A 0.80( 0.70- 0.92) 1.61E-03 0.74( 0.55- 0.99) 4.31E-02 1.02E-02 73.4 
rs1421776 Progression codom.hom A/G 4.90( 2.55- 9.44) 1.96E-06 4.18( 1.25-13.90) 1.99E-02 3.95E-02 69.0 
rs4246835 Progression codom.het G/A 0.49( 0.37- 0.64) 1.77E-07 0.46( 0.30- 0.72) 6.51E-04 5.20E-02 61.2 
rs10167220 Progression dominant G/A 1.51( 1.13- 2.00) 4.83E-03 1.16( 0.49- 2.72) 7.41E-01 1.71E-05 87.9 
rs526509 Progression additive C/A 1.41( 1.19- 1.66) 4.71E-05 1.39( 1.04- 1.85) 2.65E-02 2.85E-02 66.9 
rs6100810 Progression recessive A/G 3.03( 1.85- 4.95) 9.76E-06 2.78( 1.41- 5.48) 3.13E-03 1.44E-01 44.5 
rs12294567 Progression codom.hom A/G 3.92( 2.05- 7.52) 3.76E-05 2.66( 0.86- 8.18) 8.85E-02 1.00E-01 51.9 
rs4246835 Progression dominant G/A 0.57( 0.45- 0.72) 4.74E-06 0.55( 0.37- 0.82) 3.47E-03 4.52E-02 62.7 
rs17218455 Progression codom.hom G/A 2.75( 1.70- 4.47) 4.08E-05 2.51( 1.24- 5.07) 1.07E-02 1.28E-01 47.2 
rs6752816 Progression dominant G/A 1.74( 1.27- 2.37) 5.36E-04 1.54( 0.84- 2.83) 1.63E-01 1.48E-02 71.4 
rs2950650 Progression codom.hom A/G 3.84( 2.06- 7.15) 2.28E-05 3.43( 1.47- 7.98) 4.30E-03 2.07E-01 36.6 
rs9891348 Progression codom.het A/G 0.71( 0.54- 0.94) 1.50E-02 0.72( 0.33- 1.59) 4.21E-01 2.60E-05 87.5 
rs5027573 Progression dominant G/A 1.94( 1.33- 2.82) 5.95E-04 1.53( 0.70- 3.33) 2.87E-01 1.16E-02 72.8 
rs17831395 Progression dominant A/G 2.87( 1.72- 4.78) 5.05E-05 2.15( 0.74- 6.22) 1.59E-01 3.44E-02 70.3 
rs1568519 Progression dominant A/C 1.84( 1.32- 2.55) 3.03E-04 1.68( 0.90- 3.14) 1.06E-01 1.59E-02 71.0 
rs7721273 Progression codom.hom A/G 2.62( 1.54- 4.44) 3.65E-04 2.20( 0.87- 5.54) 9.47E-02 3.56E-02 65.0 
rs7588481 Progression dominant A/C 1.54( 1.20- 1.98) 7.34E-04 1.52( 0.96- 2.38) 7.20E-02 2.22E-02 68.8 
rs6531449 Progression additive A/G 1.21( 1.01- 1.44) 3.53E-02 1.18( 0.76- 1.82) 4.69E-01 5.36E-04 82.9 
rs7936809 Progression dominant G/A 1.33( 1.05- 1.69) 1.87E-02 1.39( 0.74- 2.59) 3.03E-01 1.54E-04 85.2 
rs3797725 Progression codom.hom A/G 2.35( 1.50- 3.67) 1.80E-04 2.10( 1.07- 4.13) 3.18E-02 1.22E-01 48.2 
rs7572970 Progression recessive G/A 2.24( 1.54- 3.27) 2.88E-05 2.16( 1.26- 3.70) 4.91E-03 1.40E-01 45.2 
  
132 
SNP 
Model All Combined Meta-analysis results 
Outcome MoI Alleles HR(95% CI) fixed P fixed HR(95% CI) random P random P het I2 
rs10437619 Progression additive A/G 1.24( 1.05- 1.45) 1.00E-02 1.19( 0.83- 1.69) 3.49E-01 2.83E-03 78.7 
rs1035856 Progression dominant G/A 2.49( 1.61- 3.84) 3.99E-05 2.49( 1.30- 4.79) 6.14E-03 1.05E-01 55.6 
rs1847325 Progression additive G/A 0.84( 0.71- 1.01) 5.77E-02 0.82( 0.55- 1.23) 3.42E-01 1.85E-03 80.0 
rs1432374 Progression additive G/A 1.16( 0.98- 1.37) 9.06E-02 1.08( 0.70- 1.67) 7.35E-01 2.82E-04 84.2 
rs10783528 Progression additive G/A 1.26( 1.07- 1.49) 6.83E-03 1.21( 0.85- 1.73) 2.86E-01 5.13E-03 76.5 
rs6757412 Progression codom.hom A/C 1.78( 1.16- 2.73) 8.18E-03 1.48( 0.60- 3.65) 3.90E-01 5.16E-03 76.5 
rs3772337 Relapse recessive A/G 1.91( 1.36- 2.69) 1.83E-04 2.14( 0.94- 4.88) 6.89E-02 1.02E-03 81.5 
rs11604069 Relapse dominant G/A 0.85( 0.75- 0.96) 1.09E-02 0.84( 0.61- 1.16) 2.92E-01 3.26E-04 83.9 
rs446027 Relapse codom.hom A/G 1.30( 1.09- 1.55) 3.53E-03 1.34( 0.89- 2.02) 1.66E-01 1.65E-03 80.3 
rs2694787 Relapse codom.hom G/A 1.71( 1.26- 2.31) 5.63E-04 1.58( 0.89- 2.80) 1.16E-01 1.87E-02 70.0 
rs2834651 Relapse codom.het A/G 1.23( 1.09- 1.39) 9.29E-04 1.34( 0.96- 1.86) 8.56E-02 2.15E-04 84.6 
rs11615759 Relapse recessive A/G 2.08( 1.46- 2.98) 5.83E-05 1.97( 1.10- 3.51) 2.20E-02 9.48E-02 57.6 
rs3736994 Relapse dominant A/G 0.86( 0.77- 0.97) 1.25E-02 0.84( 0.64- 1.12) 2.37E-01 1.21E-03 81.1 
rs4920993 Relapse recessive A/G 1.52( 1.24- 1.86) 4.22E-05 1.43( 1.01- 2.03) 4.21E-02 4.89E-02 61.9 
rs8111608 Relapse additive G/A 0.86( 0.78- 0.93) 5.58E-04 0.85( 0.72- 1.00) 4.49E-02 3.11E-02 66.2 
rs7572970 Relapse recessive G/A 1.32( 1.07- 1.63) 9.16E-03 1.16( 0.67- 2.04) 5.95E-01 5.84E-04 82.8 
rs962312 Relapse dominant G/A 1.28( 1.11- 1.46) 5.65E-04 1.36( 1.04- 1.77) 2.53E-02 2.44E-02 68.1 
rs754799 Relapse recessive A/C 1.89( 1.43- 2.49) 5.89E-06 1.89( 1.43- 2.49) 5.89E-06 3.92E-01 0.0 
rs4946483 Relapse additive G/A 1.28( 1.15- 1.43) 6.89E-06 1.28( 1.15- 1.43) 6.89E-06 5.73E-01 0.0 
rs9533040 Relapse codom.hom A/G 2.49( 1.66- 3.73) 9.79E-06 2.42( 1.41- 4.17) 1.44E-03 2.29E-01 32.2 
rs846978 Relapse dominant G/A 1.27( 1.09- 1.48) 2.00E-03 1.27( 0.95- 1.69) 1.11E-01 1.88E-02 69.9 
rs923435 Relapse codom.het A/C 0.84( 0.74- 0.95) 4.73E-03 0.83( 0.64- 1.07) 1.47E-01 7.93E-03 74.7 
rs3917265 Relapse dominant G/A 1.11( 0.97- 1.26) 1.15E-01 1.15( 0.81- 1.63) 4.29E-01 1.95E-04 84.8 
rs12435167 Relapse dominant G/A 0.88( 0.78- 0.98) 2.64E-02 0.90( 0.66- 1.21) 4.82E-01 3.46E-04 83.8 
rs2028008 Relapse dominant A/G 1.20( 1.07- 1.35) 1.95E-03 1.19( 0.95- 1.49) 1.37E-01 1.54E-02 71.2 
rs10888205 Relapse recessive G/A 1.28( 1.01- 1.63) 4.03E-02 1.19( 0.64- 2.20) 5.91E-01 4.18E-04 83.4 
rs1036332 Relapse additive C/A 0.87( 0.79- 0.95) 2.92E-03 0.85( 0.69- 1.04) 1.06E-01 5.04E-03 76.6 
  
  
133 
SNP 
Model 
Source 
SNP location 
Outcome MoI Alleles Chr Chr position HUGO (ensembl) Nearest gene (Illumina) NM (Illumina) Location 
rs754799 Recurrence recessive A/C epicuro 19 1.855.612 ADAT3;SCAMP4 SCAMP4, ADAT3 NM_079834.2 flanking_5UTR 
rs12988804 Recurrence codom.het G/A epicuro 2 169.826.057 LRP2 LRP2 NM_004525.1 intron 
rs489770 Recurrence recessive A/G mdacc 5 153.619.501 GALNT10 GALNT10 NM_198321.2 intron 
rs980761 Recurrence codom.het A/G epicuro 4 76.300.144 NA DKFZP564O0823 NM_015393.2 flanking_3UTR 
rs3736994 Recurrence dominant A/G epicuro 14 59.012.927 C14orf149 C14orf149 NM_144581.1 intron 
rs7930624 Recurrence additive C/A epicuro 11 243.841 PSMD13 PSMD13 NM_175932.1 flanking_3UTR 
rs12681007 Recurrence recessive G/A mdacc 8 92.883.202 NA RUNX1T1 NM_175634.1 flanking_3UTR 
rs6443819 Recurrence additive A/G mdacc 3 183.857.095 NA ATP11B NM_014616.1 flanking_5UTR 
rs10867878 Recurrence recessive G/A epicuro 9 84.583.137 NA RASEF NM_152573.2 flanking_3UTR 
rs9504361 Recurrence codom.het G/A epicuro 6 522.820 EXOC2 EXOC2 NM_018303.4 intron 
rs6512003 Recurrence recessive C/A epicuro 19 14.996.741 CCDC105 FLJ40365,CCDC105 NM_173482.1 flanking_3UTR 
rs6505263 Recurrence additive G/A epicuro 17 27.177.993 NA C17orf79 NM_018405.2 flanking_3UTR 
rs2943313 Recurrence dominant G/A mdacc 16 25.577.363 NA HS3ST4 NM_001012981.2 flanking_5UTR 
rs2191031 Recurrence dominant G/A epicuro 3 45.885.874 NA LZTFL1 NM_031200.1 flanking_5UTR 
rs1421776 Progression codom.hom A/G mdacc 5 143.230.072 NA HB-1 NM_021182.1 flanking_3UTR 
rs4246835 Progression codom.het G/A epicuro 9 20.023.087 NA SLC24A2 NM_020344.1 flanking_5UTR 
rs10167220 Progression dominant G/A epicuro 2 53.699.993 ASB3 ASB3 NM_145863.1 flanking_3UTR 
rs526509 Progression additive C/A epicuro 9 258.740 DOCK8 DOCK8 NM_203447.1 flanking_5UTR 
rs6100810 Progression recessive A/G epicuro 20 58.243.870 NA CDH26 NM_001004305.1 flanking_5UTR 
rs12294567 Progression codom.hom A/G epicuro 11 91.265.310 NA FAT3 NM_005959.3 flanking_5UTR 
rs4246835 Progression dominant G/A mdacc 9 20.023.087 NA SLC24A2 NM_020344.1 flanking_5UTR 
rs17218455 Progression codom.hom G/A mdacc 12 105.240.571 TCP11L2 TCP11L2 NM_152772.1 intron 
rs6752816 Progression dominant G/A epicuro 2 54.485.107 NA FLJ40298 NM_173486.1 flanking_3UTR 
rs2950650 Progression codom.hom A/G epicuro 2 182.273.888 NA NEUROD1 NM_002500.1 flanking_5UTR 
rs9891348 Progression codom.het A/G epicuro 17 50.929.373 NA MMD NM_012329.2 flanking_5UTR 
rs5027573 Progression dominant G/A mdacc 10 87.881.252 GRID1 GRID1 NM_017551.1 intron 
rs17831395 Progression dominant A/G mdacc 18 53.269.990 ONECUT2 ONECUT2 NM_004852.1 intron 
rs1568519 Progression dominant A/C mdacc 2 212.714.637 ERBB4 ERBB4 NM_005235.1 intron 
rs7721273 Progression codom.hom A/G epicuro 5 7.577.548 ADCY2 ADCY2 NM_020546.1 intron 
rs7588481 Progression dominant A/C mdacc 2 137.365.673 THSD7B CXCR4,THSD7B NM_003467.2 flanking_5UTR 
rs6531449 Progression additive A/G epicuro 4 36.178.408 NA CENTD1 NM_015230.2 flanking_5UTR 
rs7936809 Progression dominant G/A epicuro 11 25.335.857 NA LUZP2 NM_001009909.2 flanking_3UTR 
rs3797725 Progression codom.hom A/G epicuro 5 111.103.627 C5orf13 C5orf13 NM_004772.1 intron 
rs7572970 Progression recessive G/A mdacc 2 160.844.902 RBMS1 RBMS1 NM_016839.2 intron 
  
134 
SNP 
Model 
Source 
SNP location 
Outcome MoI Alleles Chr Chr position HUGO (ensembl) Nearest gene (Illumina) NM (Illumina) Location 
rs10437619 Progression additive A/G epicuro 11 25.232.451 NA LUZP2 NM_001009909.2 flanking_3UTR 
rs1035856 Progression dominant G/A mdacc 5 77.952.104 LHFPL2 LHFPL2 NM_005779.1 flanking_5UTR 
rs1847325 Progression additive G/A mdacc 15 98.885.065 LASS3 LASS3 NM_178842.2 intron 
rs1432374 Progression additive G/A epicuro 3 117.933.067 NA LSAMP NM_002338.2 flanking_5UTR 
rs10783528 Progression additive G/A epicuro 12 51.374.751 KRT77 KRT1B,KRT77 NM_175078.1 coding 
rs6757412 Progression codom.hom A/C epicuro 2 236.478.306 AGAP1 CENTG2, AGAP1 NM_014914.2 intron 
rs3772337 Relapse recessive A/G epicuro 3 1.268.647 CNTN6 CNTN6 NM_014461.2 intron 
rs11604069 Relapse dominant G/A mdacc 11 34.720.827 NA EHF NM_012153.3 flanking_3UTR 
rs446027 Relapse codom.hom A/G epicuro 8 81.614.888 NA ZBTB10 NM_023929.2 flanking_3UTR 
rs2694787 Relapse codom.hom G/A epicuro 10 117.852.840 GFRA1 GFRA1 NM_005264.2 intron 
rs2834651 Relapse codom.het A/G mdacc 21 35.150.230 RUNX1 RUNX1 NM_001001890.1 intron 
rs11615759 Relapse recessive A/G epicuro 12 23.634.296 SOX5 SOX5 NM_178010.1 intron 
rs3736994 Relapse dominant A/G epicuro 14 59.012.927 C14orf149 C14orf149 NM_144581.1 intron 
rs4920993 Relapse recessive A/G epicuro 5 117.180.846 NA DTWD2 NM_173666.1 flanking_3UTR 
rs8111608 Relapse additive G/A epicuro 19 15.004.453 NA FLJ40365 NM_173482.1 flanking_3UTR 
rs7572970 Relapse recessive G/A epicuro 2 160.844.902 RBMS1 RBMS1 NM_016839.2 intron 
rs962312 Relapse dominant G/A epicuro 6 120.953.430 NA COX6A1P3 NM_152730.3 flanking_3UTR 
rs754799 Relapse recessive A/C epicuro 19 1.855.612 ADAT3;SCAMP4 SCAMP4, ADAT3 NM_079834.2 flanking_5UTR 
rs4946483 Relapse additive G/A epicuro 6 120.792.408 NA COX6A1P3 NM_152730.3 flanking_3UTR 
rs9533040 Relapse codom.hom A/G mdacc 13 41.694.721 DGKH DGKH NM_178009.2 intron 
rs846978 Relapse dominant G/A epicuro 6 108.149.027 SCML4 SCML4 NM_198081.1 intron 
rs923435 Relapse codom.het A/C epicuro 12 127.710.640 TMEM132C SLC15A4, TMEM132C NM_145648.1 flanking_3UTR 
rs3917265 Relapse dominant G/A epicuro 2 102.144.893 IL1R1 IL1R1 NM_000877.2 intron 
rs12435167 Relapse dominant G/A epicuro 14 40.206.466 NA LRFN5 NM_152447.2 flanking_5UTR 
rs2028008 Relapse dominant A/G epicuro 7 88.949.497 NA FLJ32110 NM_181646.2 flanking_3UTR 
rs10888205 Relapse recessive G/A epicuro 10 48.186.564 NA GDF10 NM_004962.2 flanking_5UTR 
rs1036332 Relapse additive C/A mdacc 1 197.279.101 NA PTPRC NM_002838.2 flanking_3UTR 
MOI - mode of inheritance 
MAF SBC/EPICURO-minor allele frequency in the SBC/EPICURO Study; MAF MDACC - minor allele frequency in the MDACC Study 
HR-hazard ratio, 95% CI - 95% confidence interval 
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Supplementary Table 5. C-statistics for (A) multivariate Cox regression for each NMIBC outcome including all co-variables except the SNP, (B) 
multivariate Cox regression including all co-variables and each SNP at a time, and (C) multivariate Cox regression including all co-variables and all 
significant SNP for each outcome. C-statistics were estimated for each original series and after bootstrapping  
Study SNP ID Outcome MoI 
TXBC-1 
C-stat original 
TXBC-1 
C-stat boots 
SBC/EPICURO 
C-stat original 
SBC/EPICURO 
C-stat boots 
TXBC-2 
C-stat original 
TXBC-2 
C-stat boots 
Int’al Cohorts 
C-stat original 
Int’al Cohorts 
C-stat boots 
A            
Multivariate 
Cox without 
SNP 
information 
 relapse  0.63 0.61 0.62 0.60 0.71 0.69 0.67 0.66 
 progression  0.70 0.66 0.77 0.73 0.81 0.78 0.80 0.78 
 recurrence  0.64 0.62 0.64 0.61 0.69 0.66 0.68 0.67 
            
B            
Multivariate 
Cox for each 
SNP 
rs11615759 relapse recessive 0.63 0.61 0.63 0.60 NA NA 0.66 0.65 
rs754799 relapse recessive 0.63 0.61 0.62 0.60 0.71 0.68 0.67 0.66 
rs4946483 relapse additive 0.63 0.61 0.78 NA 0.72 0.69 0.73 NA 
rs4246835 progression codom.het 0.72 0.67 0.80 0.76 0.81 0.78 0.80 0.77 
rs6100810 progression recessive 0.71 0.67 0.78 0.74 0.81 0.77 0.79 0.77 
rs7572970 progression recessive 0.72 0.68 0.78 0.73 0.81 0.77 0.79 0.77 
rs12294567 progression codom.hom 0.71 0.66 0.79 0.74 0.81 0.77 0.80 0.77 
rs1035856 progression dominant   0.78 0.73   0.80 0.77 
rs17218455 progression codom.hom 0.72 0.67 0.79 0.74 0.81 0.77 0.79 0.77 
rs3797725 progression codom.hom 0.71 0.66 0.78 0.73 0.81 0.77 0.80 0.78 
 rs754799 recurrence recessive 0.65 0.62 0.64 0.61 0.69 0.66 0.68 0.67 
            
C            
Multivariate 
Cox joining 
SNPs 
 relapse  0.64 0.62 0.63 0.61 0.72 0.69 0.67 0.66 
 progression  0.75 0.70 0.84 0.78 0.82 0.76 0.79 0.75 
 recurrence  0.65 0.62 0.64 0.61 0.69 0.66 0.68 0.67 
            
TXBC-1/2: Discovery/Validation phase subset of the Texas Bladder Cancer Study; SBC/EPICURO: Spanish Bladder Cancer/EPICURO Study 
C-stat original: C-statistic obtained from the original model; C-stat boots: C-statistic obtained after 500 rounds of bootstrapping 
 
 
  
136 
Supplementary Table 6. Correlation between the significant SNPs identified in NMIBC series after Validation phase and the tumor baseline characteristics: 
stage, grade and tumor size. 
SNP 
SBC/EPICURO, Discovery International series, Validation 
Stage Grade Tumor size Stage Grade Tumor size 
N rho p-value N rho p-value N rho p-value N rho p-value N rho p-value N rho p-value 
rs754799 835 -0.03 0.31 835 -0.03 0.46 600 -0.03 0.42 835 -0.03 0.31 835 -0.03 0.46 600 -0.03 0.42 
rs4246835 836 -0.05 0.12 836 -0.05 0.16 600 -0.01 0.73 836 -0.05 0.12 836 -0.05 0.16 600 -0.01 0.73 
rs7572970 835 -0.02 0.65 835 0.02 0.58 600 0.06 0.13 835 -0.02 0.65 835 0.02 0.58 600 0.06 0.13 
rs3797725 836 -0.02 0.63 836 -0.01 0.72 600 -0.05 0.21 836 -0.02 0.63 836 -0.01 0.72 600 -0.05 0.21 
rs4946483 836 -0.02 0.49 836 -0.04 0.20 600 0.07 0.10 836 -0.02 0.49 836 -0.04 0.20 600 0.07 0.10 
rs12294567 836 0.02 0.56 836 0.04 0.30 600 -0.05 0.26 836 0.02 0.56 836 0.04 0.30 600 -0.05 0.26 
rs11615759 836 -0.04 0.24 836 -0.02 0.63 600 -0.01 0.88 836 -0.04 0.24 836 -0.02 0.63 600 -0.01 0.88 
rs17218455 836 -0.02 0.65 836 -0.02 0.63 600 -0.03 0.48 836 -0.02 0.65 836 -0.02 0.63 600 -0.03 0.48 
rs6100810 836 0.02 0.62 836 0.07 0.06 600 0.00 0.95 836 0.02 0.62 836 0.07 0.06 600 0.00 0.95 
                   
SNP 
 
TXBC-1, Discovery TXBC-2, Validation 
Stage Grade Tumor size Stage Grade Tumor size 
N rho p-value N rho p-value N rho p-value N rho p-value N rho p-value N rho p-value 
rs754799 494 0.04 0.33 477 0.07 0.12 212 0.09 0.20 358 0.05 0.37 349 0.07 0.18 185 -0.02 0.84 
rs4246835 493 0.04 0.33 476 0.05 0.32 211 0.07 0.31 345 -0.04 0.42 337 0.02 0.72 180 -0.06 0.39 
rs7572970 494 0.08 0.07 477 -0.02 0.73 212 0.08 0.25 356 -0.10 0.05 347 0.03 0.63 183 -0.09 0.23 
rs3797725 494 0.03 0.47 477 0.03 0.58 212 -0.01 0.86 352 0.03 0.51 344 0.14 0.01 182 -0.04 0.61 
rs4946483 494 -0.10 0.03 477 -0.06 0.18 212 0.09 0.21 357 -0.04 0.42 349 0.04 0.40 185 -0.07 0.37 
rs12294567 494 0.01 0.85 477 -0.07 0.10 212 -0.02 0.82 359 -0.01 0.88 350 -0.03 0.56 184 0.16 0.03 
rs11615759 494 0.00 0.98 477 0.01 0.85 212 -0.08 0.22 356 -0.07 0.19 348 -0.01 0.90 184 -0.09 0.24 
rs17218455 494 0.04 0.43 477 0.10 0.02 212 -0.08 0.27 358 0.01 0.93 349 0.00 0.99 184 0.03 0.67 
rs6100810 493 0.08 0.09 476 0.02 0.66 212 -0.17 0.01 355 -0.07 0.18 346 -0.09 0.09 184 -0.01 0.95 
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Supplementary Table 7. MIBC associations of SNPs identified in Stage I analysis with risk of BC-specific mortality, overall survival, and progression: Meta-
analysis for the Discovery phase. Chromosome and gene location, minor allele, and mode-of inheritance are also displayed. 
SNP 
Model Discovery Meta-analysis results 
Outcome MoI Alleles MAF SBC/EPICURO MAF TXBC-1 HR(95% CI) fixed P fixed HR(95% CI) random P random P het I2 
rs1015267 BC-specific mort. codom.hom G/A 0.35 0.30 3.96(2.51-6.23) 2.91E-09 3.96(2.51-6.23) 2.91E-09 9.60E-01 0.00 
rs1015267 BC-specific mort. recessive G/A 0.35 0.30 3.41(2.24-5.19) 1.01E-08 3.41(2.24-5.19) 1.01E-08 7.32E-01 0.00 
rs1008954 BC-specific mort. dominant A/G 0.07 0.05 2.75(1.88-4.02) 1.65E-07 2.75(1.88-4.02) 1.65E-07 9.56E-01 0.00 
rs11221970 BC-specific mort. dominant A/G 0.07 0.05 2.77(1.88-4.08) 2.28E-07 2.77(1.88-4.08) 2.28E-07 9.94E-01 0.00 
rs17603887 BC-specific mort. dominant G/A 0.09 0.10 2.50(1.76-3.54) 2.85E-07 2.50(1.74-3.58) 6.39E-07 3.02E-01 0.06 
rs1537010 BC-specific mort. dominant A/G 0.04 0.02 3.86(2.30-6.49) 3.15E-07 3.86(2.30-6.49) 3.15E-07 7.21E-01 0.00 
rs7035632 BC-specific mort. dominant C/A 0.07 0.07 2.51(1.73-3.63) 1.08E-06 2.51(1.73-3.63) 1.08E-06 5.26E-01 0.00 
rs2646727 BC-specific mort. additive A/G 0.40 0.43 1.70(1.37-2.11) 1.18E-06 1.70(1.37-2.11) 1.18E-06 4.01E-01 0.00 
rs404678 BC-specific mort. recessive A/G 0.40 0.37 0.29(0.18-0.48) 1.57E-06 0.29(0.18-0.48) 1.57E-06 4.83E-01 0.00 
rs2565721 BC-specific mort. additive G/A 0.46 0.48 0.60(0.49-0.74) 2.62E-06 0.60(0.48-0.75) 7.56E-06 2.95E-01 0.09 
rs9323978 BC-specific mort. dominant C/A 0.20 0.20 2.06(1.52-2.78) 2.63E-06 2.06(1.52-2.78) 2.63E-06 5.31E-01 0.00 
rs3102192 BC-specific mort. additive G/A 0.41 0.35 0.60(0.48-0.74) 4.59E-06 0.60(0.48-0.74) 4.59E-06 5.67E-01 0.00 
rs4923350 BC-specific mort. recessive A/G 0.41 0.37 2.22(1.57-3.14) 6.17E-06 2.22(1.57-3.14) 6.17E-06 3.90E-01 0.00 
rs725745 BC-specific mort. codom.het G/A 0.39 0.36 0.49(0.35-0.67) 7.44E-06 0.49(0.35-0.67) 7.44E-06 3.79E-01 0.00 
rs6074012 BC-specific mort. recessive G/A 0.45 0.49 2.06(1.49-2.83) 9.78E-06 2.05(1.40-3.01) 2.25E-04 2.33E-01 0.30 
rs4900384 BC-specific mort. dominant A/G 0.29 0.30 1.96(1.45-2.65) 1.27E-05 1.96(1.38-2.79) 1.69E-04 2.45E-01 0.26 
rs2416996 BC-specific mort. recessive G/A 0.40 0.43 2.18(1.53-3.11) 1.54E-05 2.18(1.53-3.11) 1.54E-05 3.93E-01 0.00 
rs6672666 BC-specific mort. recessive A/G 0.26 0.26 2.80(1.75-4.49) 1.71E-05 2.78(1.63-4.74) 1.67E-04 2.58E-01 0.22 
rs783145 BC-specific mort. additive A/G 0.45 0.49 0.63(0.51-0.78) 2.32E-05 0.63(0.51-0.78) 2.32E-05 5.92E-01 0.00 
rs1171509 BC-specific mort. codom.hom A/G 0.30 0.33 2.85(1.75-4.63) 2.45E-05 2.85(1.75-4.63) 2.45E-05 3.78E-01 0.00 
rs6805542 BC-specific mort. dominant A/G 0.28 0.22 1.86(1.39-2.49) 3.23E-05 1.86(1.38-2.50) 3.76E-05 3.13E-01 0.02 
rs4871475 BC-specific mort. recessive C/A 0.25 0.22 2.92(1.75-4.86) 3.90E-05 2.92(1.75-4.86) 3.90E-05 3.67E-01 0.00 
rs335305 BC-specific mort. additive A/G 0.48 0.49 1.54(1.25-1.90) 4.45E-05 1.54(1.25-1.90) 4.45E-05 3.24E-01 0.00 
rs2139142 BC-specific mort. dominant G/A 0.21 0.22 1.88(1.39-2.56) 5.23E-05 1.88(1.39-2.56) 5.23E-05 3.62E-01 0.00 
rs10437447 Overall survival dominant G/A 0.15 0.13 1.88(1.47-2.41) 4.59E-07 1.88(1.47-2.41) 4.59E-07 5.89E-01 0.00 
rs2565721 Overall survival additive G/A 0.46 0.48 0.66(0.56-0.78) 9.60E-07 0.66(0.56-0.78) 9.60E-07 5.98E-01 0.00 
rs783145 Overall survival additive A/G 0.45 0.49 0.66(0.56-0.79) 1.63E-06 0.66(0.56-0.79) 1.63E-06 6.93E-01 0.00 
rs2646727 Overall survival additive A/G 0.40 0.43 1.52(1.28-1.81) 1.92E-06 1.53(1.26-1.85) 1.25E-05 2.75E-01 0.16 
rs9915388 Overall survival dominant G/A 0.10 0.10 1.97(1.48-2.61) 2.90E-06 1.97(1.48-2.61) 2.90E-06 6.36E-01 0.00 
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rs955387 Overall survival dominant G/A 0.14 0.11 1.86(1.43-2.41) 3.07E-06 1.86(1.43-2.41) 3.07E-06 3.26E-01 0.00 
rs953517 Overall survival additive A/G 0.31 0.36 0.67(0.56-0.80) 6.85E-06 0.67(0.56-0.80) 6.85E-06 3.23E-01 0.00 
rs4795064 Overall survival dominant A/G 0.42 0.43 0.57(0.45-0.73) 8.14E-06 0.57(0.45-0.73) 8.14E-06 3.62E-01 0.00 
rs1621801 Overall survival additive C/A 0.45 0.48 0.68(0.58-0.81) 8.91E-06 0.68(0.58-0.81) 8.91E-06 6.72E-01 0.00 
rs7793188 Overall survival recessive G/A 0.34 0.30 0.41(0.27-0.61) 1.00E-05 0.41(0.27-0.61) 1.00E-05 9.44E-01 0.00 
rs7594456 Overall survival codom.het G/A 0.31 0.34 0.58(0.45-0.74) 1.58E-05 0.58(0.45-0.74) 1.58E-05 3.58E-01 0.00 
rs2173281 Overall survival additive G/A 0.31 0.30 1.50(1.25-1.80) 1.60E-05 1.50(1.25-1.80) 1.60E-05 5.21E-01 0.00 
rs6538017 Overall survival dominant G/A 0.23 0.22 1.67(1.32-2.12) 1.76E-05 1.67(1.32-2.12) 1.76E-05 4.74E-01 0.00 
rs2989509 Overall survival additive G/A 0.31 0.29 1.41(1.20-1.66) 2.40E-05 1.41(1.20-1.66) 2.40E-05 3.83E-01 0.00 
rs7103589 Overall survival recessive A/C 0.46 0.39 1.83(1.38-2.42) 2.43E-05 1.83(1.38-2.42) 2.43E-05 5.24E-01 0.00 
rs2065411 Overall survival recessive A/C 0.37 0.35 2.01(1.45-2.78) 2.44E-05 2.01(1.45-2.78) 2.44E-05 4.80E-01 0.00 
rs9471770 Overall survival dominant A/C 0.13 0.14 0.55(0.42-0.73) 2.87E-05 0.55(0.40-0.75) 1.67E-04 2.66E-01 0.19 
rs6935921 Overall survival additive A/G 0.29 0.31 1.45(1.22-1.74) 4.24E-05 1.45(1.22-1.74) 4.24E-05 4.14E-01 0.00 
rs11234582 Overall survival additive A/G 0.35 0.36 1.42(1.19-1.69) 9.69E-05 1.42(1.17-1.72) 3.19E-04 2.78E-01 0.15 
rs16927851 Progression recessive A/G 0.28 0.23 3.48(2.25-5.39) 2.08E-08 3.53(2.11-5.90) 1.62E-06 2.41E-01 0.27 
rs9849682 Progression recessive A/C 0.45 0.44 2.33(1.67-3.25) 7.08E-07 2.33(1.67-3.25) 7.08E-07 6.43E-01 0.00 
rs11732628 Progression recessive A/G 0.37 0.39 2.60(1.78-3.80) 8.41E-07 2.60(1.78-3.80) 8.41E-07 4.63E-01 0.00 
rs9668920 Progression recessive A/G 0.30 0.27 2.78(1.83-4.23) 1.73E-06 2.80(1.77-4.42) 1.02E-05 2.78E-01 0.15 
rs16927851 Progression additive A/G 0.28 0.23 1.69(1.35-2.10) 3.21E-06 1.69(1.35-2.10) 3.21E-06 4.00E-01 0.00 
rs4658680 Progression recessive G/A 0.31 0.29 2.58(1.73-3.86) 3.55E-06 2.58(1.73-3.86) 3.55E-06 6.06E-01 0.00 
rs6774177 Progression dominant G/A 0.14 0.14 2.04(1.51-2.77) 3.88E-06 2.04(1.51-2.77) 3.88E-06 3.39E-01 0.00 
rs4595635 Progression additive G/A 0.30 0.26 1.61(1.31-1.98) 5.55E-06 1.61(1.31-1.98) 5.55E-06 7.45E-01 0.00 
rs2837472 Progression recessive G/A 0.30 0.27 3.14(1.90-5.20) 7.96E-06 3.14(1.90-5.20) 7.96E-06 6.00E-01 0.00 
rs330579 Progression dominant G/A 0.39 0.37 0.51(0.38-0.69) 1.03E-05 0.51(0.38-0.69) 1.03E-05 5.76E-01 0.00 
rs1263674 Progression additive A/G 0.33 0.31 1.60(1.30-1.98) 1.08E-05 1.61(1.28-2.01) 3.22E-05 2.90E-01 0.11 
rs2052665 Progression dominant A/G 0.23 0.18 1.97(1.45-2.68) 1.39E-05 1.97(1.45-2.68) 1.39E-05 4.77E-01 0.00 
rs899333 Progression additive A/G 0.50 0.48 0.63(0.51-0.78) 1.85E-05 0.63(0.51-0.78) 1.85E-05 4.18E-01 0.00 
rs7973149 Progression additive G/A 0.33 0.30 1.55(1.26-1.90) 2.50E-05 1.55(1.26-1.90) 2.50E-05 6.62E-01 0.00 
rs11624081 Progression dominant G/A 0.10 0.12 2.04(1.46-2.85) 2.73E-05 2.04(1.46-2.85) 2.73E-05 3.95E-01 0.00 
rs4658683 Progression recessive A/G 0.26 0.21 2.78(1.71-4.52) 3.61E-05 2.78(1.71-4.52) 3.61E-05 4.25E-01 0.00 
rs162713 Progression codom.hom G/A 0.40 0.36 2.43(1.59-3.70) 3.68E-05 2.43(1.59-3.70) 3.68E-05 5.24E-01 0.00 
rs1656197 Progression additive C/A 0.49 0.46 0.65(0.53-0.80) 6.31E-05 0.65(0.53-0.80) 6.31E-05 8.15E-01 0.00 
rs12032833 Progression additive A/G 0.40 0.45 1.56(1.25-1.55) 6.44E-05 1.56(1.25-1.94) 6.44E-05 8.37E-01 0.00 
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SNP 
Model 
Source 
SNP location 
Outcome MoI Alleles Chr Chr position HUGO (ensemble) Nearest gene (Illumina) NM (Illumina) Location 
rs1015267 BC-specific mort. codom.hom G/A epicuro 11 26317792 ANO3 TMEM16C NM_031418.1 intron 
rs1015267 BC-specific mort. recessive G/A mdacc 11 26317792 ANO3 TMEM16C NM_031418.1 intron 
rs1008954 BC-specific mort. dominant A/G mdacc 11 129479865 APLP2 APLP2 NM_001642.1 intron 
rs11221970 BC-specific mort. dominant A/G epicuro 11 129488492 APLP2,U4 APLP2 NM_001642.1 intron 
rs17603887 BC-specific mort. dominant G/A epicuro 10 125213543 NA GPR26 NM_153442.1 flanking_5UTR 
rs1537010 BC-specific mort. dominant A/G epicuro 9 128033291 NA C9orf28 NM_033446.1 flanking_5UTR 
rs7035632 BC-specific mort. dominant C/A epicuro 9 115447048 NA RGS3 NM_021106.3 flanking_3UTR 
rs2646727 BC-specific mort. additive A/G epicuro 11 85716734 C11orf73,AP001148.4 HSPC138 NM_016401.2 intron 
rs404678 BC-specific mort. recessive A/G epicuro 20 4972237 NA SLC23A2 NM_203327.1 flanking_5UTR 
rs2565721 BC-specific mort. additive G/A mdacc 6 161155088 NA PLG NM_000301.1 flanking_3UTR 
rs9323978 BC-specific mort. dominant C/A epicuro 14 97550986 NA FLJ25773 NM_182560.1 flanking_5UTR 
rs3102192 BC-specific mort. additive G/A mdacc 13 60685194 NA PCDH20 NM_022843.2 flanking_3UTR 
rs4923350 BC-specific mort. recessive A/G epicuro 11 26322855 ANO3 TMEM16C NM_031418.1 intron 
rs725745 BC-specific mort. codom.het G/A epicuro 21 22763548 NA C21orf74 XR_001010.1 flanking_3UTR 
rs6074012 BC-specific mort. recessive G/A epicuro 20 44133573 NCOA5 NCOA5 NM_020967.2 intron 
rs4900384 BC-specific mort. dominant A/G epicuro 14 97568704 NA FLJ25773 NM_182560.1 flanking_5UTR 
rs2416996 BC-specific mort. recessive G/A epicuro 9 127883987 NA PBX3 NM_006195.4 flanking_3UTR 
rs6672666 BC-specific mort. recessive A/G mdacc 1 236499507 RP11-136B18.1 ZP4 NM_021186.2 flanking_5UTR 
rs783145 BC-specific mort. additive A/G mdacc 6 161072439 PLG PLG NM_000301.1 intron 
rs1171509 BC-specific mort. codom.hom A/G mdacc 10 23000205 PIP5K2A PIP5K2A NM_005028.3 intron 
rs6805542 BC-specific mort. dominant A/G mdacc 3 188644930 NA RTP4 NM_022147.2 flanking_3UTR 
rs4871475 BC-specific mort. recessive C/A epicuro 8 125334406 NA TMEM65 NM_194291.1 flanking_3UTR 
rs335305 BC-specific mort. additive A/G epicuro 4 62076355 LPHN3 LPHN3 NM_015236.3 intron 
rs2139142 BC-specific mort. dominant G/A mdacc 2 127848232 MAP3K2 MAP3K2 NM_006609.2 flanking_5UTR 
rs10437447 Overall survival dominant G/A epicuro 10 129522059 NA TMEM12 NM_152311.1 flanking_3UTR 
rs2565721 Overall survival additive G/A mdacc 6 161155088 NA PLG NM_000301.1 flanking_3UTR 
rs783145 Overall survival additive A/G mdacc 6 161072439 PLG PLG NM_000301.1 intron 
rs2646727 Overall survival additive A/G epicuro 11 85716734 C11orf73,AP001148.4 HSPC138 NM_016401.2 intron 
rs9915388 Overall survival dominant G/A mdacc 17 644926 NXN,RNMTL1 RNMTL1 NM_018146.2 flanking_3UTR 
rs955387 Overall survival dominant G/A mdacc 9 117031013 DEC1 DEC1 NM_017418.1 intron 
rs953517 Overall survival additive A/G mdacc 1 36682864 C1orf102 C1orf102 NM_145047.3 intron 
rs4795064 Overall survival dominant A/G mdacc 17 30527454 UNC45B UNC45B NM_001033576.1 intron 
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rs1621801 Overall survival additive C/A mdacc 6 161116956 NA PLG NM_000301.1 flanking_3UTR 
rs7793188 Overall survival recessive G/A epicuro 7 96334989 NA DLX5 NM_005221.4 flanking_3UTR 
rs7594456 Overall survival codom.het G/A epicuro 2 212111679 ERBB4,5S_rRNA ERBB4 NM_005235.1 intron 
rs2173281 Overall survival additive G/A epicuro 11 85618223 NA EED NM_152991.1 flanking_5UTR 
rs6538017 Overall survival dominant G/A mdacc 9 137372128 C9orf62 KIAA0649 NM_014811.3 flanking_5UTR 
rs2989509 Overall survival additive G/A mdacc 9 117041491 DEC1 DEC1 NM_017418.1 intron 
rs7103589 Overall survival recessive A/C epicuro 11 11558113 GALNTL4 GALNTL4 NM_198516.1 intron 
rs2065411 Overall survival recessive A/C epicuro 20 58051064 NA FLJ33860 NM_173644.1 flanking_5UTR 
rs9471770 Overall survival dominant A/C mdacc 6 42189620 AL512274.9 TBN NM_138572.1 flanking_3UTR 
rs6935921 Overall survival additive A/G mdacc 6 161028526 NA PLG NM_000301.1 flanking_5UTR 
rs11234582 Overall survival additive A/G epicuro 11 85605600 NA EED NM_152991.1 flanking_5UTR 
rs16927851 Progression recessive A/G mdacc 12 24747765 SRP_euk_arch BCAT1 NM_005504.4 flanking_3UTR 
rs9849682 Progression recessive A/C epicuro 3 156572679 PLCH1 PLCL3 NM_014996.1 flanking_3UTR 
rs11732628 Progression recessive A/G epicuro 4 120228595 NA SYNPO2 NM_133477.1 flanking_3UTR 
rs9668920 Progression recessive A/G mdacc 12 24744641 NA BCAT1 NM_005504.4 flanking_3UTR 
rs16927851 Progression additive A/G epicuro 12 24747765 SRP_euk_arch BCAT1 NM_005504.4 flanking_3UTR 
rs4658680 Progression recessive G/A epicuro 1 243208879 EFCAB2 EFCAB2 NM_032328.1 intron 
rs6774177 Progression dominant G/A mdacc 3 176598901 NAALADL2,U6 NAALADL2 NM_207015.1 intron 
rs4595635 Progression additive G/A epicuro 12 24731875 NA FLJ32894 NM_144667.1 flanking_5UTR 
rs2837472 Progression recessive G/A epicuro 21 40456382 DSCAM DSCAM NM_001389.3 intron 
rs330579 Progression dominant G/A epicuro 2 150633855 NA FLJ32955 NM_153041.1 flanking_5UTR 
rs1263674 Progression additive A/G mdacc 2 207763968 NA KLF7 NM_003709.1 flanking_5UTR 
rs2052665 Progression dominant A/G epicuro 18 68976818 NA NETO1 NM_138966.2 flanking_5UTR 
rs899333 Progression additive A/G epicuro 17 21012955 DHRS7B DHRS7B NM_015510.3 intron 
rs7973149 Progression additive G/A epicuro 12 24730201 NA FLJ32894 NM_144667.1 flanking_5UTR 
rs11624081 Progression dominant G/A epicuro 14 94651714 DICER1 DICER1 NM_030621.2 intron 
rs4658683 Progression recessive A/G epicuro 1 243223134 EFCAB2 EFCAB2 NM_032328.1 intron 
rs162713 Progression codom.hom G/A epicuro 3 7841171 NA GRM7 NM_000844.2 flanking_3UTR 
rs1656197 Progression additive C/A epicuro 4 36920530 AC022463.5 FLJ11017 NM_018302.1 flanking_5UTR 
rs12032833 Progression additive A/G epicuro 1 76270941 NA ST6GALNAC3 NM_152996.1 flanking_5UTR 
MOI - mode of inheritance 
MAF SBC/EPICURO-minor allele frequency in the SBC/EPICURO Study; MAF MDACC - minor allele frequency in the MDACC Study 
HR-hazard ratio, 95% CI - 95% confidence interval 
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Supplementary Table 8. C-statistics for (A) multivariate Cox regression for each MIBC outcome including all co-
variables except the SNP, (B) multivariate Cox regression including all co-variables and each SNP at a time, and (C) 
multivariate Cox regression including all co-variables and all significant SNP for each outcome. C-statistics were 
estimated for each original series and after bootstrapping  
Study SNP ID Outcome MoI 
TXBC-1 
C-stat 
original 
TXBC-1 
C-stat 
boots 
SBC/EPICURO 
C-stat original 
SBC/EPICURO 
C-stat boots 
A        
Multivariate 
Cox without 
SNP 
information 
 BC-specific mortality  0.73 0.70 0.76 0.73 
 Progression  0.67 0.61 0.69 0.67 
 Overall survival  0.71 0.69 0.73 0.71 
        
B        
Multivariate 
Cox for each 
SNP 
rs1015267 BC-specific mortality codom.hom 0.74 0.71 0.75 0.72 
rs1015267 BC-specific mortality recessive 0.74 0.71 0.75 0.72 
rs1008954 BC-specific mortality dominant 0.74 0.71 0.74 0.72 
rs11221970 BC-specific mortality dominant 0.74 0.71 0.74 0.72 
rs17603887 BC-specific mortality dominant 0.73 0.70 0.74 0.72 
rs1537010 BC-specific mortality dominant 0.73 0.70 0.74 0.72 
rs16927851 Progression recessive 0.68 0.63 0.73 0.70 
rs9849682 Progression recessive 0.68 0.63 0.73 0.70 
rs11732628 Progression recessive 0.68 0.63 0.73 0.70 
rs10437447 Overall survival dominant 0.72 0.70 0.77 0.74 
rs2565721 Overall survival additive 0.73 0.71 0.77 0.73 
        
C        
Multivariate 
Cox joining 
SNPs 
 BC-related survival  0.76 0.73 0.77 0.73 
 Progression  0.71 0.66 0.76 0.73 
 Overall survival  0.74 0.72 0.76 0.74 
        
TXBC-1: Discovery phase subset of the Texas Bladder Cancer Study; SBC/EPICURO: Spanish Bladder Cancer/EPICURO Study 
C-stat original: C-statistic obtained from the original model; C-stat boots: C-statistic obtained after 500 rounds of bootstrapping 
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Supplementary Table 9. Correlation between the significant SNPs identified in MIBC series after Discovery phase and 
the tumor baseline characteristics: stage (T), affected ganglia (N) and metastasis (M). 
SNP 
SBC/EPICURO, Discovery 
T N M 
N rho p-value N rho p-value N rho p-value 
rs9849682 235 0.06 0.39 235 -0.12 0.07 235 -0.09 0.15 
rs11732628 235 0.00 0.99 235 0.07 0.30 235 -0.08 0.23 
rs2565721 235 0.08 0.22 235 -0.05 0.46 235 -0.06 0.35 
rs1537010 234 0.12 0.07 234 -0.03 0.68 234 -0.03 0.63 
rs17603887 235 -0.01 0.89 235 -0.16 0.01 235 -0.03 0.64 
rs10437447 234 -0.07 0.26 234 -0.06 0.39 234 -0.04 0.49 
rs1015267 234 0.08 0.22 234 -0.05 0.43 234 0.09 0.19 
rs1008954 235 0.06 0.40 235 0.09 0.18 235 0.06 0.38 
rs11221970 235 0.06 0.36 235 0.11 0.11 235 0.04 0.56 
          
SNP 
 
TXBC-1, Discovery 
T N M 
N rho p-value N rho p-value N rho p-value 
rs9849682 393 -0.04 0.47 387 0.09 0.07 390 0.03 0.61 
rs11732628 393 0.00 0.97 387 -0.04 0.48 390 0.02 0.74 
rs2565721 393 -0.01 0.88 387 -0.08 0.12 390 0.00 0.99 
rs1537010 393 0.04 0.38 387 0.08 0.10 390 0.06 0.21 
rs17603887 393 0.03 0.54 387 0.02 0.67 390 0.08 0.10 
rs10437447 393 0.00 0.94 387 0.05 0.33 390 0.01 0.80 
rs1015267 393 -0.04 0.46 387 0.04 0.43 390 0.02 0.74 
rs1008954 393 0.10 0.05 387 0.06 0.27 390 0.04 0.49 
rs11221970 393 0.08 0.09 387 0.06 0.24 390 0.04 0.46 
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Supplementary Figure 1. Scatter (Manhattan) plot of chromosome position (x axis) against -log10 
(p-value) for the 3 outcomes of interest (a: recurrence, b: progression, c: relapse) in the two 
Discovery studies 
Supplementary Figure 1a. Recurrence. 
 
Supplementary Figure 1b. Progression. 
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Supplementary Figure 1c. Relapse. 
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Supplementary Figure 2. Scatter (Manhattan) plot of chromosome position (x axis) against -
log10 (p-value) for the 3 outcomes of interest (a: progression, b: BC-specific mortality, c: overall 
survival) in the two Discovery studies. 
Supplementary Figure 2a. Progression. 
 
Supplementary Figure 2b. BC-specific mortality. 
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Supplementary Figure 2c. Overall survival. 
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Supplementary Figure 3. Q-Q plot of observed against expected chi-square test in the dominant 
genetic model for the Discovery phase in NMIBC patients using adjusted analysis for tumor 
recurrence (a), progression (b) and relapse (c). 
Supplementary Figure 3a. NMIBC Recurrence. 
 
Supplementary Figure 3b. NMIBC Progression. 
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Supplementary Figure 3c. NMIBC Relapse. 
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Supplementary Figure 4. Q-Q plot of observed against expected chi-square test in the dominant 
genetic model for the Discovery phase in MIBC patients using adjusted analysis for tumor 
progression (a), BC-specific mortality (b) and overall survival (c). 
Supplementary Figure 4a. MIBC Progression. 
 
Supplementary Figure 4b. MIBC BC-specific mortality. 
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Supplementary Figure 4c. MIBC overall survival. 
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Supplementary Figure 5. Schematic view of the known genes, and neighborhood LD structure of 
the most significant SNPs associated with NMIBC recurrence, progression, and relapse. Location of 
the gene was obtained from UCSU genome browser. Pairwise LD structure by r
2
 was derived from 
Haploview software (v4.1) using Hapmap ref 27, phase III, Feb09, NCBI 36, dbSNP 126, CEU 
dataset. 
Supplementary Figure 2a. rs754799, chromosome 19, 1,848 – 1,925 Kb 
 
 
Supplementary Figure 2b. rs4246835, chromosome 9, 19,723 – 20,383 Kb 
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Supplementary Figure 6. Kaplan-Meier plots for NMIBC SNPs in Table 5 for each Discovery population. Logrank test and median follow-up 
time using reverse Kaplan-Meier estimator. 
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Supplementary Figure 7. Kaplan-Meier plots for MIBC SNPs in Table 6 for each Discovery population. Logrank test and median follow-up 
time using reverse Kaplan-Meier estimator. 
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Supplementary Figure 8. Statistical power (Y-axis) for each NMIBC (a: recurrence, b: progression and c: relapse) and each MIBC (d: 
progression, e: BC-specific mortality and f: overall survival) outcome under the participating study’s conditions of sample size, HR, proportion 
of variants, proportion of events and the type I error. 
Figure 8a. NMIBC Recurrence Figure 8b. NMIBC Progression 
  
Figure 8c. NMIBC Relapse  
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Figure 8d. MIBC Progression Figure 8e. MIBC BC-specific mortality 
  
Figure 8f. MIBC Overall survival  
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Supplementary Figure 9. Analysis of similarity of the enriched pathways obtained after the gene set analyses (GSA). Hierarchical clusters 
followed by dynamic tree cut and dynamic hybrid cut were performed in order to merge the similar cluster branches in modules (A-Z). 
Figure 9a. GO categories associated with progression in NMIBC using ALIGATOR 
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Figure 9b. GO categories and canonical pathways associated with BC-specific mortality in MIBC using GeSBAP 
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Figure 9c. GO categories and canonical pathways associated with progression in MIBC using GeSBAP 
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Figure 9d. GO categories and canonical pathways associated with progression in NMIBC using GeSBAP 
 
  
171 
Figure 9e. GO categories and canonical pathways associated with recurrence in NMIBC using GeSBAP 
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Figure 9f. GO categories and canonical pathways associated with BC-specific mortality in MIBC using GSA-SNP 
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Figure 9g. GO categories and canonical pathways associated with progression in MIBC using GSA-SNP 
 
  
174 
Figure 9h. GO categories and canonical pathways associated with progression in NMIBC using GSA-SNP 
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Figure 9i. GO categories and canonical pathways associated with recurrence in NMIBC using GSA-SNP 
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Figure 9j. GO categories and canonical pathways associated with BC-specific mortality in MIBC using ICSNPathway 
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Figure 9k. GO categories and canonical pathways associated with progression in NMIBC using ICSNPathway 
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Figure 9l. GO categories and canonical pathways associated with recurrence in NMIBC using ICSNPathway 
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Figure 9m. GO categories and canonical pathways associated with progression in MIBC using i-Gsea4Gwas 
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Figure 9n. GO categories and canonical pathways associated with progression in NMIBC using i-Gsea4Gwas 
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Figure 9o. GO categories and canonical pathways associated with recurrence in NMIBC using i-Gsea4Gwas 
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Supplementary Figure 10. Scatter plots comparing the -log10(p-values) obtained in the logistic and Cox regressions in 
NMIBC and MIBC clinical outcomes for 5M randomly selected SNP pairs. 
Figure 10a. Recurrence in NMIBC Figure 10b. Progression in NMIBC 
  
Figure 10c. Progression in MIBC Figure 10d. BC-specific mortality in MIBC 
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hat releases three transcriptions factors (GLI1, GLI2,
LI3) from the cytoplasm to enter the nucleus to acti-
pecific target genes (Fig. 1; refs. 26, 27).
controlled activation of the Shh pathway occurs in
er and many other cancers (28, 29), and Shh signal-
involved in tumor growth, recurrence, metastasis,
tem cell survival and expansion (18). PTCH1 has
investigated as a potential tumor suppressor in blad-
ncer (30–32). The role of PTCH1 and Shh signaling
dder cancer risk, however, is still being debated (33,
o our knowledge, no previous studies have ad-
d the association of genetic variations in the Shh
ay with bladder cancer susceptibility and outcome.
he current study, we determined whether genetic var-
s, or single-nucleotide polymorphisms (SNP), in
unctional components of the Shh pathway were as-
ed with bladder cancer risk. We also evaluated the
f these SNPs in modulating recurrence and the risk
gression in patients receiving or not receiving BCG
r study's NMIBC subpopulation of patients and sur-
in muscle-invasive and metastatic bladder cancer
BC) patients.
rials and Methods
subjects
Texas Bladder Cancer Study (TXBCS) recruitedpment. Normally inactivated in adult tissues, the bladder cancer cases from The University of Texas M.D.pathway.
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www.ason Cancer Center and Baylor College of Medicine
gh a daily review of computerized appointment sche-
as a part of an ongoing project since 1995. Cases
ll newly diagnosed within 1 year before recruitment,
ogically confirmed, and previously untreated with
therapy or radiotherapy. Control subjects with no
diagnosis of any type of cancer, except nonmelano-
in cancer, were recruited from Kelsey Seybold, the
t private multispecialty physician group in Houston
These participants were matched 1:1 to the cases
on sex, age (±5 years), and ethnicity to evaluate
ain effect of the genotype. There were no age, gender,
ge restrictions on recruitment. Because more than
f our recruited cases were pure transitional cell car-
a and the etiology of transitional cell carcinoma dif-
om that of squamous cell carcinoma, we included
ts with NMIBC and MiMBC in this study (Supple-
ry Table S1). In addition, because 90.6% of the
ts in our capture population were Caucasians, we in-
only Caucasians in this study so as to limit the con-
ing effect of population structure. Individuals who
smoked or had smoked less than 100 cigarettes in
her lifetime were defined as never smokers. Cases
ad quit smoking at least 1 year before diagnosis
ntrols who had quit smoking at least 1 year before
terview were defined as former smokers. Individuals
ere currently smoking or who had stopped <1 year
being diagnosed (cases) or before interview (con-
were defined as current smokers. Current and former
rs were defined as ever smokers.
independent validation set for the TXBCS NMIBC
t data was obtained from the Spanish Bladder
r (SBC)/Epidemiology of Cancer of the Urothelium
URO) study. All incident NMIBC patients were trea-
ring 1998-2001 in 18 general or university-affiliated
tals located in five geographic areas of Spain. The
ation study included NMIBC patients who received
nly and excluded NMIBC patients who received
ainly because of substantial differences in BCG re-
s between the TXBCS and SBC/EPICURO study.
miologic and clinical data collection
demiologic data of the TXBCS were collected by
Anderson interviewers in a 45-minute interview on
graphics, family history, and smoking status. Imme-
y after the interview, a blood sample was collected
NA extraction. The clinical data for TXBCS such as
r size, grade, stage, presence of carcinoma in situ,
er of tumor foci at diagnosis, intravesical therapy,
of recurrence and progression events, systemic che-
rapy, radical cystectomy, pathologic findings at cy-
my, and mortality were collected by trained chart
ers. All patients were followed up with periodic cys-
ic examinations. The end points of outcome assess-
in this study included recurrence, defined as a newly
bladder tumor following a previous negative fol-p cystoscopy; progression, defined as the transition
non–muscle-invasive to invasive or metastatic tu-
hazar
multi
acrjournals.organd overall survival, which was calculated from
te of diagnosis to the date of death or last follow-
hichever came first. All of the human participation
dures were approved by the University of Texas
Anderson Cancer Center, Baylor College of Medicine,
elsey Seybold institutional review boards. Written
ed consent was obtained from all patients before
iew. Clinical data collection in the SBC/EPICURO
has been described in detail previously (36). Written
ed consent was obtained from all participants, and
udy was approved by the local institutional ethics
ittee of each participating hospital and by the insti-
al review boards of the Institut Municipal d'Investi-
Mèdica and U.S. National Cancer Institute.
typing
otyping for the TXBCS was done at M.D. Anderson
r Center. Laboratory personnel were blinded to case
ontrol status. Genomic DNA was isolated from pe-
al blood using the QIAamp DNA Blood Maxi Kit
en) according to the manufacturer's protocol. We
ined literature search and database mining to select
date genes in the Shh pathway following a procedure
viously described (4). A total of 177 haplotype-tag-
NPs from 11 Shh pathway genes, including GLI1,
GLI3, GLI4, HHIP (Hedgehog-interacting protein),
, SUFU, SHH, SMO, PTCH, and PTCH2, were select-
r genotyping. The genotyping of 150 Shh SNPs in
GLI3, GLI4, SUFU, PTCH, PTCH2, SMO, and SHH
one using the Illumina iSelect custom SNP array
rm, and 27 Shh SNPs in GLI1, STK36, and HHIP
obtained from our published genome-wide associa-
tudy using the Illumina Human-Hap610 BeadChips
according to the manufacturer's Infinium II assay
col (Illumina), with 750 ng of input DNA for each
e. All the genotyping data were analyzed and exported
BeadStudio software (Illumina). The average call rate
e SNP array was 99.7%. SNPs selected for replication
genotyped with the Infinium Illumina Human 1M
BeadChip in SBC/EPICURO patients (38).
tical analysis
st statistical analyses were done using the Intercooled
10 statistical software package (Stata). Pearson's χ2
Fisher's exact test was used to compare the difference
tribution of categorical variables, and Wilcoxon rank
est or Student's t test was used for continuous vari-
where appropriate. Hardy-Weinberg equilibrium
sted using a goodness-of-fit χ2 analysis. The effects
otypes of SNPs on bladder cancer risks were estimat-
odds ratios and 95% confidence intervals (95% CI)
unconditional multivariate logistic regression under
minant, recessive, and additivemodels of inheritance
ed for age, gender, and smoking status, where appro-
. For clinical outcome analyses, the main effect of
dual SNPs on time to the event of each end point,
d ratios (HR), and 95% CIs were estimated by
variate Cox proportional hazard regression, adjusting
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Cance1238e, gender, smoking status, tumor grade, tumor stage,
eatments. The patients who were lost to follow-up or
efore the end point were censored. Because many
and tests were done in the analysis, the Q value (a
iscovery rate adjusted P value) was used to adjust
nificance level for individual SNPs (39–41). We cal-
d theQ value by the Q value package implemented in
software. We applied a bootstrap resampling method
ernally validate the results. We generated 100 boot-
ed samples for SNPs that remained significant after
ple comparison. Each bootstrap sample was drawn
the original data set, and a P value was obtained for
NP in the dominant, recessive, and additive models.
ied analysis was used to compare the effects of indi-
l genotypes on different treatment subgroups. In the
tion study in SBC/EPICURO patients, HRs and 95%
re estimated by a multivariate Cox proportional haz-
odel, with adjustments for area, sex, stage, T-stage and
multiplicity, tumor size, and treatment. The individ-
fects of all SNPs on recurrence in TUR-only NMIBC
ts in the combined TXBCS and SBC/EPICURO were
arized in a meta-analysis. All statistical analyses were
ded. Kaplan-Meier plots and log-rank tests were ap-
to compare the difference between the recurrence-free
al time of homozygous wild-type and variant geno-
which was calculated from the diagnosis date to
d of the follow-up or recurrence.
lts
ct characteristics
tal of 803 Caucasian patients with transitional cell
oma of bladder cancer and 803 Caucasian controls
included in this study (Supplementary Table S1).
and controls were perfectly matched on sex (P =
and no significant difference was observed for cases
± 10.9 years) and controls (64.7 ± 11.1 years) on age
.10). As we predicted, cases were more likely to be
t smokers (23.3%) than controls (8.3%, P < 0.01),
mong ever smoking participants, cases had a signifi-
higher mean pack-years (43.0 ± 30.7) than did the
ls (29.9 ± 27.9; P < 0.01).
re were 419 NMIBC patients and 318 MiMBC pa-
with full follow-up data among the 803 cases from
se-control study. Of 419 NMIBC patients, 228 cases
ped a recurrence. Table 1 shows the distribution of
graphic and clinical variables in TXBCS study. The
tage of male patients with recurrence (56.8%) was
cantly higher than that of females (43.4%; P = 0.03).
were no statistical differences between the recur-
and nonrecurrence groups in smoking status and
l factors (tumor stage and grade) except for treat-
We categorized the 419 NMIBC patients into the
ollowing treatment subgroups: TUR only, iBCG (re-
after TUR), mBCG (received after the TUR and
), and others (such as intravesical chemotherapy
BCG). Patients receiving mBCG were less likely to
p recurrence than those without mBCG (P < 0.01).
rs123
and r
r Prev Res; 3(10) October 2010g these patients, 71 had progression. Factors associ-
ith progression included sex, age, stage, grade, and
ent. Male patients (18.7%) were more likely to prog-
an women (9.2%; P = 0.05) and patients who had
ession were significantly older at diagnosis (mean
6.2 years) than patients without progression (mean
2.7 years; P = 0.02). Higher stage and grade are signif-
risk factors for progression. Patients receiving mBCG
ent were less likely to progress (P < 0.01). Because
is primarily administered to those with higher risk
urrence, we compared the stages and grades of
C patients who received TUR only or any type of
(iBCG and mBCG). As expected, patients receiving
had higher stage and grade than the TUR-only sub-
(P < 0.001; data not shown). In the 204 patients
eceived BCG treatment, there were 65 (32%) stage
G1, 26G2, 34G3, and one unknown grade), 120
) stage T1 (14G2, 104G3, and two unknown grade),
8 (9%) stage Tis (11G3 and seven unknown grade; all
ot shown). Of the 318 MiMBC patients, 184 (58%)
alive at the end of our study period. There was a
icant difference between deceased and alive patients
ms of age, gender, stage, and treatment regimen
.05; Supplementary Table S2).
characteristics of TUR-only NMIBC patients of the
S and SBC/EPICURO study are listed in Table 2.
were 146 such patients in TXBCS, 97 of whom
ecurrence. There were no significant differences be-
TXBCS patients who did and did not have recur-
in gender, age, smoking status, stage, or grade
2). There were 356 NMIBC patients in the SBC/EPI-
study, among whom 133 showed recurrence. There
o significant differences between SBC/EPICURO pa-
with and without recurrence in gender, age, smoking
, or stage, although grade was higher in patients with
ence.
iations between SNPs and bladder cancer risk
ong the 177 individual SNPs we analyzed in relation
cer risk (Supplementary Table S3), three SNPs on
LI3 gene, rs3735361, rs3823720, and rs10951671,
d nominal significance (P < 0.05; Table 3); however,
of these associations remained significant after ad-
g for multiple testing (data not shown). These same
GLI3 SNPs were consistently at the top of the list of
ssociations with risk in an analysis restricted to the
MIBC patients (versus 803 controls; Supplementary
S4) or, albeit nonsignificantly, in an analysis restrict-
he 318MiMBC patients (versus 803 controls; Supple-
ry Table S5).
rence predictors in TUR-only patients
e SNPs had a nominally significant individual
ation with recurrence in patients receiving TUR on-
≤ 0.05) in the TXBCS (Supplementary Table S6).
f these nine SNPs (i.e., rs17172001, rs1017024,
3560, rs2718107, rs2310897, and rs11594179)
s11677381, which is in strong linkage with GLI2
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Yes (n No (n P* Yes (n No (n P*
Sex
Mal
Fem 33 43 7 69
Age (y
Mea 63.0 63.6 0.63 66.2 62.7 0.02
Smoki 0.63 0.40
Nev 64 58 16 105
Form 117 89 37 169
Cur 47 44 18 73
Stage 0.28 <0.01
Ta 105 88 21 172
Tis 16 7 7 16
T1 104 96 42 157
Grade 0.20 <0.01
G1 5 11 1 15
G2 81 69 12 138
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TUR 97 49 16 129
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www.a85068 (R2 = 1), were genotyped in the validation data
m the 356 NMIBC patients of SBC/EPICURO (Sup-
ntary Table S6). The SNPs rs1233560 (of SHH) and
85068 (GLI2) were significantly associated with recur-
in both the TXBCS and SBC/EPICUROstudy (Table 4).
currence HR was 2.07 (95% CI, 1.33-3.21; P = 1.3 ×
for GLI2 rs11685068 and 1.39 (95% CI, 1.14-1.70;
0 × 10−3) for SHH rs1233560 in a meta-analysis of
mbined TXBCS and SBC/EPICURO data.
rence predictors in BCG patients
04 patients receiving BCG treatment (including 122
ts in iBCG subgroup and 82 patients in mBCG sub-
), nine SNPs located on GLI3, GLI2, and HHIP were
ated individually with time to recurrence at P < 0.05.
motherapy but no BCG.adjustment of multiple testing, two variant geno-
of GLI3, rs6463089 and rs3801192, remained signif-
recurr
in pa
acrjournals.organd associated with a 2.40-fold (95% CI, 1.50-3.84)
.54-fold (95% CI, 1.47-4.39) increased recurrence
espectively, compared with their corresponding ho-
gous wild-type genotype (Table 5). Interestingly, var-
enotypes of GLI3 rs6463089 and rs3801192 showed
tective effect on recurrence in the TUR-only sub-
, with HRs of 0.74 (95% CI, 0.42-1.33, P = 0.32)
.43 (95% CI, 0.21-0.88, P = 0.02), respectively
5). In the Kaplan-Meier estimates of recurrence-free
al in the BCG treatment group, compared with
nts with the homozygous wild-type genotype
463089 (recurrence-free median survival time
], 16.3 months; Plog-rank < 0.01) and rs3801192
months, Plog-rank = 0.02), those with at least one var-
llele at either of these two SNPs showed a shorterd clinical variables for NMIBC patients of the TXBCSence-free M
tients receC (n =ST of 5.5 months
iving TUR only,
Cancer Prev R(Fig. 2). Conversel
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e 195 (56.8) 148 (43.2) 64 (18.7) 278 (81.3)
ale (43.4) (56.6) (9.2) (90.8)
)
n (SD) y (11.2) (11.4) (9.9) (11.5)
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BCG 30 (36.6) 52 (63.4) 15 (18.3) 67 (81.7)
thers 10 (16.7) 50 (83.3) 3 (5.0) 57 (95.0)
E: The numbers of each variable may not add up to 419 due to missing data.
alues were derived from Pearson's χ2 test or Fisher's exact test for categorical variables, and Student's t test for continuous
ables.
oking status: individuals who had smoked more than 100 cigarettes in their lifetime were defined as ever smokers; others were
er smokers. Smokers included current smokers and former smokers. Individuals who had quit smoking at least 1 y before
nosis were categorized as former smokers.
atment: TUR, subgroup who had no further therapy after TUR; iBCG, subgroup who received iBCG after TUR; mBCG, sub-
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Cance1240zygous wild-type genotype (rs6463089 recurrence-
ST, 6.4 months; rs3801192 recurrence-free MST,
onths), those with the variant alleles at either of
two SNPs had longer recurrence-free MST (for
3089, 10.6 months, Plog-rank = 0.22; for rs3801192,
9 months, Plog-rank = 0.01; Fig. 2). Although we did
nduct validation assessments of SNP association in
patients because of BCG differences between the
nosis were categorized as former smokers. Six patients without
SBC/EPICURO study.PICURO study and TXBCS (also stated in Materials
et
for th
le ssociatio cted Shh –relate
e Genot Cas
rs373 GG/G 7
Flank AA
rs382 GG/G 7
justed by age, gender, and smoking status.
r Prev Res; 3(10) October 2010
 validate associations in the primary analysis. The
l HRs and 95% CIs generated by bootstrapping were
tent with our initial results. Table 5 lists the number
es that the bootstrap-generated P value was 0.05,
, or 0.0001 for each SNP. The significant results of
s6463089 and rs3801192 in the BCG group reached
icance at P = 0.05 in >90% of 100 bootstrap sam-
. The bootstrap findings indicate that the results
rence had missing data for smoking status variable in2. Host chara tics for NMIBC patients receiving TURese SNPs i
d
e/
08
95
04in the TXBCS and SBC/EPICUROT SBC/EPn the primary analy
ladder c
OR (9
Ref
1.42 (1
Ref
Cancer Pstudysis were unlikely du
P
0.04
revention ResearcRecurr (%) Recur n (%)= 97) = 49) = 133) = 223)0.18 0.59
e 77 (69.4) 34 (30.6) 118 (36.9) 202 (63.1)
ale (57.1) 42.9) (41.7) (58.3)
)
n (SD) y (12.2) 13.7) (10.07) (10.39)
ng status†er (60.9) 39.1) (43.6) (56.4)
er (71.6) 28.4) (32.7) (67.3)rent (63.6) 36.4) (42.1) (57.9)(63.9) 36.1) (37.7) (62.3)
(68.9) 31.1) (50) (50)
(100) 0.0) (32.1) (67.9)(G)
(50) 50) (29.8) (70.2)1 4 4 ( 57 134
2 55 (64.7) 30 (35.3) 57 (48.3) 61 (51.7)
3 34 (69.4) 15 (30.6) 19 (40.4) 28 (59.6)
alues were derived from Pearson's χ2 test or Fisher's exact test for categorical variables, and Student's t test for continuous
ables.
oking status: individuals who had smoked more than 100 cigarettes in their lifetime were defined as ever smokers; others were
er smokers. Smokers included current smokers and former smokers. Individuals who had quit smoking at least 1 y before
recure
hods), we performed bootstrap sampling to inter- to chance alone.3. A n between sele pathway SNPs and b ancer riskhSNP ype control 5% CI)*5361 (G>A) A /733 erence
ing 3′ UTR /70 .01-1.99)
3720 (G>A) A /738 erence
′ UTR /65 .11-2.20)3 AA 99 1.57 (1 0.01
rs10951671 (G>A) GG/GA 748/769 Reference
Intron AA 55/34 1.75 (1.11-2.74) 0.02
reviations: OR, odds ratio; UTR, untranslated region.
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www.aession in NMIBC patients
also assessed the association of SNPs with progres-
f NMIBC; however, we did not observe any SNPs
icantly associated with bladder cancer progression
not shown). Compared with recurrence, the progres-
ate in NMIBC patients is relatively low; therefore, we
t have adequate sample size to do the stratification
is by BCG treatment status.
ll survival in MiMBC patients
SNPs on GLI2, rs735557 and rs4848632, and the
SNP rs208684 showed individual associations with
l survival in MiMBC patients (P < 0.05; Supplemen-
able S7). All three associations became nonsignifi-
however, after adjusting for multiple comparisons and a
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present results have important implications for the
l management of NMIBC. Nine SNPs were signifi-
associated with recurrence of NMIBC patients in
BCS who received TUR treatment only; two of these
SHH rs1233560 and GLI2 rs11685068, were vali-
independently in the SBC/EPICURO cohort. With
TXBCS and replicated SBC/EPICURO results, SHH
3560 and GLI2 rs11685068 have potential real-time
l utility for predicting recurrence in NMIBC patients
ing TUR only. In NMIBC patients who received
two variant genotypes of GLI3 (rs6463089 and
1192) were significantly associated with an increased
f recurrence and a shorter recurrence-free survival
-fold changes in each) after adjusting for multiple
arisons, and the associations were internally validat-
bootstrap analysis. These results suggest that NMIBC
ts with wild-type genotypes of these two GLI3 SNPs
od candidates for BCG therapy, whereas those with
(44, 4
ment
acrjournals.org
 riant genotypes of these two SNPs should be spared
herapy.
homozygous variant genotypes of three SNPs in
showed significant associations with increased over-
dder cancer risk in our 803 bladder cancer cases and
ontrols. These associations remained at the top of
st of risk-associated SNPs in the case-control study
ted to the 419 NMIBC cases or 318 MiMBC cases
s 803 controls). These associations became nonsig-
nt, however, after adjusting for multiple compari-
n the overall analysis and the analysis stratified for
C or MiMBC. Further validation studies in indepen-
opulations are warranted to clarify the associations
se SNPs with bladder cancer risk. Two GLI2 SNPs
n SHH SNP were significantly associated with overall
al in MiMBC patients, but these associations became
gnificant after adjusting for multiple comparisons.
suggested that Shh signaling plays an important role
development and prognosis of bladder cancer. For
le, the most frequent loss-of-heterozygosity region
IBC is the locus of the Shh pathway gene PTCH
22 (42). Changes in the level of Shh pathway gene
sions also might predict overall survival in bladder
r patients (43). All previous studies were conducted
or tissues, where they showed that somatic changes
h genes (such as gene expression level and loss of
zygosity) may be involved in cancer development.
tudy was the first, however, to examine germ-line
c variations in Shh signaling as cancer susceptibility
s and predictors of outcome.
found that certain Shh pathway SNPs affected recur-
in patients receiving BCG. Although its antitumor
anism is not fully understood, BCG can trigger a
local immune response that leads to the expression
ny cytokines at the tumor site and to an influx of
locytes and mononuclear cells into the bladder wall4. Significant SN associations with recurrence in TUR-onl5). It is h
can direcNMIBC patients in the TXBCS andypothesized that
tly inhibit urothe
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bined 459/36/2 2.07 (1.33-3.21) 1.3 × 10−3 152/245/100 1.39 (1.14-1.70) 1.0 × 10−3
reviations: DOM, dominant; ADD, additive.
I2 rs11685068 is not genotyped in the Spanish study, but in strong linkage with rs11677381 with R2 = 1.0. The validation result
11685068 was derived from the result of rs11677381.treat-
rowth
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Table 5. Recurrence in NMIBC patients receiving BCG treatment versus those receiving TUR only and
internal bootstrap validation
BCG vs TUR only
SNP Gene Genotype Best
model*
BCG subgroup recurrence TUR-only subgroup recurrence
Yes/No HR
(95% CI)†
P Yes/No HR
(95% CI)†
P
ww wv + vv ww wv + vv
rs6463089 GLI3 G>A DOM 92/78 26/5 2.40
(1.50-3.84)
2 × 10−4 78/38 14/11 0.74
(0.42-1.33)
0.32
rs3801192 GLI3 G>A DOM 100/77 17/6 2.54
(1.47-4.39)
9 × 10−4 83/37 9/12 0.43
(0.21-0.88)
0.02
rs277534 GLI2 A>G DOM 69/46 49/37 0.60
(0.40-0.90)
0.01 63/31 29/18 1.02
(0.64-1.61)
0.95
rs3801210 GLI3 G>A ADD 52/37 65/46 1.43
(1.08-1.89)
0.01 38/14 54/35 0.86
(0.62-1.20)
0.39
rs6974655 GLI3 C>A DOM 67/42 51/41 0.62
(0.42-0.93)
0.02 50/21 42/28 0.72
(0.47-1.10)
0.13
rs2237425 GLI3 G>C ADD 76/60 42/20 1.45
(1.04-2.03)
0.03 70/38 22/11 1.08
(0.71-1.63)
0.73
rs2286294 GLI3 A>G DOM 28/29 89/51 1.63
(1.04-2.55)
0.03 31/11 61/37 0.97
(0.62-1.52)
0.90
rs2306924 HHIP A>G DOM 25/15 93/68 0.61
(0.38-0.99)
0.04 18/14 74/35 1.44
(0.83-2.50)
0.19
rs7785287 GLI3 G>A ADD 73/58 44/25 1.39
(1.00-1.93)
0.05 56/36 36/13 1.30
(0.89-1.89)
0.18
Internal bootstrap validation of significant results in patients receiving BCG treatment
SNP Gene Genotype Best model* Bootstrap‡
BCG subgroup recurrence
HR (95% CI)† P < 0.0001 P < 0.001 P < 0.05
rs6463089 GLI3 G>A DOM 2.40
(1.55-3.71)
46 68 92
rs3801192 GLI3 G>A DOM 2.54
(1.46-4.40)
34 56 93
rs277534 GLI2 A>G DOM 0.60
(0.38-0.94)
8 18 66
rs3801210 GLI3 G>A ADD 1.43
(1.06-1.91)
9 23 69
rs6974655 GLI3 C>A DOM 0.62
(0.38-1.02)
3 16 58
rs2237425 GLI3 G>C ADD 1.45
(1.11-1.91)
3 6 55
rs2286294 GLI3 A>G DOM 1.63
(1.01-2.62)
3 11 53
rs2306924 HHIP A>G DOM 0.61
(0.36-1.02)
4 16 61
rs7785287 GLI3 G>A ADD 1.39
(1.02-1.89)
1 10 46
NOTE: Significant SNPs after correcting for multiple comparisons by Q value with a false discovery rate of ≤10% are in boldface.
Abbreviations: w-wild type allele; v-variant allele; ww, homozygous wildtype genotype; wv, heterozygous variant genotype; vv,
homozygous variant genotype.
*Best model: the model with smallest P value.
†Adjusted by age, sex, smoking status, tumor stage, and tumor grade using Cox proportional hazard regression where appropriate.
‡We did internal validation of the results choosing from the best genetic model using bootstrap 100 times.
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Large-Scale Pathway-Based Analysis of Bladder Cancer
Genome-Wide Association Data from Five Studies of
European Background
Idan Menashe1*., Jonine D. Figueroa1., Montserrat Garcia-Closas2, Nilanjan Chatterjee1, Nuria
Malats3, Antoni Picornell3, Dennis Maeder1, Qi Yang1, Ludmila Prokunina-Olsson1, Zhaoming Wang4,
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Abstract
Pathway analysis of genome-wide association studies (GWAS) offer a unique opportunity to collectively evaluate
genetic variants with effects that are too small to be detected individually. We applied a pathway analysis to a bladder
cancer GWAS containing data from 3,532 cases and 5,120 controls of European background (n = 5 studies). Thirteen
hundred and ninety-nine pathways were drawn from five publicly available resources (Biocarta, Kegg, NCI-PID,
HumanCyc, and Reactome), and we constructed 22 additional candidate pathways previously hypothesized to be
related to bladder cancer. In total, 1421 pathways, 5647 genes and ,90,000 SNPs were included in our study. Logistic
regression model adjusting for age, sex, study, DNA source, and smoking status was used to assess the marginal trend
effect of SNPs on bladder cancer risk. Two complementary pathway-based methods (gene-set enrichment analysis
[GSEA], and adapted rank-truncated product [ARTP]) were used to assess the enrichment of association signals within
each pathway. Eighteen pathways were detected by either GSEA or ARTP at P#0.01. To minimize false positives, we
used the I2 statistic to identify SNPs displaying heterogeneous effects across the five studies. After removing these
SNPs, seven pathways (‘Aromatic amine metabolism’ [PGSEA = 0.0100, PARTP = 0.0020], ‘NAD biosynthesis’ [PGSEA = 0.0018,
PARTP = 0.0086], ‘NAD salvage’ [PARTP = 0.0068], ‘Clathrin derived vesicle budding’ [PARTP = 0.0018], ‘Lysosome vesicle
biogenesis’ [PGSEA = 0.0023, PARTP,0.00012], ’Retrograde neurotrophin signaling’ [PGSEA = 0.00840], and ‘Mitotic
metaphase/anaphase transition’ [PGSEA = 0.0040]) remained. These pathways seem to belong to three fundamental
cellular processes (metabolic detoxification, mitosis, and clathrin-mediated vesicles). Identification of the aromatic
amine metabolism pathway provides support for the ability of this approach to identify pathways with established
relevance to bladder carcinogenesis.
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Introduction
Genome-wide association studies (GWAS) have served as a
useful tool to identify common genetic variants associated with
various complex traits [1]. As expected, each variant explains a
tiny portion of the heritable component of their associated
phenotypes [2,3]. Recently, Park and colleagues estimated that
some proportion of the ‘missing heritability’ may reside in
additional common low-penetrance susceptibility variants that
can be discovered in larger GWAS [4]. In principle, other
methods could complement the primary single-locus tests of
GWAS in identifying additional susceptibility loci. One such
approach is pathway (gene-set) analysis [5,6], which examines
whether association signals of a collection of functionally related
loci (typically genes) consistently deviate from what is expected
by chance. This approach may suggest new candidate
susceptibility loci and possibly provide insights into the
mechanisms underlying complex traits. Pathway-based analyses
have been applied to GWAS of complex diseases, including
multiple sclerosis [7], type-2 diabetes [8,9], Crohn’s disease
[10,11], Parkinson’s disease [12,13], colon [14] and breast [15]
cancers.
Bladder cancer is the fourth most common malignancy among
men in the western world [16]. Epidemiological studies have
shown that exposure to aromatic amines (AAs) from tobacco
smoking or occupation is strongly associated with bladder cancer
risk [16,17,18,19]. Additionally, genetic studies have demon-
strated that functional polymorphisms in two genes involved in
carcinogen metabolism (N-acetyltransferase 2 [NAT2] and
glutathione S-transferase M1 [GSTM1]) are associated with
bladder cancer risk [20,21]. Notably, the risk of bladder cancer
associated with NAT2 slow acetylation genotype is restricted to
smokers [20,22]. Recently, a series of GWAS have identified
previously unknown susceptibility loci for bladder cancer, with
the prospects of more to be discovered [22,23,24,25]. To identify
additional regions that harbor plausible candidate genes and
shed further light on genetic basis of this disease, we applied
pathway analysis to the first stage of the NCI’s CGEMS bladder
cancer GWAS containing 3,532 cases and 5,120 controls [22].
We report here seven pathways implicated in diverse carcino-
genic processes to be enriched with bladder cancer susceptibility
loci.
Materials and Methods
Study population
We applied our analyses to primary scan data of 591,637 SNPs
from NCI’s bladder cancer GWAS containing 3,532 cases and
5,120 controls of European ancestry from five studies (Spanish
Bladder Cancer Study [SBCS], New England, Maine and
Vermont Bladder Cancer Study [NEBCS-ME/VT], Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study [ATBC],
the American Cancer Society Cancer Prevention Study II
Nutrition Cohort [CPS-II], and the Prostate, Lung, Colorectal
and Ovarian Cancer Screening Trial [PLCO]) [22].
Pathway data construction
We collected gene-sets from five publicly available pathway
resources: BioCarta [26], Kyoto Encyclopedia of Genes and
Genomes (KEGG) [27], NCI’s Pathway Interaction Database
(PID) [28], Reactome [29], and Encyclopedia of Homo sapiens
Genes and Metabolism (HumanCyc) [30]. Inclusion criteria of
pathways for analysis were those containing 5–100 genes to avoid
testing too narrowly- or too broadly- defined functional categories.
In addition, we constructed 22 candidate pathways (Table S2)
based on known bladder cancer risk factors and general
carcinogenic processes [31,32,33] which were not represented in
the public databases above. Specifically, selection of genes was
determined through 1) biochemical data for the detoxification of
aromatic amines [34,35]; 2) Ingenuity pathway lists [36]; and 3)
Gene ontology lists [37].
To explore the similarity between pathways in our database, we
assessed the percentage of overlapping genes between each two
pathways (A and B) as:
Overlap(%)~
(
N½A\B
N½A|B
z
N½A\B
minfNA,NBg )
2
|100% ð1Þ
where NA and NB are the number of genes within pathways A and
B.
SNPs from the first stage of the NCI bladder cancer GWAS
[22] were mapped to genes in these pathways if they were located
in a region encompassing 20 kb 59 upstream and 10 kb 39
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downstream from the genes’ coding regions (NCBI’s human
genome build 36.3). These gene’s boundaries were selected
attempting to capture most of the gene’s coding and regulatory
variants [38] as well as minimizing the overlap between genes.
Overall, 1,422 pathways containing 5,647genes (24.3621.7
[mean 6 SD] genes per pathway) and ,92,000 SNPs were
included in our database. A complete list of the studied pathways
is available in Table S1.
Statistical analysis
SNPs with MAF,1% among controls were excluded from the
analysis. We fitted logistic regression models adjusted for age, sex,
study center, DNA source (buccal/blood), and smoking status
(current/former/never/occasional), to assess the marginal effect of
each SNP (1 degree of freedom trend test) on the risk of bladder
cancer, as previously described [22]. For each gene Gj (j=1, …, N,
where N is the total number of genes in our dataset), the SNP with
the lowest p-value among all SNPs that were mapped to its region
was selected to represent the gene in the pathway analysis. We
used two approaches to test for overrepresentation of association
signals within pathways in our database:
A. Gene-set enrichment analysis (GSEA; [12]): In this approach,
the 2log10 of the p-value of each gene’s best SNP was used
as the gene’s test statistics (rj=2log10(pj). Then, a weighted
Kolmogorov-Smirnov procedure was used to assess for
overrepresentation of gene’s statistics Enrichment Score (ES)
within each pathway (S) [15].
ESs~ max
1ƒjƒN
f
X
Gj[S,jƒj
rj
 
Ws
{
X
Gj=[S,jƒj
1
N{NH
g ð2Þ
where, WS~
P
Gj[S
rj
  and NH is the number of genes in a
pathway.
A. The statistical significance of ESS was empirically evaluated
using 10,000 permutations (permuting the genotype data
between individuals and keeping the LD between SNPs
intact).
B. Adaptive Rank-Truncated Product (ARTP; [39]): In this
approach the genes’ best SNP p-values (pj) in each pathway
were ordered from lowest to highest. Then, the mathematical
product was computed for all possible sets of p(j) such that
W (K)~ P
K
j~1
(p(j)) ð3Þ
with K, 1#K#L, being all possible integers (the truncation
points) between 1 and L, with L being the number of genes in
a pathway. In words, W(K) is simply the product of the K
smallest P-values in a pathway. Next, we used the minP
statistics [40,41] to evaluated what is the K truncation point
where the W(K) get the most statistically significant value.
minP~ min
1ƒjƒJ
s
^
(Kj) ð4Þ
where s
^
(Kj) be the estimated P-value for W(Kj), K1#…#K.
B. We then used two-level permutation procedure (10, 000
permutations, permuting the genotype data between individ-
uals and keeping the LD structure between SNPs intact) to
estimate s
^
(Kj), and to adjust for multiple testing over the
different truncation points used.
Using both the GSEA and ARTP methods that employ
different approaches to assess the enrichment of gene-based
signals within predefined gene-sets may facilitate capturing a
broader range of candidate pathways for bladder cancer
susceptibility.
Finally, we calculated a false discovery rate (FDR) to assess the
proportion of expected false positive findings in the GSEA and
ARTP analyses. In short, we normalized the GSEA and ARTP
statistics for each pathway (NSs(GSEA) and NSs(ARTP) respectively)
based on the mean and standard deviation of the corresponding
permutation data [12]. This procedure allows a direct compar-
ison of pathways with different sizes and gene compositions.
Then, we used these normalized statistics to calculate the FDR
as:
FDR~
Pper
S NS
per
S §NSSPper
S NS
per
S
=
P
S NSS§NSSP
S NSS
ð5Þ
Genetic heterogeneity analysis
To minimize false positives, we estimated the I-squared statistic
(I2) [42] to identify SNPs displaying heterogeneous effects across
the five studies [ATBC, CPSII, NEBCS (ME, VT), PLCO, and
SBCS]. I2describes the proportion of total variation in study
estimates that is due to heterogeneity. In short, a meta-analysis was
applied to every SNP belonging to one of the top pathways using
the genotype frequency counts of cases and controls to estimate
per-allele OR and CI’s. SNPs with I2 P-values,0.2 were removed
from further analyses. We evaluated the OR, CI and p values for
both the meta-analysis and they were similar in both models, and
did not change the interpretation of the data. These analyses were
done using STATA (Version 11, STATA Corporation, College
Station, TX).
Results
Overall, there was good correlation between the results of the
GSEA and the ARTP methods (r = 0.74, P,0.0001). A detailed
examination of the results revealed that, on average, GSEA
performed better in detecting pathways enriched with multiple
weak association signals while ARTP appeared to be more
powerful in detecting pathways where only few genes with
relatively strong signals are dominating. Notably, the AA
metabolism pathway, which contains several known bladder
cancer susceptibility loci, was detected by both GSEA and ARTP
methods (PGSEA=0.0100, PARTP=0.0020). Therefore, we used its
significance level as a reference for highlighting additional
candidate susceptibility pathways. Of the 1421 pathways exam-
ined, 18 were significantly enriched with association signals at the
P,0.01 level (Table 1). Of these, seven pathways were detected by
both GSEA and ARTP, four pathways were detected only by
GSEA, and seven were detected only by ARTP. After removing
SNPs with heterogeneous effects across the five studies (I2 P-
value,0.2), the enrichment signals remained significant (P,0.01)
in seven pathways belonging to four cellular processes (‘‘aromatic
amine [AA] metabolism’’, ‘‘Nicotinamide adenine dinucleotide
[NAD] metabolism’’, ‘‘Clathrin-mediated vesicles’’, and ‘‘Mito-
sis’’). For clarity, from this point forward, we will refer only to the
results from the post heterogeneity analysis.
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Aromatic amine [AA] metabolism
Table 2 displays the results for the genes in the AA pathway.
The enrichment signals in this pathway were mainly driven by
SNPs in the UGT1A9 and NAT2 genes. SNPs in these genes were
identified in the primary analysis of this GWAS [22]. Removing
these two genes from the pathway analyses reduced the
enrichment signal in the AA metabolism pathway in both methods
but still ranked it relatively high using the GSEA (PGSEA=0.0130,
PARTP=0.1217). Apart from UGT1A9 and NAT2, five additional
genes in this pathway had SNPs with significant genetic effect
(Ptrend,0.05). These included NAT1, UGT1A4, UGT1A6, NQO1
and CYP1B1.
Some of the genes in the AA metabolism pathway (i.e. CYP1A1
and CYP1A2; UGT1A4, UGT1A6 and UGT1A9; SULT1A1 and
SULT1A2) occur on the same chromosomal locus and conse-
quently share similar tagging SNPs. To assess the effect of this
redundancy on the pathway enrichment signal, we pooled together
genes with overlapping SNPs and treated them as a single genetic
unit in our pathway analyses. Consequently, the number of loci
included in the AA metabolism pathway was reduced to seven,
(Table S2) and the corresponding enrichment signals were
strengthened (PGSEA=0.0046, PARTP=0.0001). Even when remov-
ing the NAT2 and UGT1A regions from this gene-set, its cor-
responding enrichment signal remains relatively high (PGSEA=
0.024, PARTP=0.0921).
NAD metabolism
Two nicotinamide adenine dinucleotide (NAD) metabolism
pathways were detected in this analysis. The ‘‘NAD biogenesis I’’
pathway (HumanCyc) was detected by both GSEA and ARTP
(PGSEA=0.0018, PARTP=0.0086), and the ‘‘NAD salvage II’’
pathway (HumanCyc) was detected only by the ARTP method
(PARTP=0.0068). Table 3 presents the results for the genes in these
pathways. The three NMNAT genes (NMNAT1, NMNAT2, and
NMNAT3) that are shared by both of these two pathways harbor
SNPs with significant genetic effect (Ptrend,0.05) and therefore
likely to dominate the significant enrichment signals in these
pathways. Other genes displaying significant bladder cancer risk
are QPRT in the ‘‘NAD I’’ pathway, and ACP6, ITGB1BP3,
ACPL2 in the ‘‘NAD II’’ pathway.
Vesicle biogenesis and budding
Three pathways involved in clathrin-dependent vesicle biogen-
esis and budding were detected in this analysis. The ‘‘Lysosome
Vesicle Biogenesis’’ pathway (Reactome) showed the strongest
enrichment signal among all pathways in this study, and was
detected by both GSEA and ARTP (PGSEA=0.0023,
PARTP,0.0001). The ‘‘Clathrin derived vesicle budding’’ pathway
(Reactome) was detected only by ARTP (PARTP=0.0018), while
the ‘‘Retrograde neurotrophin signaling’’ pathway (Reactome) was
detected only by GSEA (PGSEA=0.0084). Table 4 displays the
Table 1. Pathways enriched with bladder cancer susceptibility loci at a P#0.01 level using GSEA and ARTP.
GSEA ARTP
Gene
overlap
(%)
Pathway source
#
genes1 # genes2 p-value3 FDR4 # genes2 p-value3 FDR4
Aromatic amine metabolism Self 11 (5); 1 (0.0059); 0.0100 (.0.5) (9); 1 (0.0012); 0.0020 (0.28) NA
NAD biosynthesis I (from aspartate) HumanCyc 5 (4); 4 (0.0021); 0.0018 (.0.5) (4); 4 (0.0086); 0.0086 (0.36) 44%
NAD salvage pathway II HumanCyc 9 (5); 6 (0.0150); 0.0583 (.0.5) (7); 8 (0.0033); 0.0068 (0.32)
Clathrin derived vesicle budding Reactome 15 (6); 6 (0.0210); 0.0189 (.0.5) (9); 9 (0.0018) 0.0018 (0.35)
Lysosome Vesicle Biogenesis Reactome 10 (6); 7 (0.0031); 0.0023 (.0.5) (7); 7 (,0.0001);
,0.0001
(0.16) 49%
Retrograde neurotrophin signaling Reactome 9 (4); 4 (0.0092); 0.0084 (.0.5) (4) ;4 (0.0192); 0.0192 (0.41)
Mitotic Metaphase/Anaphase Transition Reactome 8 (3); 3 (0.0043); 0.0040 (.0.5) (3); 3 (0.0187); 0.0187 (0.43) 55%
Mitotic Prometaphase Reactome 80 (12); 12 (0.0955); 0.2567 (.0.5) (13); 12 (0.0095); 0.0346 (0.37)
Control of skeletal myogenesis by hdac and
calcium/calmodulin-dependent kinase (camk)
BioCarta 21 (11); 10 (0.1216); 0.2322 (.0.5) (7); 3 (0.0040); 0.0617 (0.29) 12%
B cell receptor signaling pathway KEGG 75 (29); 28 (0.1121); 0.1931 (.0.5) (10); 9 (0.0059); 0.0244 (0.38)
Syndecan-1-mediated signaling events PID 15 (12); 9 (0.0014); 0.0388 (.0.5) (12); 11 (0.0092); 0.1666 (0.43) 18%
Syndecan-2-mediated signaling events PID 31 (19); 16 (0.0048); 0.0559 (.0.5) (31); 31 (0.0078); 0.1404 (0.42)
TGF-beta signaling pathway KEGG 85 (41); 36 (0.0090); 0.0988 (.0.5) (57); 57 (0.0251); 0.2196 (.0.5) NA
Activated AMPK stimulates fatty-acid
oxidation in muscle
Reactome 8 (4); 3 (0.0434); 0.2470 (.0.5) (8); 8 (0.0017); 0.0454 (0.41)
AMPK inhibits chREBP transcriptional activity Reactome 5 (3); 2 (0.0010); 0.0411 (.0.5) (3); 2 (0.0014); 0.0465 (0.33) 39%
Reversal of insulin resistance by leptin BioCarta 10 (5); 7 (0.0170); 0.6432 (.0.5) (10); 2 (0.0028); 0.1635 (0.37)
Maturity onset diabetes of the young KEGG 25 (12); 11 (0.0067); 0.0308 (.0.5) (12); 16 (0.0390); 0.1908 (.0.5) NA
Metabolism of polyamines Reactome 12 (6); 4 (0.0055); 0.0460 (.0.5) (7); 5 (0.0040); 0.0657 (0.32) NA
Results of the top ranked pathways (P,0.01) using GSEA and ARTP. In parenthesis are results prior of removal SNPs displaying heterogeneous signals.
1The number of genes in the pathway.
2The number of genes underlying the enrichment signal in the pathway.
3P-value of the enrichment score based on 10,000 permutations.
4False-discovery rate calculated based on the normalized statistics of the permutation data to account for the variable sizes of genes and pathways.
doi:10.1371/journal.pone.0029396.t001
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results for the genes in these pathways. Three genes are shared by
the three pathways: CLTA and CLTC, which encode for the light
and heavy chains of clathrin respectively, and SH3GL2 which is
associated with clathrin-mediated endocytosis. The association of
SNPs in these three genes with bladder cancer risk ranked them
among the top four genes in these pathways.
Mitosis
The ‘‘Mitotic metaphase/anaphase transition’’ (Reactome)
was detected by the GSEA method (PGSAE= 0.0040) and was
marginally significant using ARTP (PARTP=0.0187). Interesting-
ly, all eight genes in this pathway are included in the more
comprehensive ‘‘Mitotic prometaphase’’ pathway that was
detected in the initial pathway screening, but had a less
significant signal after removing SNPs with heterogeneous
signals (Table 1). Results for the eight genes included in the
‘‘Mitotic metaphase/anaphase transition’’ pathway are present-
ed in Table 5. Three SNPs in three genes (FBXO5, SMC3 and
SPC24) were associated with significant protective effect on
bladder cancer (Ptrend,0.05).
Table 3. Summary of genes in the NAD metabolism pathways used for pathway-based analysis of multi-study bladder cancer
GWAS.
Pathway Gene # SNPs1 SNP2 SNP3 rank MAF4 Allelic OR (95% CI)5 P-value6
NAD1/NAD2 NMNAT3 36 rs7636269 1 0.48 1.12 1.05 1.20 0.0004
NAD2 ACP6 16 rs1344 1 0.41 1.11 1.04 1.18 0.0017
NAD1 QPRT 7 rs3862476 1 0.07 1.19 1.04 1.35 0.0087
NAD1/NAD2 NMNAT2 36 rs4652795 1 0.38 0.92 0.86 0.98 0.0099
NAD1/NAD2 NMNAT1 8 rs1220398 1 0.14 0.89 0.81 0.98 0.0169
NAD2 ITGB1BP3 8 rs2304191 1 0.11 1.11 1.01 1.23 0.0355
NAD2 ACPL2 31 rs3210458 2 0.09 1.12 1.00 1.25 0.0421
NAD2 NUDT12 5 rs371315 1 0.28 1.07 1.00 1.15 0.0686
NAD2 NT5C3L 6 rs9907244 1 0.43 0.95 0.89 1.01 0.1094
NAD1 NADSYN1 17 rs4945007 1 0.06 1.10 0.96 1.25 0.1555
NAD2 C9orf95 19 rs7021664 1 0.08 0.94 0.83 1.06 0.3193
1Number of SNPs genotyped in the gene region (20 kb 59 upstream and 10 kb 39 downstream from the gene’s coding region).
2The SNP representing the gene in the pathway analysis after the removal of SNPs with heterogeneous effects.
3The rank of the SNP among all SNPs in the gene’s region based on their p-values.
4Minor allele frequency among controls.
5Per allele odds ratios +95% confidence intervals from logistic regression models adjusting for age, sex, study center, DNA source , and smoking.
61 d.f. trend test.
doi:10.1371/journal.pone.0029396.t003
Table 2. Summary of genes in the aromatic amine metabolism pathway used for pathway-based analysis of multi-study bladder
cancer GWAS.
Gene # SNPs1 SNP2
SNP3
rank MAF4
Allelic OR (95%
CI)5 P-value6
UGT1A9 72 rs11892031 1 0.08 0.77 0.68 0.87 3.661025
NAT2 15 rs4646249 1 0.28 0.89 0.83 0.95 0.0013
NAT1 11 rs9650592 1 0.11 0.86 0.78 0.96 0.0054
UGT1A4 41 rs4148328 1 0.38 0.91 0.85 0.98 0.0086
UGT1A6 62 rs4148328 1 0.38 0.91 0.85 0.98 0.0086
NQO1 6 rs1437135 1 0.20 0.91 0.84 0.99 0.0275
CYP1B1 13 rs2855658 1 0.43 0.94 0.88 1 0.0477
CYP1A1 4 rs2472297 2 0.22 1.03 0.95 1.11 0.4758
CYP1A2 5 rs2472297 4 0.22 1.03 0.95 1.11 0.4758
SULT1A1 1 rs1968752 1 0.37 1.01 0.95 1.08 0.7321
SULT1A2 1 rs4788073 1 0.37 0.99 0.93 1.06 0.8344
1Number of SNPs genotyped in the gene region (20 kb 59 upstream and 10 kb 39 downstream from the gene’s coding region).
2The SNP representing the gene in the pathway analysis after the removal of SNPs with heterogeneous effects.
3The rank of the SNP among all SNPs in the gene’s region based on their p-values.
4Minor allele frequency among controls.
5Per allele odds ratios +95% confidence intervals from logistic regression models adjusting for age, sex, study center, DNA source , and smoking.
61 d.f. trend test.
doi:10.1371/journal.pone.0029396.t002
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Discussion
Our pathway-based analysis of a large bladder cancer GWAS
using two complementary pathway-based methods (GSEA and
ARTP) identified an overrepresentation of association signals in
seven pathways (‘Aromatic amine metabolism’, ‘NAD biosynthe-
sis’, ‘NAD salvage’, ‘Clathrin derived vesicle budding’, ‘Lysosome
vesicle biogenesis’, ‘Retrograde neurotrophin signaling’, and
‘Mitotic metaphase/anaphase transition’) and suggest involvement
in at least three cellular processes (metabolic detoxification,
mitosis, and clathrin-mediated vesicles).
The identification of the AA metabolism pathway in this study by
both GSEA and ARTP could be considered a good indication for
the utility of this approach, since AA metabolism has established
relevance to bladder cancer susceptibility. Interestingly, the
enrichment signal in this pathway is driven by variations in the
UGT1A gene cluster and theNAT1,NAT2, andNQO1 genes (Table 1)
that are involved in detoxification processes in the AA pathway
[34,35]. The strong enrichment signal left in this pathway even after
the removal of the UGT1A and NAT2 genes from the analysis
indicates that other genetic variations affecting aromatic amines
detoxification may contribute to bladder cancer susceptibility.
The detection of the NAD metabolism pathway may be relevant
to bladder cancer susceptibility through several carcinogenic
mechanisms. First, NAD homeostasis has been shown to play a
role in various redox reactions that may lead to irreversible cellular
damage and consequently to the initiation of malignant tumor
[43]. In addition, NAD has been shown to be involved in DNA
repair and telomere maintenances [44] as well as in energy
production both of which are important processes in cancer
development. Interestingly, NAD metabolism pathway has been
implicated in a recent pathway-based analysis of colon cancer
GWAS [14]. Colon and bladder cancers have been associated with
NAT2 acetylation status. For bladder cancer, in which N-
acetylation is a detoxification step, NAT2 slow acetylator
phenotype presents a higher risk. In contrast, for heterocyclic
amine-related colon cancer in which N-acetylation is negligible
and O-acetylation is a carcinogen-activation step, NAT2 rapid
acetylator phenotype presents a higher risk [45]. Thus, similar
metabolic pathways could play diverse roles in the etiology of these
two cancers.
Three clathrin-mediated vesicle pathways are also highlighted
in this study. Clathrin-coated vesicles play essential role in
intracellular trafficking, endocytosis, and exocytosis [46]. In this
realm, it has been shown that clathrin-mediated vesicle pathways
regulate the signaling and cellular localization of several growth
factors [47] that are known to play a role in cancer susceptibility.
Interestingly, clathrin may be also relevant to the Mitotic
Metaphase/Anaphase transition pathway that was also implicated
in this study. During mitosis, clathrin helps stabilizing the
Table 4. Summary of genes in the Clathrin-mediated vesicle pathways used for pathway-based analysis of multi-study bladder
cancer GWAS.
Pathway Gene # SNPs1 SNP2
SNP3
rank MAF4 Allelic OR (95% CI)5 P-value6
Clathrin/Lysosome/Retrograde CLTA 10 rs10972786 1 0.06 1.27 1.11 1.45 0.0004
Clathrin/Lysosome ARRB1 29 rs667791 1 0.39 1.11 1.04 1.19 0.0014
Clathrin/Lysosome/Retrograde SH3GL2 92 rs2209426 1 0.17 0.87 0.80 0.95 0.0020
Clathrin/Lysosome/Retrograde CLTC 10 rs7224631 1 0.09 1.19 1.06 1.32 0.0023
Clathrin/Lysosome DNAJC6 38 rs1325607 1 0.21 1.12 1.03 1.21 0.0057
Clathrin/Lysosome HSPA8 8 rs11218950 1 0.05 0.80 0.68 0.95 0.0087
Retrograde NGF 45 rs12760036 1 0.10 0.85 0.76 0.96 0.0096
Clathrin/Lysosome AP1G1 7 rs9932707 1 0.45 1.07 1.00 1.14 0.0353
Clathrin VAMP2 3 rs3202848 1 0.37 0.93 0.86 1.00 0.0572
Clathrin VAMP8 9 rs719023 1 0.39 0.94 0.88 1.00 0.0631
Retrograde DNAL4 7 rs738141 1 0.17 1.08 1.00 1.18 0.0645
Clathrin SNAP23 3 rs4924682 1 0.01 1.27 0.95 1.70 0.1087
Clathrin/Lysosome DNM2 16 rs4804528 1 0.43 0.95 0.89 1.02 0.1437
Retrograde DNM1 13 rs13285411 1 0.12 0.93 0.84 1.03 0.1463
Clathrin/Lysosome AP1B1 14 rs5763140 1 0.11 1.08 0.97 1.19 0.1500
Clathrin/Lysosome ARF1 4 rs3768331 1 0.38 1.05 0.98 1.12 0.1536
Clathrin GBF1 15 rs1057050 1 0.06 0.90 0.78 1.04 0.1673
Retrograde NTRK1 13 rs1888861 1 0.23 0.95 0.88 1.03 0.2275
Retrograde AP2A2 12 rs7483870 1 0.23 0.96 0.89 1.04 0.3014
Retrograde AP2A1 9 rs2286948 1 0.36 1.03 0.96 1.10 0.3694
Clathrin STX4 1 rs10871454 1 0.39 1.00 0.94 1.07 0.9722
1Number of SNPs genotyped in the gene region (20 kb 59 upstream and 10 kb 39 downstream from the gene’s coding region).
2The SNP representing the gene in the pathway analysis after the removal of SNPs with heterogeneous effects.
3The rank of the SNP among all SNPs in the gene’s region based on their p-values.
4Minor allele frequency among controls.
5Per allele odds ratios +95% confidence intervals from logistic regression models adjusting for age, sex, study center, DNA source, and smoking.
61 d.f. trend test.
doi:10.1371/journal.pone.0029396.t004
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kinetochore fibers which are required for the proper function of
the mitotic spindle [48]. Thus, the overrepresentation of
association signals in two distinct pathways associated with mitosis
suggest that perturbations in the mitotic process, and particularly
those related to the metaphase/anaphase transition, may modify
the risk of human bladder cancer.
Strengths of our study are the large sample size; the use of
primary scan data from five independent studies allowing us to
address consistency of effects across the different populations; and
the use of two complementary pathway-based methods. A limitation
of our study is the lack of pathway-based signals to reach a
noteworthy FDR significance level, with only one pathway
(Lysosome Vesicle Biogenesis) having an FDR value ,0.2. This
could be partially due to the inherent limits of the methods used, the
inadequate annotation of relevant pathways in public databases, or
due to weak association signals in our data. Recent analysis of
bladder cancers using RNA expression data, have also highlighted
enrichment of genes with similar processes as we identified in our
genomic data here, including metabolic processes, which provide
further plausibility that the pathways identified may be relevant to
bladder cancer susceptibility [49]. Furthermore, the high rank of the
AA metabolism pathway in both GSEA and ARTP support the
power of these methods to highlight pathways with established
relevance to bladder cancer susceptibility and may therefore
similarly suggest the involvement of metabolic detoxification,
mitosis and clathrin-mediated pathways in bladder carcinogenesis.
Supporting Information
Table S1 Details and results for all 1423 pathways
included in this study.
(XLS)
Table S2 List of genes included in the 22 self-construct-
ed candidate pathways.
(XLS)
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